Aratana Therapeutics (PETX) Inactive 10-K16 Mar 152014 FY Annual reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Dec. 31, 2014	Mar. 09, 2015	Jun. 30, 2014
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Entity Registrant Name	ARATANA THERAPEUTICS, INC.
Entity Central Index Key	1509190
Current Fiscal Year End Date	-19
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Trading Symbol	petx
Entity Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding		34,910,462
Entity Public Float			$382,560,857

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$9,823	$41,084	[1]
Short-term investments	88,249	4,670	[1]
Accounts receivable	352
Receivable from stockholder		1,001	[1]
Inventories	427	55	[1]
Prepaid expenses and other current assets	900	274	[1]
Deferred tax asset	158	1,124	[1]
Total current assets	99,909	48,208	[1]
Property and equipment, net	620	98	[1]
Long-term marketable securities	2,452
Goodwill	41,398	25,646	[1]
Intangible assets, net	62,323	38,354	[1]
Other long-term assets	1,201	37	[1]
Total assets	207,903	112,343	[1]
Current liabilities:
Accounts payable	1,532	2,307	[1]
Accrued expenses	3,229	2,495	[1]
Current portion-loan payable		5,625	[1]
Current portion-note payable		3,000	[1]
Current portion-deferred licensing revenue		45	[1]
Current portion-contingent consideration	4,248	2,572	[1]
Deferred income		800	[1]
Deferred tax liability	413
Other current liabilities	46	57	[1]
Total current liabilities	9,468	16,901	[1]
Loan payable	14,963	9,310	[1]
Contingent consideration		1,543	[1]
Deferred tax liability	1,610	1,124	[1]
Other long-term liabilities	30	75	[1]
Total liabilities	26,071	28,953	[1]
Commitments and contingencies (Notes 11 and 12)			[1]
Stockholders' equity:
Common stock, $0.001 par value; 100,000,000 shares authorized at December 31, 2014 and December 31, 2013, 34,147,861 and 23,425,487 issued and outstanding at December 31, 2014 and December 31, 2013, respectively	34	23	[1]
Treasury stock	-1,081
Additional paid-in capital	254,993	112,515	[1]
Accumulated deficit	-67,964	-29,148	[1]
Accumulated other comprehensive loss	-4,150
Total stockholders' equity	181,832	83,390	[1]
Total liabilities and stockholders' equity	$207,903	$112,343	[1]

[1]	as restated

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Consolidated Balance Sheets [Abstract]
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	34,147,861	23,425,487
Common stock, shares outstanding	34,147,861	23,425,487

Consolidated_Statements_Of_Ope

Consolidated Statements Of Operations (USD $)	3 Months Ended								12 Months Ended
Consolidated Statements Of Operations (USD $)	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013		Dec. 31, 2012
Revenues:
Licensing and collaboration revenue									$500,000	$15,000	[1]
Product sales									267,000	108,000	[1]
Total revenues	248,000	43,000	300,000	176,000	123,000				767,000	123,000	[1]
Costs and expenses:
Cost of product sales									333,000	108,000	[1]
Royalty expense									72,000	1,000	[1]
Research and development									19,985,000	10,925,000	[1]	7,291,000
Selling, general and administrative									17,938,000	8,572,000	[1]	2,987,000
In-process research and development									2,157,000		[1]	1,500,000
Amortization of acquired intangible assets									1,891,000	298,000	[1]
Total costs and expenses									42,376,000	19,904,000	[1]	11,778,000
Loss from operations									-41,609,000	-19,781,000	[1]	-11,778,000
Other income (expense)
Interest income									123,000	75,000	[1]	21,000
Interest expense									-1,060,000	-432,000	[1]
Other income (expense), net									2,287,000	478,000	[1]	121,000
Total other income (expense)									1,350,000	121,000	[1]	142,000
Loss before income taxes									-40,259,000	-19,660,000	[1]	-11,636,000
Income tax benefit									1,443,000	12,722,000	[1]
Net loss					4,466,000	-4,671,000	-3,440,000	-3,293,000	-38,816,000	-6,938,000	[1]	-11,636,000
Unaccreted dividends on convertible preferred stock												-2,035,000
Net loss and comprehensive loss attributable to common stockholders	($10,256,000)	($10,130,000)	($9,278,000)	($9,152,000)	$4,466,000	($4,671,000)	($4,248,000)	($4,066,000)	($38,816,000)	($6,938,000)	[1]	($13,671,000)
Net loss per share, attributable to common stockholders, basic and diluted									($1.30)	($0.63)	[1]	($34.53)
Weighted average shares outstanding, basic and diluted									29,767,429	11,059,382	[1]	395,918

[1]	as restated

Consolidated_Statements_Of_Com

Consolidated Statements Of Comprehensive Loss (USD $)	12 Months Ended
Consolidated Statements Of Comprehensive Loss (USD $)	Dec. 31, 2014	Dec. 31, 2013		Dec. 31, 2012
Consolidated Statements Of Comprehensive Loss [Abstract]
Net loss	($38,816,000)	($6,938,000)	[1]	($13,671,000)
Other comprehensive loss:
Foreign currency translation adjustments	-5,402,000
Unrealized gain on available-for-sale securities	1,252,000
Other comprehensive loss	-4,150,000
Comprehensive loss	($42,966,000)	($6,938,000)	[1]	($13,671,000)

[1]	as restated

Consolidated_Statements_Of_Cha

Consolidated Statements Of Changes In Convertible Preferred Stock And Stockholders' Equity/(Deficit) (USD $)		Common Stock [Member]	Convertible Preferred Stock [Member]	Convertible Preferred Stock [Member]	Convertible Preferred Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Treasury Stock [Member]	Series B Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	Total
In Thousands, except Share data		USD ($)	Series B Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)			USD ($)
			USD ($)	USD ($)
Balance at Dec. 31, 2011					$22,155	$303	($10,574)					($10,271)
Balance, shares at Dec. 31, 2011		300,841			15,320,832
Issuance of preferred/common stock, net of issuance cost			7,699	9,343
Issuance of preferred/common stock, net of issuance cost, shares			2,570,834	2,349,541							2,349,541
Compensation expense related to stock options and restricted stock awards						106						106
Vesting of restricted stock awards						139						139
Vesting of restricted stock awards, shares		15,042
Vesting of stock awards early exercised		1				106						107
Vesting of stock awards early exercised, shares		514,940
Net loss							-11,636					-11,636
Balance at Dec. 31, 2012		1			39,197	654	-22,210					-21,555
Balance, shares at Dec. 31, 2012		830,823			20,241,207
Issuance of preferred/common stock, net of issuance cost		6		2,756		34,274						34,280
Issuance of preferred/common stock, net of issuance cost, shares		6,612,500		693,571							693,571
Compensation expense related to stock options and restricted stock awards						1,025						1,025
Vesting of restricted stock awards, shares		230,298
Vesting of stock awards early exercised						118						118
Vesting of stock awards early exercised, shares		270,419
Issuance of common stock related to stock option exercises						57						57
Issuance of common stock related to stock option exercises, shares		270,173
Effect of a 1 for 1.662 reverse split on preferred stock					-8,338,699
Conversion of shares of preferred stock to common stock		13			-41,953	41,940						41,953
Conversion of shares of preferred stock to common stock, shares		12,596,079			-12,596,079
Dividends for preferred shares issued upon initial public offering		1				-1
Dividends for preferred shares issued upon initial public offering, shares		755,823
Issuance of common stock relating to Vet Therapeutics, Inc. acquisition		1				14,699						14,700
Issuance of common stock relating to Vet Therapeutics, Inc. acquisition, shares		624,997
Issuance of common stock related to private investment in public entity		1				19,749						19,750
Issuance of common stock related to private investment in public entity, shares		1,234,375
Net loss	[1]						-6,938					-6,938
Balance at Dec. 31, 2013	[1]	23				112,515	-29,148					83,390
Balance, shares at Dec. 31, 2013	[1]	23,425,487
Issuance of preferred/common stock, net of issuance cost		11				135,067						135,078
Issuance of preferred/common stock, net of issuance cost, shares		10,325,000
Compensation expense related to stock options and restricted stock awards						7,130						7,130
Vesting of restricted stock awards, shares		240,528
Vesting of stock awards early exercised						56						56
Vesting of stock awards early exercised, shares		152,272
Issuance of common stock related to stock option exercises						225						225
Issuance of common stock related to stock option exercises, shares		81,941
Repurchase of common stock									-1,081			-1,081
Repurchase of common stock, shares		-77,367
Other comprehensive loss								-4,150				-4,150
Net loss							-38,816					-38,816
Balance at Dec. 31, 2014		$34				$254,993	($67,964)	($4,150)	($1,081)			$181,832
Balance, shares at Dec. 31, 2014		34,147,861

[1]	as restated

Consolidated_Statements_Of_Cha1

Consolidated Statements Of Changes In Convertible Preferred Stock And Stockholders' Equity/(Deficit) (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Issuance of stock, issuance cost	$10,627	$5,394
Reverse stock split ratio on shares		1.662
Series B Convertible Preferred Stock [Member]
Issuance of stock, issuance cost			13
Series C Convertible Preferred Stock [Member]
Issuance of stock, issuance cost		$19	$55

Consolidated_Statements_Of_Cas

Consolidated Statements Of Cash Flows (USD $)	12 Months Ended
Consolidated Statements Of Cash Flows (USD $)	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Cash flows from operating activities
Net loss	($38,816,000)		($6,938,000)	[1]	($11,636,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Acquired in-process research and development	2,157,000			[1]	1,500,000
Stock-based compensation expense	7,130,000		1,025,000	[1]	106,000
Depreciation and amortization expense	2,043,000		313,000	[1]	13,000
Non-cash interest expense	41,000		23,000	[1]
Change in fair value of contingent consideration	-133,000		305,000	[1]
Change in fair value of derivative instruments	-465,000
Gain on disposition of property and equipment	1,000		0
Deferred income benefit	-1,443,000		-12,722,000	[1]
Changes in operating assets and liabilities:
Accounts receivable	-102,000
Inventories	-372,000
Prepaid expenses	-642,000		-249,000	[1]
Other assets	-45,000		-14,000	[1]	-32,000
Accounts payable	-1,143,000		1,527,000	[1]	536,000
Accrued expenses and other liabilities	482,000		579,000	[1]	897,000
Deferred income	-880,000				800,000
Net cash used in operating activities	-32,188,000		-16,151,000	[1]	-7,816,000
Cash flows from investing activities
Purchase of property and equipment, net	-471,000		-94,000	[1]	-10,000
Cash paid for acquisitions, net of cash received	-12,075,000		-30,994,000	[1]
Purchase of investments	-371,449,000		-5,169,000	[1]	-6,627,000
Proceeds from maturities of investments	286,670,000		6,881,000	[1]	6,627,000
Purchase of derivative instruments	-643,000
Purchase of in-process research and development	-2,157,000				-1,000,000
Change in restricted cash			141,000	[1]
Net cash used in investing activities	-100,125,000		-29,235,000	[1]	-1,010,000
Cash flows from financing activities
Proceeds from the issuance of debt, net of discount			14,914,000	[1]
Repurchase of common stock	-1,081,000
Proceeds from the issuance of restricted stock					139,000
Cash proceeds	225,000		153,000	[1]	266,000
Repurchase, early exercised stock			-6,000	[1]
Proceeds from public offering, net of commission	137,220,000		36,897,000	[1]
Payments of public offering costs	-2,153,000		-2,617,000	[1]
Issuance of common stock private investment in public entitiy			19,750,000	[1]
Cash paid for promissory notes	-18,067,000
Cash paid for contingent consideration	-15,166,000
Net cash provided by financing activities	100,978,000		72,497,000	[1]	16,797,000
Effect of exchange rate changes on cash	74,000
Net increase in cash and cash equivalents	-31,261,000		27,111,000	[1]	7,971,000
Cash and cash equivalents, beginning of period	41,084,000	[1]	13,973,000	[1]	6,002,000
Cash and cash equivalents, end of period	9,823,000		41,084,000	[1]	13,973,000	[1]
Supplemental disclosure of cash flow information
Cash paid for interest	942,000		357,000	[1]
Supplemental disclosure of noncash investing and financing activities:
Accrued third-party milestone payment					500,000
Conversion of preferred stock into common stock			41,953,000	[1]
Payment of dividends on preferred stock			4,535,000	[1]
Issuance of common stock relating to Vet Therapeutics, Inc. acquisition			14,700,000	[1]
Vet Therapeutics Inc., [Member]
Supplemental disclosure of noncash investing and financing activities:
Contingent consideration relating to acquisition			4,115,000	[1]
Note payable related to acquisition			3,000,000	[1]
Okapi Sciences NV [Member]
Cash flows from investing activities
Cash paid for acquisitions, net of cash received	-43,376,000
Supplemental disclosure of noncash investing and financing activities:
Contingent consideration relating to acquisition	15,166,000
Note payable related to acquisition	15,134,000
Series B Convertible Preferred Stock [Member]
Cash flows from financing activities
Proceeds from the issuance of convertible preferred stock, net of issuance costs					7,699,000
Series C Convertible Preferred Stock [Member]
Cash flows from financing activities
Proceeds from the issuance of convertible preferred stock, net of issuance costs			3,406,000	[1]	8,693,000
Payments of public offering costs			($9,000)		($55,000)

[1]	as restated

Nature_Of_The_Business_And_Bas

Nature Of The Business And Basis Of Presentation	12 Months Ended
Nature Of The Business And Basis Of Presentation	Dec. 31, 2014
Nature Of The Business And Basis Of Presentation [Abstract]
Nature Of The Business And Basis Of Presentation	1. Nature of the Business and Basis of Presentation
	Aratana Therapeutics, Inc. (the “Company,” or “Aratana”) was incorporated on December 1, 2010 under the laws of the State of Delaware. The Company is a pet therapeutics company focused on licensing, developing and commercializing of innovative biopharmaceutical products for companion animals. The Company has licensed and is developing more than 18 therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target serious medical conditions such as pain and inflammation, stimulation of appetite, cancer, and other serious diseases for dogs and cats.
	Since its inception, the Company has devoted substantially all of its efforts to research and development, recruiting management and technical staff, building a commercial infrastructure, acquiring operating assets and raising capital.
	The Company is subject to risks common to companies in the biotechnology and pharmaceutical industries. There can be no assurance that the Company’s licensing efforts will identify viable product candidates, that the Company’s research and development will be successfully completed, that adequate protection for the Company’s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. The Company operates in an environment of substantial competition from other animal health companies. In addition, the Company is dependent upon the services of its employees and consultants, as well as third-party contract research organizations and manufacturers and collaborators.
	The consolidated financial statements include the accounts of Aratana and its wholly owned subsidiaries. The Company has one operating segment. All intercompany balances and transactions have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).
	The Company has incurred recurring losses and negative cash flows from operations and has cumulative net losses of $67,964 from inception (December 1, 2010) to December 31, 2014. The Company expects that its cash and cash equivalents and short-term investments, which include the remaining net proceeds received in its public offerings of common stock that closed on February 3, 2014 and September 22, 2014, and existing Credit Facility will fund operations through December 31, 2016. The Company expects an increase in investment related to its research and development and commercial activities and, as a result, the Company may need additional capital to fund its operations, which the Company may obtain from public or private equity, debt financings or other sources, such as corporate collaborations and licensing arrangements.

Restatement_Of_Consolidated_Fi

Restatement Of Consolidated Financial Statements	12 Months Ended
Restatement Of Consolidated Financial Statements	Dec. 31, 2014
Restatement Of Consolidated Financial Statements [Abstract]
Restatement Of Consolidated Financial Statements	2. Restatement of Consolidated Financial Statements

	This Annual Report on Form 10-K for the fiscal year ended December 31, 2014 (“Annual Report”) includes the restatement of our Consolidated Financial Statements and the related disclosures for the previously reported year ended December 31, 2013. The Company has restated its consolidated financial statements for the year ended December 31, 2013, resulting from the Company’s determination that the valuation related to the intangible asset AT-004 acquired during the merger with Vet Therapeutics, Inc. during October 2013 should have included technology royalty payments that are the responsibility of Aratana.

	Due to the exclusion of certain royalty payments from the valuation of an acquired intangible asset, the Company determined that the value of the intangible asset AT-004 (VTI’s B-cell lymphoma product) was overstated. The correction of the valuation of the AT-004 intangible asset and the corresponding deferred tax liability also reduces the valuation allowance released and the resulting income tax benefit. The effect of the correction of the purchase price accounting error will be to decrease amortizable intangible assets by $7,786, increase goodwill by $4,850, decrease the income tax benefit by $2,651 and decrease the net deferred tax liabilities by $257, in each case, as of December 31, 2013.

	As a result, the Company has restated its Consolidated Balance Sheet, the related Consolidated Statements of Operations, Comprehensive Loss, Changes in Convertible Preferred Stock and Stockholders’ Equity (Deficit), and Cash Flows for the year ended December 31, 2013. The following tables present the impact of the restatement on the Company’s the Company’s consolidated financial statements.

	ARATANA THERAPEUTICS, INC.
	CONSOLIDATED BALANCE SHEETS




			31-Dec-13
			PREVIOUSLY			RESTATEMENT
			REPORTED			ADJUSTMENT			AS RESTATED
	Assets
	Current assets:
	Cash and cash equivalents		$	41,084		$	—		$	41,084
	Short-term marketable securities			4,670			—			4,670
	Receivable from stockholder			1,001			—			1,001
	Inventory			55			—			55
	Prepaid expenses and other current assets			274			—			274
	Deferred tax asset			1,381			-257			1,124
	Total current assets			48,465			-257			48,208
	Property and equipment, net			98			—			98
	Goodwill			20,796			4,850			25,646
	Intangible assets, net			46,140			-7,786			38,354
	Other long-term assets			37			—			37
	Total assets		$	115,536		$	-3,193		$	112,343
	Liabilities and Stockholders' Equity
	Current liabilities:
	Accounts payable		$	2,307		$	—		$	2,307
	Accrued expenses			2,495			—			2,495
	Current portion – loan payable			5,625			—			5,625
	Current portion – note payable			3,000			—			3,000
	Current portion – deferred licensing revenue			45			—			45
	Current portion – contingent consideration			2,572			—			2,572
	Deferred income			800			—			800
	Other current liabilities			57			—			57
	Total current liabilities			16,901			—			16,901
	Loan payable			9,310			—			9,310
	Contingent consideration			1,543			—			1,543
	Deferred tax liability			1,666			-542			1,124
	Other long-term liabilities			75			—			75
	Total liabilities			29,495			-542			28,953
	Stockholders’ equity:
	Common stock			23			—			23
	Additional paid-in capital			112,515			—			112,515
	Accumulated deficit			-26,497			-2,651			-29,148
	Total stockholders’ equity			86,041			-2,651			83,390
	Total liabilities and stockholders’ equity		$	115,536		$	-3,193		$	112,343
	___________________________


	ARATANA THERAPEUTICS, INC.
	CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS



			YEAR ENDED DECEMBER 31, 2013
			PREVIOUSLY			RESTATEMENT
			REPORTED			ADJUSTMENT			AS RESTATED

Revenues:
Licensing revenue		$	15		$	—		$	15
Product sales			108			—			108
Total revenues			123			—			123
Costs and expenses:
Cost of product sales			108			—			108
Royalty expense			1			—			1
Research and development			10,925			—			10,925
General and administrative			8,572			—			8,572
In-process research and development			—			—			—
Amortization of acquired intangible assets			380			-82			298
Total costs and expenses			19,986			-82			19,904
Loss from operations			-19,863			82			-19,781
Other income (expense)
Interest income			75			—			75
Interest expense			-432			—			-432
Other income			478			—			478
Total other income (expense)			121			—			121
Loss before income taxes		$	-19,742		$	82		$	-19,660
Income tax benefit			15,455			-2,733			12,722
Net loss and comprehensive loss		$	-4,287		$	-2,651		$	-6,938
Net loss attributable to common stockholders		$	-4,287		$	-2,651		$	-6,938
Net loss per share, attributable to common stockholders, basic and diluted		$	-0.39		$	-0.24		$	-0.63



ARATANA THERAPEUTICS, INC.
CONSOLIDATED STATEMENT OF CASH FLOWS











		YEAR ENDED DECEMBER 31, 2013
		PREVIOUSLY			RESTATEMENT
		REPORTED			ADJUSTMENT			AS RESTATED
Cash flows from operating activities
Net loss		$	-4,287		$	-2,651		$	-6,938
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense			1,025			—			1,025
Depreciation and amortization expense			395			-82			313
Non-cash interest expense			23			—			23
Deferred income taxes			-15,455			2,733			-12,722
Changes in operating assets and liabilities:
Prepaid expenses			-249			—			-249
Other assets			-14			—			-14
Accounts payable			1,527			—			1,527
Accrued expenses and other liabilities			579			—			579
Net cash used in operating activities			-16,151			—			-16,151
Cash flows from investing activities
Purchases of property and equipment, net			-94			—			-94
Cash paid for acquisitions, net of cash received			-30,994			—			-30,994
Purchase of marketable securities			-5,169			—			-5,169
Proceeds from maturities of marketable securities			6,881			—			6,881
Change in restricted cash			141			—			141
Net cash used in investing activities			-29,235			—			-29,235
Cash flows from financing activities
Proceeds from the issuance of Series C convertible preferred stock, net of issuance costs			3,406			—			3,406
Proceeds from the issuance of debt, net of discount			14,914			—			14,914
Proceeds from stock option exercises			153			—			153
Repurchase, early exercised stock			-6			—			-6
Proceeds from public offering, net of commission			36,897			—			36,897
Payments of public offering costs			-2,617			—			-2,617
Issuance of common stock private investment in public entity			19,750			—			19,750
Net cash provided by financing activities			72,497			—			72,497
Net increase in cash and cash equivalents			27,111			—			27,111
Cash and cash equivalents, beginning of year			13,973			—			13,973
Cash and cash equivalents, end of year		$	41,084		$	—		$	41,084

Summary_Of_Significant_Account

Summary Of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Summary Of Significant Accounting Policies [Abstract]
Summary Of Significant Accounting Policies	3. Summary of Significant Accounting Policies
	Use of Estimates
	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from those estimates.
	Cash and Cash Equivalents

	The Company classifies all highly liquid investments with stated maturities of three months or less from the date of purchase as cash equivalents. The Company held no cash equivalents as of December 31, 2013. In 2013, the Company held no overnight reverse repurchase agreements. Beginning in 2014, the Company began accounting for its overnight reverse repurchase agreements as cash equivalents.

	Short-term Investments
	Reverse repurchase agreements other than overnight reverse repurchase agreements are classified as short-term investments. In 2013, the Company held no reverse repurchase agreements. During 2014, the Company began accounting for its reverse repurchase agreements with maturities greater than overnight as short-term investments and classified them as available-for-sale. Short-term investments for both 2014 and 2013 include short-term marketable securities as described below, consisting of certificate of deposits.
	Marketable Securities
	The Company classifies all highly liquid investments with stated maturities of greater than three months from the date of purchase as marketable securities. The Company determines the appropriate classification of investments in marketable securities at the time of purchase and re-evaluates such designation at each consolidated balance sheet date. The Company classifies and accounts for marketable securities as available-for-sale. The Company may or may not hold securities with stated maturities greater than 12 months until maturity. After consideration of the risk versus reward objectives, as well as the Company’s liquidity requirements, the Company may sell these securities prior to their stated maturities. These securities are viewed as being available to support current operations. As a result, the Company classifies securities with maturities beyond 12 months as long-term assets under the caption long-term marketable securities in the consolidated balance sheet. The Company reports available-for-sale investments at fair value as of each consolidated balance sheet date and records any unrealized gains and losses as a component of stockholders’ equity (deficit). At December 31, 2013, the fair value of marketable securities approximated cost and as such, no gains or losses were recorded as a component of other comprehensive income (loss). At December 31, 2014, investments in equity securities were classified as long-term marketable securities and were carried at fair value, as determined by quoted market prices, as such, gains were recorded as a component of other comprehensive income. The cost of securities sold is determined on a specific identification basis, and realized gains and losses are included in other income (expense) in the consolidated statements of operations. If any adjustment to fair value reflects a decline in the value of the investment, the Company considers available evidence to evaluate the extent to which the decline is “other than temporary” and recognizes the impairment by releasing other comprehensive income to the consolidated statement of operations. There were no such adjustments necessary during the year ended December 31, 2014.

	Accounts Receivable
	Accounts receivable are uncollateralized customer obligations due under normal trade terms generally requiring payment within 30 days of the invoice date.
	The Company provides an allowance for doubtful accounts equal to the estimated losses that will be incurred in collection of accounts receivable. This estimate is based on the current review of existing receivables and historical experience in the industry. The allowance and associated accounts receivable are reduced when the receivables are determined to be uncollectible. Currently, the Company considers accounts receivable to be fully collectible.
	Inventories
	Inventories are stated at the lower of cost or market and consist of raw materials, work-in-process and finished goods. Cost is determined by the average cost method for raw materials and standard cost for work-in-process and finished goods, which approximates average cost. Market is considered the lower of prevailing replacement cost or net realizable value. Inventories acquired in business combinations are recorded at fair value as of acquisition date.
	Property and Equipment
	The Company records property and equipment at historical cost or, in the case of a business combination, at fair value on the date of the business combination, less accumulated depreciation and amortization. Depreciation expense is recognized using the straight-line method over the following estimated useful lives:




	Laboratory and office equipment	3–5 years
	Computer equipment	3–5 years
	Furniture	3–7 years
	Vehicles	3–5 years
	Leasehold improvements	3–10 years
	Leasehold improvements are amortized over the shorter of the life of the related asset or the term of the lease.
	Expenditures for repairs and maintenance of assets are charged to expense as incurred. Costs of major additions and betterments are capitalized and depreciated on a straight-line basis over their useful lives. When property and equipment are disposed of, the cost and respective accumulated depreciation and amortization are removed from the books. Any gain or loss on disposal is recorded in the consolidated statements of operations.
	Goodwill
	Goodwill relates to amounts that arose in connection with the Company’s business combinations (Note 20) and represents the difference between the purchase price and the estimated fair value of the identifiable tangible and intangible net assets when accounted for using the acquisition method of accounting. Goodwill is not amortized, but is subject to periodic review for impairment.

	The Company tests goodwill at the reporting unit level for impairment on an annual basis and between annual tests, if events and circumstances indicate impairment may exist. Events that would indicate impairment and trigger an interim impairment assessment include, but are not limited to, current economic and market conditions, including a decline in market capitalization, a significant adverse change in legal factors, business climate or operational performance of the business and an adverse action or assessment by a regulator.

	The Company completed its annual goodwill impairment testing during the third quarter of 2014. The Company determined as of the testing date that it still consisted of one operating segment which is comprised of one reporting unit. In performing step one of the assessment, the Company determined that its fair value, determined to be its market capitalization, was greater than its carrying value, determined to be stockholders’ equity. Based on this result, step two of the assessment was not required to be performed, and the Company determined there was no impairment of goodwill as of the testing date.

	Impairment charges related to goodwill have no impact on the Company’s compliance with financial covenants.
	Intangible Assets
	The Company’s intangible assets consist of intellectual property rights acquired for currently marketed products and intellectual property rights acquired for in-process research and development (“IPR&D”). All of the Company’s intangible assets were recorded in connection with the Company’s business combinations (Note 20). The Company’s intangible assets are recorded at fair value at the time of their acquisition. The Company amortizes intangible assets over their estimated useful lives once the acquired technology is developed into a commercially viable product.
	The estimated useful lives of the individual categories of intangible assets are based on the nature of the applicable intangible asset and the expected future cash flows to be derived from the intangible asset. Amortization of intangible assets with finite lives is recognized over the time the intangible assets are estimated to contribute to future cash flows. The Company amortizes finite-lived intangible assets using the straight-line method.

	Indefinite-lived IPR&D intangible assets are assessed for impairment at least annually. In addition, all intangible assets are reviewed for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows for definite-lived intangible assets and discounted cash flows for indefinite-lived IPR&D intangible assets expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted (definite-lived) or discounted (indefinite-lived) future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. To date, the Company has not recorded any impairment losses on intangible assets.

	The Company completed its annual indefinite-lived IPR&D intangible assets impairment testing during the fourth quarter of 2014. For purposes of impairment testing, the fair value of the indefinite-lived IPR&D intangible assets were determined by using the framework of ASC 820, Fair Value Measurement. When determining the fair value of the indefinite-lived IPR&D intangible assets, the Company revisited all assumptions used in measuring the indefinite-lived IPR&D intangible assets at the time of acquisition, and evaluated and considered new and updated data and information available. The Company noted the fair values for all indefinite-lived IPR&D intangible assets were greater than the carrying value. As such, no impairment was recognized as of the testing date.

	Derivative Financial Instruments

	In 2013, the Company held no derivative financial instruments. Beginning in 2014, the Company began accounting for its derivative instruments as either assets or liabilities and carries them at fair value. The Company’s sole derivative (Note 11) is a warrant to purchase common stock and is adjusted to fair value through current income.

	Foreign Currency

	During 2013, the Company had limited foreign currency exposure. With the acquisition of Okapi Sciences (Note 20) in 2014, the Company is exposed to effects of foreign currency from translation. Transactions in foreign currencies are translated into the relevant functional currency at the rate of exchange at the date of the transaction. Transaction gains and losses are recognized in other income (expense) in the consolidated statements of operations. The results of operations for subsidiaries, whose functional currency is not the U.S. Dollar, are translated into the U.S. Dollar at the average rates of exchange during the period, with the subsidiaries’ balance sheets translated at the rates accumulated at the balance sheet date. The cumulative effect of these exchange rate adjustments is included in a separate component of other comprehensive income (loss) in the consolidated balance sheets. Gains and losses arising from intercompany foreign currency transactions are included in loss from operations unless the gains and losses arise from long-term investments in subsidiaries. Gains and losses from long-term investments in subsidiaries are included in a separate component of other comprehensive income (loss).

	Business Combinations
	The Company’s business acquisitions were made at a price above the fair value of the assets acquired and liabilities assumed, resulting in goodwill, based on the Company’s expectations of synergies and other benefits of combining the businesses. These synergies and benefits include elimination of redundant facilities, functions and staffing; use of the Company’s existing commercial infrastructure to expand sales of the products of the acquired businesses; and use of the commercial infrastructure of the acquired businesses to expand product sales in a cost-efficient manner.
	Significant judgment is required in estimating the fair value of intangible assets and in assigning their respective useful lives. The fair value estimates are based on available historical information and on future expectations and assumptions deemed reasonable by management, but which are inherently uncertain.
	The Company generally employs the income method to estimate the fair value of intangible assets, which is based on forecasts of the expected future cash flows attributable to the respective assets. Significant estimates and assumptions inherent in the valuations reflect a consideration of other marketplace participants, and include the amount and timing of future cash flows (including expected growth rates and profitability), the underlying product life cycles, economic barriers to entry, a brand’s relative market position and the discount rate applied to the cash flows. Unanticipated market or macroeconomic events and circumstances may occur, which could affect the accuracy or validity of the estimates and assumptions.
	Net assets acquired are recorded at their fair value and are subject to adjustment upon finalization of the fair value analysis. The Company is not aware of any information that indicates the final fair value analysis will differ materially from the preliminary estimates.
	Contingent consideration is recorded as a liability and measured at fair value using a discounted cash flow model utilizing significant unobservable inputs, including the probability of achieving each of the potential milestones and an estimated discount rate commensurate with the risks of the expected cash flows attributable to the milestones. Significant increases or decreases in any of the probabilities of success would result in a significantly higher or lower fair value, respectively, and commensurate changes to this liability. At each reporting date, we revalue the contingent consideration obligations to the reporting date fair values and record increases and decreases in the fair values as income or expense in the consolidated statements of operations until actual settlement occurs.
	Increases or decreases in the fair values of the contingent consideration obligations may result from changes in discount periods and rates, changes in the timing and amount of earn-out criteria and changes in probability assumptions with respect to the likelihood of achieving the various earn-out criteria.

	On January 6, 2014, the Company acquired Okapi Sciences, a Leuven, Belgium based company with a proprietary antiviral platform and three clinical/development stage product candidates. The aggregate purchase price was approximately $44,439, which consisted of $14,139 in cash, a promissory note in the principal amount of $15,134 with a maturity date of December 31, 2014, and a contingent consideration of up to $16,308 with an acquisition fair value of $15,166. The promissory note bore interest at a rate of 7% per annum, payable quarterly in arrears, and was subject to mandatory prepayment in the event of a specified equity financing by the Company. On February 4, 2014, the promissory note and accrued interest was paid in cash in the amount of $15,158. On March 17, 2014, the contingent consideration was settled in cash in the amount of $15,235.
	Deferred Public Offering Costs
The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as other assets until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders’ equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering. Should it no longer be considered probable that the equity financing will be consummated, the deferred offering costs would be expensed immediately as a charge to operating expenses in the consolidated statements of operations. The Company recorded $0 and $33 deferred offering costs as of December 31, 2014 and 2013, respectively.
Income Taxes
The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred taxes are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.
The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.
Debt Issuance Costs, net
Debt issuance costs, net represent legal and other direct costs related to the Company’s Credit Facility (Note 12). These costs are recorded as debt issuance costs on the consolidated balance sheet at the time they are incurred and are amortized to interest expense through the scheduled final principal payment date. During the year ended December 31, 2014, the Company recorded an additional $11 of debt issuance costs and recognized $41 of amortization expense related to debt issuance costs. During the year ended December 31, 2013, the Company recorded $83 of debt issuance costs and recognized $33 of amortization expense related to debt issuance costs.

Revenue Recognition

The Company’s principal revenue streams were licensing and collaboration and product sales. Beginning in 2014, as a result of the Okapi Sciences NV acquisition (Note 20), the Company generates revenue from research and development services. Revenues from the performance of research and development services are recorded as licensing and collaboration revenue in the consolidated statements of operations and are recognized on a proportional basis as costs are incurred.
The Company recognizes revenue when all of the following conditions are met:
	·	there is persuasive evidence of an agreement or arrangement;
	·	delivery of products has occurred or services have been rendered;
	·	the seller’s price to the buyer is fixed or determinable; and
	·	collectibility is reasonably assured.
The Company’s principal revenue streams and their respective accounting treatments are discussed below:
(i) Product sales - Revenue for the sale of products is recognized when delivery has occurred and substantially all the risks and rewards of ownership have been transferred to the customer. Revenue for the sale of products are recorded net of sales returns, allowances and discounts.
(ii) Royalty revenue - Royalty revenue relating to the Company’s out-licensed technology is recognized when reasonably estimable. The revenues are recorded based on estimates of the licensee’s sales that occurred during the relevant period. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically in the following quarter. If the Company is unable to reasonably estimate royalty revenue or does not have access to the information, then the Company records royalty revenue on a cash basis.
(iii) Licensing and collaboration revenues - Revenues derived from product out-licensing arrangements typically consist of an initial up-front payment on inception of the license and subsequent milestone payments contingent on the achievement of certain clinical and sales milestones. Product out licensing arrangements may require the Company to provide multiple deliverables to the licensee which would require the total selling price to be allocated between each of the separable elements in the arrangement using the relative selling price method. An element is considered separable if it has value to the customer on a stand-alone basis. The selling price used for each separable element will be based on vendor specific objective evidence (“VSOE”) if available, third party evidence if VSOE is not available, or estimated selling price if neither VSOE nor third party evidence is available. Revenue is then recognized as each of the separable elements to which the revenue has been allocated is delivered.
Milestone payments which are non-refundable, non-creditable and contingent on achieving certain development, regulatory, or commercial milestones are recognized as revenues either on achievement of such milestones or over the period the Company has continuing substantive performance obligations.
Research and Development Costs
Research and development costs are expensed as incurred. Included in research and development costs are wages, stock-based compensation and employee benefits, and other operational costs related to the Company’s research and development activities, including facility-related expenses, external costs of outside contractors engaged to conduct both preclinical and clinical studies and allocation of corporate costs. Payments received from external parties to fund the Company’s research and development activities are used to reduce the Company’s research and development expenses. If IPR&D is acquired in an asset purchase then the acquired IPR&D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred.
Patent Costs
All patent-related costs incurred in connection with filing and prosecuting patent applications are recorded as selling, general and administrative expenses as incurred, as recoverability of such expenditures is uncertain.

Shipping
Shipping costs are included in cost of product sales.

Sales Tax
The Company collects and remits taxes assessed by various governmental authorities. These taxes may include sales, use and value added taxes. These taxes are recorded on a net basis and are excluded from sales.

Accounting for Stock-Based Compensation

The Company’s stock-based compensation program grants awards that may consist of stock options and restricted stock awards. The fair values of stock option grants are determined as of the date of grant using the Black-Scholes option pricing method. This method incorporates the fair value of the Company’s common stock at the date of each grant and various assumptions such as the risk-free interest rate, expected volatility based on the volatility of the Company’s common stock price, expected dividend yield, and expected term of the options. The fair values of restricted stock awards are determined based on the fair value of the Company’s common stock. Prior to the Company’s initial public offering of its common stock in June 2013, the fair value of the common stock was determined by management and the Board of Directors, on the date of grant. Beginning in the first quarter of 2014, the Company began to base expected volatility on the historical volatility of its common stock, as adequate historical data regarding the volatility of its common stock price had become available.
The fair values of the stock-based awards, including the effect of estimated forfeitures, are then expensed over the requisite service period, which is generally the award’s vesting period. The Company classifies stock-based compensation expense in the consolidated statements of operations in the same manner in which the respective award recipient’s payroll costs are classified.
For stock-based awards granted to consultants and nonemployees, compensation expense is recognized over the period during which services are rendered by such consultants and nonemployees until completed. At the end of each financial reporting period prior to completion of the service, the value of these awards is re-measured using the then-current fair value of the Company’s common stock and updated assumption inputs in the Black-Scholes option pricing model.
For stock-based awards granted to employees under the 2010 Equity Incentive Plan (the “2010 Plan”), the Company allows employees to exercise certain awards prior to vesting. However, the employee may not sell or transfer these awards prior to vesting. For most of these awards, the Company has the right, but not the obligation, to repurchase any unvested (but issued) shares of common stock upon termination of employment or service at the lesser of (1) the original purchase price per share or (2) the fair value of the common share on the date of termination. If a stock option is early exercised in this circumstance, the consideration received for an exercise of an option is considered a deposit of the exercise price, and the related dollar amount is recorded as a liability. The unvested shares and liability are reclassified to equity as the award vests. The Company has 90 days from the effective termination of employment or service to repurchase unvested shares that are issued upon the exercise of a stock option prior to its vesting. If, after 90 days, the Company has elected not to repurchase the unvested shares, the shares would become vested in full. The Company would then apply modification accounting and any resulting compensation expense would be immediately recognized related to the award. Upon vesting, these shares would be considered issued and outstanding shares of common stock for accounting purposes.

In addition, the Company has granted restricted stock awards subject to repurchase to one employee, under which the Company has the right, but not the obligation, upon termination of the holder’s employment or service, to repurchase unvested shares at the greater of (1) the original purchase price per share or (2) the fair value of the common share on the date of termination (Note 16).

Comprehensive Loss

During 2014, there were differences between net loss and comprehensive loss. The Company includes foreign currency translation adjustments related to the translation of foreign subsidiaries’ balance sheets and unrealized holding gains and losses on available-for-sale securities in comprehensive loss. For the year ended December 31, 2013, there was no difference between net loss and comprehensive loss.
Net Loss Per Share
The Company follows the two-class method when computing net loss per share, as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.
The Company’s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Similarly, restricted stock awards granted by the Company entitle the holder of such awards to dividends declared or paid by the Board of Directors, regardless of whether such awards are unvested, as if such shares were outstanding common shares at the time of the dividend. However, the unvested restricted stock awards are not entitled to share in the residual net assets (deficit) of the Company. Accordingly, in periods in which the Company reports a net loss or a net loss attributable to common stockholders resulting from preferred stock dividends, accretion or modifications, net losses are not allocated to participating securities. The Company reported a net loss attributable to common stockholders in each of the years ended December 31, 2014, 2013 and 2012.
Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities, including outstanding stock options. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of shares of common stock, including potential dilutive shares of common stock assuming the dilutive effect of potentially dilutive securities. For periods in which the Company has reported net losses, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since their impact would be anti-dilutive to the calculation of net loss per share. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders for each of the years ended December 31, 2014, 2013 and 2012.
Concentration of Credit Risk and of Significant Suppliers and Customers
Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, short-term investments and accounts receivable. At December 31, 2014, the Company’s short-term investments included reverse repurchase agreements that are tri-party, have maturities of 90 days or less at the time of investment and the underlying collateral is U.S. government securities including U.S. treasuries, agency debt and agency mortgage securities. At December 31, 2014 and 2013, all of the Company’s fixed income marketable securities were invested in Certificates of Deposit (“CDs”) insured by the Federal Deposit Insurance Corporation (“FDIC”). The Company also generally maintains balances in various operating accounts in excess of federally insured limits at two accredited financial institutions. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.
The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients (“API”), and formulated drugs related to these programs. These programs would be adversely affected by a significant interruption in the supply of API.
Fair Value Measurements
Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, is used to measure fair value:
	·	Level 1—Quoted prices in active markets for identical assets or liabilities.
	·	Level 2—Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.
	·	Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.
Segment Data
The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company is a pet therapeutics company developing compounds to address unmet and under-served medical needs in companion animals. All assets were held in the United States and Belgium as of December 31, 2014.

Recently Issued and Adopted Accounting Pronouncements
Intangibles—Goodwill and Other: Testing Goodwill for Impairment: In September 2011 the Financial Accounting Standards Board (“FASB”) issued guidance that simplifies how an entity tests goodwill for impairment. This guidance allows an entity the option to first assess qualitative factors to determine whether it is necessary to perform the current two-step impairment test. If an entity believes, as a result the existence of its qualitative, events and circumstances indicates that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the quantitative two-step impairment test is required; otherwise, no further testing is required. This update does not change the current guidance for testing other indefinite-lived intangible assets for impairment. If an entity concludes that it is not more likely than not that the indefinite-lived intangible asset is impaired, then the entity is not required to take further action. However, if an entity concludes otherwise, then it is required to determine the fair value of the indefinite-lived intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying amount. An entity also has the option to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to performing the quantitative impairment test. An entity will be able to resume performing the qualitative assessment in any subsequent period. The adoption of this standard in 2014 resulted from the Company’s business combination and did not have any impact on the Company’s financial position, results of operations, comprehensive income or cash flows as the guidance did not apply be until the first year the Company completed a goodwill impairment test.

Revenue from Contracts with Customers

In May 2014, the Financial Accounting Standards Board (“FASB”) issued guidance on recognizing revenue in contracts with customers. The guidance affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). This guidance will supersede the revenue recognition requirements in topic, Revenue Recognition, and most industry-specific guidance. This guidance also supersedes some cost guidance included in subtopic, Revenue Recognition – Construction-Type and Production-Type Contracts. In addition, the existing requirements for the recognition of a gain or loss on the transfer of nonfinancial assets that are not in a contract with a customer (e.g., assets within the scope of topic, Property, Plant, and Equipment, and tangible assets within the scope of topic, Intangibles – Goodwill and Other) are amended to be consistent with the guidance on recognition and measurement (including the constraint on revenue) in this guidance. The Company does not expect that this guidance will have a material impact on its consolidated financial statements.

The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

These changes become effective for the Company on January 1, 2017 and early adoption is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is currently assessing the impact, if any, this new guidance will have on the Company’s financial condition, results of operations or cash flows.

Development Stage Entities — Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance, Consolidations

In June 2014, the FASB issued guidance that removes all incremental reporting requirements from GAAP for development stage entities, including the removal of the topic development stage entities. These changes eliminate the requirement to report inception-to-date information in the statements of income, cash flows, and shareholder equity. These changes become effective for the Company on January 1, 2015 and early adoption is permitted. The Company opted to adopt this guidance as of June 30, 2014. The adoption of this guidance resulted in decreased financial statement disclosures, but did not impact the Company’s financial condition, results of operations or cash flows.

Disclosure of Uncertainties about an Entities Ability to Continue as a Going Concern

In August 2014, the FASB issued guidance which requires management to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide disclosure in the footnotes under certain circumstances. This guidance is effective for fiscal years ending after December 15, 2016 with early adoption permitted. The Company does not expect that this guidance will have a material impact on its consolidated financial statements.

Fair_Value_Of_Financial_Assets

Fair Value Of Financial Assets And Liabilities	12 Months Ended
Fair Value Of Financial Assets And Liabilities	Dec. 31, 2014
Fair Value Of Financial Assets And Liabilities [Abstract]
Fair Value Of Financial Assets And Liabilities	4. Fair Value of Financial Assets and Liabilities
	Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
	As of December 31, 2014 and 2013 the following financial assets and liabilities are measured at fair value on a recurring basis using quoted prices in active markets for identical assets (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3).



						FAIR VALUE MEASUREMENTS AS OF
			CARRYING			DECEMBER 31, 2014 USING:
			VALUE			LEVEL 1		LEVEL 2			LEVEL 3		TOTAL
	Assets:
	Cash equivalents:
	Certificates of deposit		$	6,972		$	—	$	6,972		$	—	$	6,972
	Money market fund			45			—		45			—		45
	Short-term investments:
	Short-term marketable securities - Certificate of deposit			249			—		249			—		249
	Reverse repurchase agreements			88,000			—		88,000			—		88,000
	Long-term marketable securities:
	Common Stock			2,452			2,452		—			—		2,452
	Derivative financial instruments			1,108			—		1,108			—		1,108
			$	98,826		$	2,452	$	96,374		$	—	$	98,826
	Liabilities:
	Contingent consideration		$	4,248		$	—	$	—		$	4,248	$	4,248
			$	4,248		$	—	$	—		$	4,248	$	4,248




						FAIR VALUE MEASUREMENTS AS OF
			CARRYING			DECEMBER 31, 2013 USING:
			VALUE			LEVEL 1		LEVEL 2			LEVEL 3		TOTAL
	Assets:
	Short-term investments:
	Short-term marketable securities - Certificate of deposits		$	4,670		$	—	$	4,670		$	—	$	4,670
			$	4,670		$	—	$	4,670		$	—	$	4,670
	Liabilities:
	Contingent consideration(1)		$	4,115		$	—	$	—		$	4,115	$	4,115
			$	4,115		$	—	$	—		$	4,115	$	4,115
	__________________
		-1		Contingent consideration consists of current portion: $2,572 and long-term contingent consideration: $1,543 in the consolidated balance sheet.
	Certain estimates and judgments are required to develop the fair value amounts shown above. The fair value amounts shown above are not necessarily indicative of the amounts that the Company would realize upon disposition, nor do they indicate the Company’s intent or ability to dispose of the financial instrument.
	The following methods and assumptions were used to estimate the fair value of each material class of financial instrument:
		·		Cash equivalents – the fair value of the cash equivalents has been determined to be amortized cost.
		·		Reverse repurchase agreements – the fair value of reverse repurchase agreements has been determined to be amortized cost.
		·		Marketable securities (long-term) – the fair value of marketable securities has been based on quoted prices in active markets or exchanges for identical assets.
		·		Marketable securities (short-term) – the fair value of marketable securities has been estimated based on quoted prices in active markets prices for identical assets or for similar assets in markets that are not active.
		·		Derivative financial instruments – the fair value of the derivative instruments has been estimated using a modified Black-Scholes model. Inputs into the Black-Scholes model include interest rates, stock volatilities and dividend data.
		·		Contingent consideration – the fair value of the contingent consideration payable has been estimated using the income approach using a probability weighted discounted cash flow method. Inputs into the discounted cash flow method include the probability of and period in which the relevant milestone event is expected to be achieved and the discount rate to be applied in calculating the present values of the relevant milestones.
	Transfers Between Levels of the Fair Value Hierarchy
	Transfers between levels of the fair value hierarchy are reported at the beginning of the reporting period in which they occur. During the year ended December 31, 2014, transfer of investments between Level 1 and Level 2 were $2,452. In the third quarter of 2014, the Company re-classified its common stock investment in Advaxis (Note 14) to a Level 1 investment from Level 2, because the Company is no longer precluded from selling shares due to restrictions imposed by Rule 144 of the Securities Act of 1933. Previously, the Company calculated a lack of marketability discount on the fair value of the Advaxis common stock because of trading restrictions on the shares. The Company considered the inputs used to calculate the lack of marketability discount Level 2 inputs and, as a result, the Company classified this investment as Level 2. The Company determined the lack of marketability discount by using a Black-Scholes model to value a hypothetical put option to approximate the cost of hedging the stock until the restriction ended.
	During the year ended December 31, 2013, there were no transfers between levels of the fair value hierarchy.

	Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level 3)

	The change in the fair value of the Company’s contingent consideration payable, which is measured at fair value on a recurring basis using significant unobservable inputs (Level 3), is as follows:

	Contingent consideration


			2014			2013
	As of January 1,		$	4,115		$	—
	Initial recognition of contingent consideration payable			15,166			3,810
	Settlement of contingent consideration payable			-15,235			—
	Recognition of change in fair value in the consolidated statement of operations (within selling, general and administrative)			202			305
	As of December 31,		$	4,248		$	4,115

Quantitative Information about Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level 3)
Quantitative information about the Company’s recurring Level 3 fair value measurements is included below:
Financial liabilities:



		FAIR VALUE AT MEASUREMENT DATE
					Valuation		Significant			Weighted
At December 31, 2014		Fair value			technique		unobservable inputs	Range		average
Contingent consideration		$	4,248		Income approach (probability weighted discounted cash flow)		Probability of milestones being achieved	25.00% to 97.50%		68.43%
							Assumed market participant discount rate	5.50%
							Periods in which milestones are expected to be achieved	2015






		FAIR VALUE AT MEASUREMENT DATE
					Valuation		Significant			Weighted
At December 31, 2013		Fair value			technique		unobservable inputs	Range		average
Contingent consideration		$	4,115		Income approach (probability weighted discounted cash flow)		Probability of milestones being achieved	3.8% to 95.00%		71.44%
							Assumed market participant discount rate	5.50%
							Periods in which milestones are expected to be achieved	2014 to 2015


Contingent consideration payable represents the future amount the Company may be required to pay in conjunction with the Vet Therapeutics, Inc. acquisition in October 2013. The amount of contingent consideration which may ultimately be payable by the Company in relation to the Vet Therapeutics acquisition is dependent upon the achievement of specified future milestones, such as certain regulatory and manufacturing milestones for AT-004. The Company assesses the probability, and estimated timing, of these milestones being achieved and re-measures the related amounts of contingent consideration at each balance sheet date.

The fair value of the Company’s contingent consideration payable could significantly increase or decrease due to changes in certain assumptions which underpin the fair value measurements. Each set of assumptions and milestones are specific to the contingent consideration payable. The assumptions include, among other things, the probability and expected timing of certain milestones being achieved. The Company regularly reviews these assumptions, and makes adjustments to the fair value measurements as required by facts and circumstances.

On January 2, 2015 the Company was granted a full product license for AT-004. The approval resulted in $3,000 of the contingent consideration being earned and due to the former Vet Therapeutics shareholders per the terms of Vet Therapeutics merger agreement. Further, on February 24, 2015 in connection with the mutual termination of the NAH Agreement for AT-004, the Company obtained consent from the shareholder representative of the former Vet Therapeutics shareholders that the $3,000 payment shall cause the Company to have no further obligation or liability under the merger agreement. The Company paid the $3,000 contingent consideration in March 2015. During the first quarter of 2015, the Company will record a credit of $1,249 to reduce the fair value of the contingent consideration to zero as a result of the agreement with the Vet Therapeutics shareholders (Note 20).

Financial Assets and Liabilities that are not Measured at Fair Value on a Recurring Basis
The carrying amounts and estimated fair value as at December 31, 2014 of the Company’s financial assets and liabilities which are not measured at fair value on a recurring basis are as follows:



		31-Dec-14
		CARRYING VALUE			FAIR VALUE
Financial liabilities:
Loan payable (Level 2)		$	14,963		$	14,933




		31-Dec-13
		CARRYING VALUE			FAIR VALUE
Financial liabilities:
Loan payable (Level 2)		$	14,935		$	15,040
Certain estimates and judgments were required to develop the fair value amounts. The fair value amount shown above is not necessarily indicative of the amounts that the Company would realize upon disposition, nor do they indicate the Company’s intent or ability to dispose of the financial instrument.
The fair value of loan payable was estimated using discounted cash flow analysis discounted at current rates.

Investments

Investments	12 Months Ended
Investments	Dec. 31, 2014
Investments [Abstract]
Investments	5. Investments

	Marketable Securities
	As of December 31, 2014 and 2013, the fair value of available-for-sale marketable securities by type of security was as follows:



		31-Dec-14
				GROSS		GROSS
		AMORTIZED		UNREALIZED		UNREALIZED		FAIR
		COST		GAINS		LOSSES		VALUE
	Short-term marketable securities:
	Certificate of Deposit	$	249	$	—	$	—	$	249
	Long-term marketable securities:
	Common stock		1,200	$	1,252	$	—	$	2,452
	Total	$	1,449	$	1,252	$	—	$	2,701

	At December 31, 2014, unrealized gains in the amount of $1,252 were recorded as a component of other comprehensive loss.



		31-Dec-13
				GROSS		GROSS
		AMORTIZED		UNREALIZED		UNREALIZED		FAIR
		COST		GAINS		LOSSES		VALUE
	Short-term marketable securities:
	Certificates of deposit	$	4,670	$	—	$	—	$	4,670
	Total	$	4,670	$	—	$	—	$	4,670

	At December 31, 2014 and 2013, short-term marketable securities consisted of investments that mature within one year. Short-term marketable securities are recorded as short-term investments in the consolidated balance sheets.

	Reverse Repurchase Agreements
	The Company, as part of its cash management strategy, may invest excess cash in reverse repurchase agreements. All reverse repurchase agreements are tri-party and have maturities of 90 days or less at the time of investment. The underlying collateral is U.S. government securities including U.S. treasuries, agency debt and agency mortgage securities. The underlying collateral posted by each counterparty is required to cover 102% of the principal amount and accrued interest after the application of a discount to fair value.

Receivable_From_Stockholder

Receivable From Stockholder	12 Months Ended
	Dec. 31, 2014
Receivable From Stockholder [Abstract]
Receivable From Stockholder	6. Receivable from Stockholder
	At December 31, 2014 and 2013, receivable from stockholder consisted of the following:




		DECEMBER 31,		DECEMBER 31,
		2014		2013
	Receivable from stockholder	$	—	$	1,001
	The receivable from stockholder as of December 31, 2013, arose from the Vet Therapeutics, Inc. acquisition. In conjunction with the payment of the initial closing considerations of the acquisition, a former Vet Therapeutics, Inc. equity and option shareholder, who subsequently became a Company employee, was paid $1,001 in excess of the initial closing current consideration due to the individual. The entire amount has been remitted back to the Company.

Inventories

Inventories	12 Months Ended
Inventories	Dec. 31, 2014
Inventories [Abstract]
Inventories	7. Inventories

	Inventories are stated at the lower of cost or market and are comprised of the following:




		DECEMBER 31,		DECEMBER 31,
		2014		2013
	Raw materials	$	115		—
	Work-in-process		206	$	55
	Finished goods		106		—
		$	427	$	55

Property_And_Equipment_Net

Property And Equipment, Net	12 Months Ended
Property And Equipment, Net	Dec. 31, 2014
Property And Equipment, Net [Abstract]
Property And Equipment, Net	8. Property and Equipment, Net
	Property and equipment consisted of the following:



		DECEMBER 31,		DECEMBER 31,
		2014		2013
	Laboratory and office equipment	$	478	$	90
	Computer equipment and software		68		40
	Furniture		71		2
	Vehicles		34		—
	Leasehold improvements		102		—
	Construction in process		49		7
	Total property and equipment		802		139
	Less: Accumulated depreciation and amortization		-182		-41
	Property and equipment, net	$	620	$	98
	Depreciation expense was $152, $16, and $13 for the years ended December 31, 2014, 2013 and 2012, respectively. During the year ended December 31, 2014, $53 in assets were sold for a $1 loss. No gain/loss was recognized during the year ended December 31, 2013.

Goodwill

Goodwill	12 Months Ended
Goodwill	Dec. 31, 2014
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	9. Goodwill

	In 2013, the Company completed its acquisition of Vet Therapeutics (Note 20). The fair value of consideration exceeded the fair value of assets and liabilities acquired, which resulted in goodwill of $25,646 (see Note 20). In January 2014, the Company completed its acquisition of Okapi Sciences. The fair value of consideration exceeded the fair value of assets and liabilities acquired which resulted in goodwill of $17,909.

	Goodwill is recorded as an indefinite-lived asset and is not amortized for financial reporting purposes but is tested for impairment on an annual basis or when indications of impairment exist. No goodwill impairment losses have been recognized. Goodwill is not expected to be deductible for income tax purposes. The Company performs its annual impairment test of the carrying value of the Company’s goodwill during the third quarter of each year.

	The following is a summary of goodwill as of December 31, 2014:



		GROSS		IMPAIRMENT		NET
		CARRYING AMOUNT		LOSSES		CARRYING VALUE
	Goodwill	$	41,398	$	—	$	41,398
	The change in the net book value of goodwill for the year ended December 31, 2014, is shown in the table below:




		2014		2013
				(As Restated)
	As of January 1,	$	25,646	$	—
	Acquisition		17,909		25,646
	Effect of foreign currency exchange		-2,157		—
	As of December 31,	$	41,398	$	25,646

Intangible_Assets_Net

Intangible Assets, Net	12 Months Ended
Intangible Assets, Net	Dec. 31, 2014
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets, Net	10. Intangible Assets, Net

	In January 2014, the Company completed its acquisition of Okapi Sciences (Note 20). The Company acquired certain identifiable intangible assets related to Okapi Sciences’ technology.

	The following is a summary of unamortized intangible assets:



		GROSS
		CARRYING
	Unamortized intangible assets:	VALUE

	Intellectual property rights acquired for IPR&D	$	25,860

	The following is a summary of amortized intangible assets:



		GROSS				NET		WEIGHTED
		CARRYING		ACCUMULATED		CARRYING		AVERAGE
	Amortized intangible assets:	VALUE		AMORTIZATION		VALUE		USEFUL LIFE
	Intellectual property rights for currently marketed products:
	AT-004	$	28,572	$	1,726	$	26,846	20	Years
	AT-005(1)	$	10,080	$	462	$	9,618	20	Years

	(1) AT-005 received a conditional license in early 2014 which initiated amortization for this intangible.
	The change in the net book value of other intangible assets is shown in the table below:



		2014		2013
				(As Restated)
	As of January 1,	$	38,354	$	—
	Acquisitions		29,400		38,652
	Amortization charged		-1,891		-298
	Effect of foreign currency exchange		-3,540		—
	As of December 31,	$	62,323	$	38,354
	The estimated useful lives of the individual categories of intangible assets were based on the nature of the applicable intangible asset and the expected future cash flows to be derived from the intangible asset. Amortization of intangible assets with finite lives is recognized over the shorter of the respective lives of the agreement or the period of time the intangible assets are expected to contribute to future cash flows. The Company amortizes finite-lived intangible assets using the straight-line method. Amortization of intangible assets for the year ended December 31, 2014 amounted to $1,891. Indefinite-lived IPR&D intangible assets are not amortized until a product reaches its first conditional license or approval, then it is amortized over their estimated useful life.
	The following is a summary of estimated aggregate amortization expense of intangible assets for each of the five succeeding years as of December 31, 2014:









	YEAR ENDING DECEMBER 31,
	2015	$	1,933
	2016		1,933
	2017		1,933
	2018		1,933
	2019		1,933

	On February 24, 2015 the Company and Elanco mutually terminated the NAH Agreement (Note 14). Due to the termination, the Company became responsible for all commercial and manufacturing activities associated with AT-004 beginning in 2015. Therefore, the Company conducted an impairment assessment and concluded that the AT-004 intangible asset was not impaired. The assessment included re-launching the product in the second half of 2015, as well as manufacturing expenses, technology royalties, post-approval studies, marketing, and selling expenses to commercialize the product.

Derivative_Financial_Instrumen

Derivative Financial Instruments	12 Months Ended
Derivative Financial Instruments	Dec. 31, 2014
Derivative Financial Instruments [Abstract]
Derivative Financial Instruments	11. Derivative Financial Instruments

	The Company records all derivatives in the consolidated balance sheets at fair value in the other long-term assets. In 2014, the Company’s derivative financial instrument is not designated as a hedging instrument and is adjusted to fair value through earnings in the other income (expense).

	The following table shows the Company’s derivative instrument at gross fair value:




		FAIR VALUE OF DERIVATIVES NOT
		DESIGNATED AS HEDGE INSTRUMENT
		31-Dec-14			31-Dec-13
	Derivative assets:
	Warrant (Notes 4 and 14)	$	1,108		$	—

	The following table shows the gain recognized in other income (expense):





		GAIN RECOGNIZED IN
		OTHER INCOME
		YEAR ENDED
		DECEMBER 31,
		2014			2013
	Derivative assets:
	Warrant	$	465		$	—

	The following table shows the notional principal amounts of the Company’s outstanding derivative instruments and credit risk amounts associated with outstanding or unsettled derivative instruments as of December 31, 2014:




		31-Dec-14
		NOTIONAL/		CREDIT
		PRINCIPAL/SHARES		RISK
	Instruments not designated as hedging instruments:
	Warrant	153,061		$	476


	The notional principal shares amounts for outstanding derivative instruments provide one measure of the transaction volume outstanding and do not represent the amount of the Company’s exposure to credit or market loss. The credit risk amount represents the Company’s gross exposure to potential accounting loss on derivative instruments that are outstanding or unsettled if all counterparties failed to perform according to the terms of the contract, based on then-current market prices at each respective date.

Debt

Debt	12 Months Ended
	Dec. 31, 2014
Debt [Abstract]
Debt	12. Debt

	Converted Loans

	On March 4, 2013, the Company entered into a Credit Facility (the “Credit Facility”) with Square 1 Bank (“Square 1”) as lender. The Credit Facility provided for an initial term loan of $5,000 in principal (the “Initial Term Loan”) and additional term loans not to exceed $5,000 in principal, with total borrowings not to exceed $10,000. On October 11, 2013, the Company and Vet Therapeutics entered into an amendment of the Credit Facility (the “Credit Facility Amendment”), which, among other things, increased the amount that remained available for the Company to draw by an additional $5,000, to a total of $10,000 (the “Additional Term Loan”). Simultaneously with the closing of the Credit Facility Amendment on October 11, 2013, the Company borrowed the total $10,000 available, and upon consummation of the merger with Vet Therapeutics, Vet Therapeutics became a co-borrower under the Credit Facility.

	On June 13, 2014, the Company and Vet Therapeutics entered into an additional amendment of the Credit Facility (the “Second Credit Facility Amendment”), which, among other things, converted $15,000 in outstanding term loans under the Credit Facility into non-revolving loans (the “Converted Loans”) and modified certain terms and conditions of the loans, including fixing the interest rate at a fixed annual rate of 5.50%. The Company is obligated to make interest-only payments on any loans funded under the Credit Facility until June 13, 2016, on which date all amounts owed with respect to such non-revolving term loans will be due. If the Company and Vet Therapeutics remain in compliance with the terms of the Credit Facility through June 13, 2016 and Square 1, and the Company and Vet Therapeutics mutually agree to the structure of the financial covenants going forward, the Company and Vet Therapeutics shall have the option (subject to Square 1’s agreement to such financial covenant structure) to amortize the principal amount of the loans under the Credit Facility starting on June 13, 2016. If the Company and Vet Therapeutics elect to amortize the principal amount of the loans under the Credit Facility on June 13, 2016 (subject to Square 1’s agreement to financial covenant structure going forward), the principal amount of the loans shall be payable in 24 equal monthly installments of principal, plus all accrued but unpaid interest, beginning on the date that is one month immediately following June 13, 2016.

	On the issuance date of March 4, 2013, the Initial Term Loan was recorded in the consolidated balance sheet, net of discount of $73, related to fees assessed by the lender at the time of borrowing. The additional $13 of fees assessed by Square 1 in connection with the Second Credit Facility Agreement were capitalized and will be recognized over the term of the loan as the amendment was determined to be a debt modification. The carrying value of this debt is being accreted to the principal amount of the debt by charges to interest expense using the effective-interest method over the two-year term of the Converted Loans to the maturity date of June 13, 2016. At December 31, 2014, the debt discount balance totaled $39. Accretion amounts recognized as interest expense for the year ended December 31, 2014, were $41.

	Estimated future principal payments under the Credit Facility, as amended are as follows:



	YEARS ENDING DECEMBER 31,
	2015	$	—
	2016		15,000
	2017		—
	2018		—
	2019		—
	Thereafter		—
	Total	$	15,000

	During the years ended December 31, 2014 and 2013, the Company recognized $875 and $357 of interest expense related to the Credit Facility, respectively.

	Promissory Note

	In connection with the acquisition of Vet Therapeutics, the Company executed a promissory note in the principal amount of $3,000 with a maturity date of December 31, 2014. The promissory note bore interest at a rate of 7% per annum, payable quarterly in arrears, and was subject to prepayment in the event of specified future equity financings by the Company. On February 4, 2014, the promissory note and accrued interest of $20 was paid by the Company.

Accrued_Expenses_Other_Current

Accrued Expenses, Other Current Liabilities And Other Long-Term Liabilities	12 Months Ended
	Dec. 31, 2014
Accrued Expenses, Other Current Liabilities And Other Long-Term Liabilities [Abstract]
Accrued Expenses, Other Current Liabilities And Other Long-Term Liabilities	13. Accrued Expenses, Other Current Liabilities and Other Long-Term Liabilities
	Accrued expenses, other current liabilities and other long-term liabilities consisted of the following:




		DECEMBER 31,		DECEMBER 31,
		2014		2013
	Accrued expenses:
	Accrued payroll and related expenses	$	2,017	$	1,017
	Accrued professional fees		429		600
	Accrued royalty expense		72		70
	Accrued interest expense		41		71
	Accrued research and development costs		663		662
	Accrued other		7		75
		$	3,229	$	2,495

	Other current liabilities:
	Early exercise of stock-based awards	$	46	$	57
		$	46	$	57

	Other long-term liabilities:
	Early exercise of stock-based awards	$	30	$	75
		$	30	$	75

Agreements

Agreements	12 Months Ended
Agreements	Dec. 31, 2014
Agreements [Abstract]
Agreements	14. Agreements
	RaQualia Pharma Inc. (“RaQualia”)
	On December 27, 2010, the Company entered into two Exclusive License Agreements with RaQualia (the “RaQualia Agreements”), that granted the Company global rights, subject to certain exceptions for injectables in Japan, Korea, China and Taiwan for development and commercialization of licensed animal health products for compounds RQ-00000005 (AT-002) and RQ-00000007 (AT-001). The transaction was accounted for as a purchase of assets, as the acquired assets did not constitute a business under the guidance of ASC 805, Business Combinations. The Company paid cash to RaQualia as consideration for the technology licenses for AT-001 and AT-002 and will be required to pay RaQualia milestone payments associated with AT-001 and AT-002 of up to $10,000 and $8,500, respectively, upon the Company’s achievement of certain development and regulatory milestones, as well as mid-single digit royalties on the Company’s product sales, if any. As of December 31, 2014 and December 31, 2013, the Company had not accrued or paid any milestone or royalty payments since execution of the RaQualia Agreements.
	The Company does not expect to achieve any additional milestones related to the RaQualia Agreements within the next twelve months.
	On July 12, 2012, the Company entered into an API Development Agreement with RaQualia (the “RaQualia API Agreement”) to develop the active pharmaceutical ingredient in relation to compound RQ-00000007 (AT-001). Under the terms of the RaQualia API Agreement, RaQualia was required to pay $800 to the Company upon execution of the agreement. The Company was also eligible to receive another $800 payment for the successful development and delivery of the API to RaQualia. The Company delivered the API to RaQualia during the fourth quarter of 2014. In October 2014, the Company received notice that API delivered to RaQualia was accepted. Per the terms of the AT-001 RaQualia Agreement, the Company was entitled to an $800 payment for the successful development and delivery of the API to RaQualia. The Company recognized $1,600 in other income, consisting of the $800 deferred income related to the payment received at execution and the $800 payment from RaQualia based on the successful delivery during the fourth quarter of 2014.
	Pacira Pharmaceuticals, Inc. (“Pacira”)
	On December 5, 2012, the Company entered into an Exclusive License, Development, and Commercialization Agreement with Pacira (the “Pacira Agreement”) that granted the Company global rights for development and commercialization of licensed animal health products for a bupivacaine liposome injectable suspension for the treatment of post-operative pain. Under the terms of the Pacira Agreement, the Company paid an initial license fee of $1,000. On the date of acquisition, the licensed technology had not reached technological feasibility in animal health indications and had no alternative future use in the field of animal health. Accordingly, in-process research and development of $1,000 was expensed upon acquisition. The Company will be required to pay Pacira milestone payments of up to $42,500 upon the Company’s achievement of certain regulatory and commercial milestones, as well as tiered royalties on the Company’s product sales, if any. Under the terms of the agreement, a $500 milestone payment was payable upon the earlier of the dosing of the first client-owned animal in a clinical field trial or December 31, 2013. As this milestone payment was due on December 31, 2013, even if a dosing had not then commenced, it was considered to be a time-based milestone payment. Accordingly, this milestone payment was considered to be a portion of the minimum consideration paid for the acquisition of the AT-003 license and, as such, was accrued upon the execution of the Pacira Agreement. During 2013, the Company paid the $500 milestone payment.
	The Company does not expect to achieve additional milestones related to the Pacira Agreement within the next twelve months.
	Alere Inc. (“Alere”) (formerly Inverness Medical Innovations, Inc.)
	On April 2, 2009, Vet Therapeutics entered into a Collaboration Agreement with Alere (the “Alere Agreement”) to develop monoclonal antibodies for canine CD20, a B-lymphocyte antigen and canine CD52, a CAMPATH-1 antigen. The Company is required to pay low to mid-single digit royalties on net product sales allocable to the collaboration’s monoclonal antibody targets, if any. During each of the years ended December 31, 2014 and December 31, 2013, the Company had recognized $1 in royalty expense related to the Alere Agreement. This agreement applies to AT-004, AT-005 and would apply to any other products that would utilize the technology.
	Crucell Holland B.V. (“Crucell”)
	On April 2, 2013, Vet Therapeutics entered into a Commercial License Agreement with Crucell (the “Crucell Commercial Agreement”), under which the Company received a commercial license to prepare recombinant antibodies. The Company is required to pay single digit royalties on net product sales by the Company allocable to Crucell’s producer cells and/or producer cell know-how, if any. The Company is required to pay Crucell a minimum royalty of $70 that is subject to a yearly inflation index adjustment. The Company may also be required to pay up to $405 in sales milestone payments, based on future sales of certain products. No accrual has been made for the milestone payments as sales milestone levels have not been achieved. During the year ended December 31, 2014, the Company had recognized $72 in royalty expense which includes the accrued the minimum royalty of $70 related to the Crucell Commercial Agreement. This agreement applies to AT-004, AT-005 and would apply to any other products that would utilize the technology.
	Elanco Animal Health, Inc. (“Elanco”) (formerly Novartis Animal Health, Inc. “NAH”)
	On December 6, 2012, Vet Therapeutics entered into an Exclusive Commercial License Agreement with NAH (the “NAH Agreement”), under which Vet Therapeutics granted a commercial license to NAH for AT-004 for the United States and Canada. Vet Therapeutics received an upfront nonrefundable payment in the amount of $2,000 and another $2,000 for obtaining a Conditional License for AT-004. Under this agreement the Company was entitled to another $5,000 upon the achievement of various regulatory and development milestones. As of December 31, 2014 these milestones had not been achieved. In addition, the Company would receive tiered royalties based on future net sales of AT-004 by NAH. The Company was responsible for the manufacturing of AT-004 until the successful transfer of the manufacturing technology to NAH’s chosen manufacturer. Product sold to NAH was provided for cost plus an agreed upon margin.

	On January 2, 2015 the Company was granted a full product license from the USDA for AT-004. The approval resulted in a $3,000 milestone being earned and due to the Company per the terms of the NAH Agreement. During the first quarter of 2015, the Company will recognize $3,000 of licensing revenue related to the milestone payment.

	On February 24, 2015 the Company and Elanco agreed to terminate the NAH Agreement. In consideration for the return of the commercial license granted to NAH, the Company paid Elanco $2,500 in March of 2015, and will be required to pay an additional $500 upon the first commercial sale by the Company. The Company has determined that it is probable that the $500 payment will be paid and will record the $500 as a current liability in the first quarter of 2015, as the Company believes the first commercial sale will occur in the second half of 2015. The Company will record the $3,000 payable to NAH as a reduction in revenue in the first quarter which will offset the $3,000 milestone payment NAH will make to the Company.

	On August 21, 2013, Okapi Sciences entered into an Exclusive License, Development, and Commercialization Agreement with Elanco (the “Elanco AT-006 Agreement”) that granted Elanco global rights for development and commercialization of licensed animal health products for an anti-viral for the treatment of feline herpes virus induced ophthalmic conditions. As a result of the Company’s acquisition of Okapi Sciences, the Company has assumed the rights and obligations under this agreement. The Company is responsible for the development and obtaining regulatory approval of AT-006 and Elanco is responsible for the commercialization. The Company will be entitled to receive from Elanco milestone payments of up to €7,500 upon Aratana’s achievement of certain regulatory milestones and Elanco achievement of certain commercial milestones, as well as tiered royalties on Elanco’s product sales, if any. The Company is entitled to receive from Elanco up to $2,500 in reimbursement for development expenses, unless additional monies are approved by the joint steering committee. As of the acquisition date, Okapi Sciences had incurred $930 of development expenses. The remaining funding of up to $1,570 will be recognized as revenue as development expenses are incurred by the Company and all revenue recognition criteria are met.

	During the year ended December 31, 2014, the Company recognized $452 of research and development services revenue related to the Elanco AT-006 Agreement. As of December 31, 2014, the Company had not accrued or received any milestone or royalty payments since execution of the Elanco AT-006 Agreement.
	Kansas Bioscience Authority (“KBA”) Programs
	On March 6, 2012, the Company was awarded a research and development grant from KBA, a non-principal owner independent entity of the State of Kansas, which could provide up to $1,333 in research and development funding to the Company over a period of approximately two years. The grant will support pre-formulation, formulation, manufacture and pivotal studies of the Company’s first two companion animal development programs, AT-001 and AT-002. The grant has an initial term of approximately 24 months ending on March 31, 2014. The Company recognizes funding received under this grant in other income in the consolidated statements of operations when payment is received from KBA. During the year ended December 31, 2014, the Company recognized income from the KBA research and development grant of $62. The Company received $641 during the life of the agreement. During the year-ended December 31, 2013, the Company recognized income of $478 under this grant and during the year-ended December 31, 2012, the Company recognized income of $100.
	Further, in private offerings the Company conducted in December 2010, November 2011, February 2012 and January 2013, the Company issued to the KBA shares of convertible preferred stock in exchange for aggregate proceeds of approximately $1,300. Such shares have subsequently converted to common stock.
	Pursuant to Kansas law, the Company may be required to repay any financial assistance received from the KBA, which may include an obligation to repurchase the shares of its capital stock purchased by the KBA, subject to the discretion of the KBA, if the Company relocates the operations in which the KBA invested outside of the State of Kansas within ten years after receiving such financial assistance. Further, pursuant to the agreement accompanying the voucher award, the KBA may terminate the agreement and require the Company to repay the grant if it initiates procedures to dissolve and wind up or if it ceases operations within the State of Kansas within 10 years following the final grant payment. The Company has determined these contingencies to be within its control and will only account for the repayment of the equity and grant if it becomes probable that the Company is going to relocate the operations in which the KBA invested outside of the State of Kansas within the ten-year period or for the repayment of only the grant if it becomes probable that the Company is going to initiate procedures to dissolve and wind up or cease operations within the State of Kansas within the ten-year period.

	Advaxis Inc. (“Advaxis”)

	On March 19, 2014, the Company entered into an Exclusive License Agreement with Advaxis (the “Advaxis Agreement”) that granted the Company containing the active pharmaceutical ingredient exclusive global rights for development and commercialization of certain animal health products for Advaxis’ included in ADXS-cHER2 product in animal health applications. The Company is developing this product for the treatment of osteosarcoma in dogs (“AT-014”) as well as three additional cancer immunotherapy products for the treatment of three other types of cancer. Under the terms of the Advaxis Agreement, the Company paid $2,500 in exchange for the license, 306,122 shares of common stock, and a warrant to purchase 153,061 shares of common stock. The consideration was allocated to the common stock and warrant based on their fair values on the date of issuance of $1,200 and $643, respectively. The remaining consideration of $657 was allocated to the licensed technology. On the date of acquisition, the licensed technology had not reached technological feasibility in animal health indications and had no alternative future use in the field of animal health. Accordingly, in-process research and development of $657 was expensed upon acquisition. The Company will be required to pay Advaxis milestone payments of up to an additional $6,000 in clinical and regulatory milestones for each of the four products, assuming approvals in both cats and dogs, in both the United States and the European Union. In addition, the Company agreed to pay up to $28,500 in commercial milestones, as well as tiered royalties ranging from mid-single digit to 10% on the Company’s product sales, if any.

	The Company does not expect to achieve additional milestones related to the Advaxis Agreement within the next twelve months.

	Under the terms of the subscription agreement, the Company acquired 306,122 shares of common stock and a warrant to purchase another 153,061 shares of common stock for $1,843. The warrant is exercisable through March 19, 2024, at an exercise price of $4.90 per share of common stock and is to be settled through physical share issuance or net share settlement where the total number of issued shares is based on the amount the market price of common stock exceeds the exercise price of $4.90 on date of exercise. Neither the common stock nor warrant have registration rights. The Company allocated the consideration of $1,843 to Advaxis common stock ($1,200) and the Advaxis warrant ($643) based on their respective fair values and recorded the purchase in marketable securities and other long-term assets, respectively. See Note 4 for subsequent fair value matters related to the Advaxis common stock and warrant.

	In January 2015, Aratana sold 124,971 shares of Advaxis common stock for proceeds of $1,500.

	Vet-Stem, Inc. (“Vet-Stem”)

	On June 12, 2014, the Company entered into an Exclusive License Agreement with Vet-Stem (the “Vet-Stem Agreement”) that granted the Company the exclusive United States rights for commercialization and development of Vet-Stem’s allogeneic stem cells being developed for the treatment of pain and inflammation of canine osteoarthritis (“AT-016”). Vet-Stem is responsible for the development and obtaining regulatory approval of AT-016 and the Company is responsible for the commercialization of licensed products. Under the terms of the Vet-Stem Agreement, the Company paid an initial license fee of $500. On the date of acquisition, the licensed technology had not reached technological feasibility in animal health indications and had no alternative future use in the field of animal health.

	Accordingly, in-process research and development of $500 was expensed upon acquisition. The Company will be required to pay Vet-Stem milestone payments of up to $4,500 upon Vet-Stem’s achievement of certain development and regulatory milestones, as well as tiered royalties in the low double digit percentages on the Company’s product sales, if any. The Company could be required to pay to Vet-Stem up to $3,600 in reimbursement for development expenses, unless additional monies are approved by the joint steering committee.

	The Company expects Vet-Stem to achieve multiple development and regulatory milestones related to the Vet-Stem Agreement within the next twelve months.

	Atopix Therapeutics Ltd.

	On October 10, 2014, the Company entered into an Exclusive License Agreement with Atopix (the “Atopix Agreement”) that granted the Company an exclusive global license for development and commercialization of animal health products containing the active pharmaceutical ingredient included in Atopix’s CRTH2 antagonist product for the treatment of atopic dermatitis (“AT-018”). Under the terms of the Atopix Agreement, the Company paid an initial license fee of $1,000. On the date of acquisition, the licensed technology had not reached technological feasibility in animal health indications and had no alternative future use in the field of animal health. Accordingly, in-process research and development of $1,000 was expensed upon acquisition. The Company will be required to pay Atopix milestone payments of up to an additional $4,500 in clinical and regulatory milestones, assuming approvals in both cats and dogs, in both the United States and the European Union, as well as tiered royalties in the mid-single digits on the Company’s product sales, if any.

	The Company does not expect to achieve additional milestones related to the Atopix Agreement within the next twelve months.
	Exclusive Option Programs
	The Company’s business model is to identify innovative proprietary compounds from human biopharmaceutical companies and to develop these product candidates into regulatory-approved therapeutics specifically for use in pets. To this end, the Company has developed a process in which, in exchange for a fee, it enters into a time-limited option agreement (the “Exclusive Option Program”) with a biopharmaceutical company (the “Potential Licensor”). During the option period the Company obtains from the Potential Licensor the data and information necessary to perform studies to evaluate the compound. Once the Company has evaluated the compound, it can choose to either terminate the Exclusive Option Program with no further obligation, or exercise the option to enter into an exclusive, worldwide license agreement (the “License Agreement”) to develop and commercialize products for non-human animal health applications. The fee associated with the Exclusive Option Program is generally non-refundable and non-creditable.
	The principal terms of the License Agreement, if entered into by the Company, will generally consist of an exclusive, world-wide license to all non-human animal health applications in exchange for an upfront license fee, milestone payments upon the achievement of certain regulatory milestones, as well as royalties on sales.
	No Exclusive Option Programs were entered into during the year ended December 31, 2014.
	In January 2014, one of the option periods expired and the Company elected not to opt-in to the License Agreement via exercise of the option or extend the option period.

	During June 2014, the Company entered into an amendment to extend the option with a third party for a molecule to treat seizures in dogs (“AT-Beta”) for an additional 12 months in exchange for a non-refundable, non-creditable extension fee which was charged to expense.

	During the years ended December 31, 2014 and December 31, 2013, the Company recognized expenses of $307 and $915, respectively, due to these exclusive option programs as Research and development expense.

Preferred_Stock

Preferred Stock

12 Months Ended

Dec. 31, 2014

Equity [Abstract]

Preferred Stock

15. Preferred Stock

As of December 31, 2014 and 2013, there were no preferred shares outstanding. The Company’s Certificate of Incorporation, as amended on July 2, 2013, authorizes the Company to issue 10,000,000 shares of $0.001 par value preferred stock. The Company’s Board of Directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of one or more series of preferred stock

As of December 31, 2012, the Company had issued Series A, Series A-1, Series B, and Series C convertible preferred stock (collectively, the “Preferred Stock) having various rights and privileges pertaining to cumulative and noncumulative dividends, voting, liquidation and redemption.

Preferred Stock consisted of the following as of December 31, 2012:

PREFERRED

COMMON

PREFERRED

STOCK

ISSUED AND

LIQUIDATION

CARRYING

ISSUABLE UPON

AUTHORIZED

OUTSTANDING

PREFERENCE

VALUE

CONVERSION

Series A convertible preferred stock

10,000,000

9,999,999

11,674

9,951

6,016,849

Series A-1 convertible preferred stock

2,750,000

5,500

4,662

1,654,632

Series B convertible preferred stock

5,166,667

5,141,667

16,691

15,241

3,093,655

Series C convertible preferred stock

3,000,000

2,349,541

9,404

9,343

1,413,671

20,916,667

20,241,207

43,269

39,197

12,178,807

In February 2013, the Board of Directors of the Company approved an amendment of the Company’s Certificate of Incorporation. The amendment to the Certificate of Incorporation increased the number of authorized shares of Series C Preferred Stock to 3,050,000 and decreased the number of authorized shares of Series B Preferred Stock to 5,141,667.

On June 26, 2013, the holders of at least seventy-five percent of the then-outstanding shares of Series A Preferred Stock elected and consented to the automatic conversion of each outstanding share of Preferred Stock into shares of common stock immediately prior to the consummation of the public offering contemplated by the Company’s Registration Statement on Form S-1 (No. 333-187372).

Immediately prior to the consummation of the initial public offering, all shares of the Company’s then-outstanding convertible preferred stock and accumulated dividends automatically converted into an aggregate of 13,351,902 shares of common stock, inclusive of accumulated dividends.

Issuances

Through December 31, 2012, the Company had issued 15,320,832 shares of Series A, A-1, B and C Preferred Stock. On February 15, 2012, the Company issued 2,570,834 shares of the Series B Preferred Stock (“Series B Preferred Stock”) at an issuance price of $3.00 and received gross proceeds of $7,712. In connection with the 2012 Series B Preferred Stock financing, the Company paid issuance costs totaling $13.

In 2012, the Company issued 2,349,541 shares of Series C convertible preferred stock (the “Series C Preferred Stock”) at an issuance price of $4.00 per share and received gross proceeds of $9,398. In connection with the Series C Preferred Stock financing, the Company paid issuance costs totaling $55.

In 2013, the Company issued 693,571 shares of Series C Preferred Stock at a purchase price of $4.00 per share for gross proceeds of $2,774. In connection with the Series C Preferred Stock financing, the Company paid issuance costs totaling $9.

On May 22, 2013, the Company effected a 1-for-1.662 reverse stock split of its issued and outstanding shares of common stock and a proportional adjustment to the conversion ratio for each series of Convertible Preferred Stock (Note 16). Accordingly, all share and per share amounts for all periods presented in these consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the reverse stock split and adjustment of the preferred share conversion ratios.

Issuance costs incurred in the Series A, Series A-1, Series B and Series C Preferred Stock financings were recorded as a reduction to gross proceeds.

Conversion Rights

Optional Conversion

The shares of Series A, Series A-1, Series B and Series C Preferred Stock were convertible into shares of common stock at the option of the shareholders at any time after the date of issuance. Each share of Preferred Stock would be converted into shares of common stock at the applicable Series A, Series A-1, Series B and Series C conversion rate then in effect, which is calculated by dividing the original issue price by the respective conversion price. The conversion prices for Series A, Series A-1, Series B and Series C Preferred Stock was equal to $1.662 per share, $3.324 per share, $4.986 per share and $6.648 per share, respectively, and was subject to adjustments as set forth in the Company’s Certificate of Incorporation, as amended. As such, as of December 31, 2012, the shares of the Series A, Series A-1, Series B and Series C Preferred Stock were all convertible into shares of common stock on a 1-for-0.601685 basis.

Automatic Conversion

Each share of Preferred Stock would automatically be converted into shares of common stock: (i) at any time upon the affirmative election of the holders of at least 75% of the then-outstanding shares of Series A Preferred Stock, or (ii) immediately upon closing of an underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, covering the offer and sale of common stock on the NASDAQ Global Market or New York Stock Exchange in which (1) the per share price is at least $9.00 (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like) and (2) the aggregate offering proceeds from the offering are at least $40,000. The conversion prices and rates for each series of Preferred Stock were the same in the event of an automatic conversion as they would have been in the event of an optional conversion.

Upon both an automatic conversion and an optional conversion, the Board of Directors could have elected to either pay any accumulated and unpaid dividends in cash or convert those dividends into additional shares of common stock to be determined by dividing each stockholder’s accumulated and unpaid dividends by the fair value of the Company’s common stock on the date of conversion, as determined by the Board of Directors.

Redemption Rights

There were no redemption rights afforded the holders of Series A, Series A-1, Series B and Series C Preferred Stock. The holders of Preferred Stock had liquidation rights in the event of a deemed liquidation that, in certain situations, was not solely within the control of the Company. Therefore, the Series A, Series A-1, Series B and Series C Preferred Stock were classified outside of stockholders’ deficit.

Common_Stock

Common Stock	12 Months Ended
Common Stock	Dec. 31, 2014
Equity [Abstract]
Common Stock	16. Common Stock

	As of December 31, 2014, there were 34,147,861 shares of the Company’s common stock outstanding, net of 561,651 shares of unvested restricted common stock. As of December 31, 2013, there were 23,425,487 shares of the Company’s common stock outstanding, net of 672,251 shares of unvested restricted common stock.
	Authorized Common Stock
	In February 2013, the Board of Directors of the Company approved an amendment of the Company’s Certificate of Incorporation and increased the number of authorized shares of common stock to 25,041,667. On July 2, 2013, the Company increased the number of authorized shares of its common stock from 25,041,667 to 100,000,000, par value $0.001 per share.
	Voting Rights
	Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the Board of Directors, if any. As of December 31, 2014 and 2013, the Board of Directors had not declared any dividends in any period.
	Stock-Based Awards
	During the year ended December 31, 2013, the Company issued common stock pursuant to the 2010 Equity Incentive Plan (Note 17) and the 2013 Incentive Award Plan (Note 17). During the years ended December 31, 2014, and December 31, 2013, the Company reacquired from its terminated employees 0 and 33,447 unvested shares of common stock, respectively, that had been issued upon the exercise of a stock option prior to its vesting. During the year ended December 31, 2014, the Company issued common stock pursuant to the 2013 Incentive Award Plan (Note 17).
	Reverse Stock Split
	On May 22, 2013, the Company effected a 1-for-1.662 reverse stock split of its issued and outstanding shares of common stock. No fractional shares were issued in connection with the reverse stock split. Accordingly, all share and per share amounts for all periods presented in these consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the reverse stock split.
	Initial Public Offering
	In July 2013, the Company completed the initial public offering of its common stock in which the Company issued and sold 6,612,500 shares of common stock at a public offering price of $6.00 per share. The Company received net proceeds of approximately $34,274 after deducting underwriting discounts and commissions of approximately $2,777 and other offering expenses of approximately $2,617.
	Preferred Convertible Stock Conversion
	On June 26, 2013, the holders of at least 75% of the then-outstanding shares of Series A Preferred Stock elected and consented to the automatic conversion of each outstanding share of Preferred Stock into shares of common stock immediately prior to the consummation of the public offering contemplated by the Company’s Registration Statement on Form S-1 (No. 333-187372).
	Immediately prior to the consummation of the initial public offering, all shares of the Company’s then-outstanding convertible preferred stock and accumulated dividends automatically converted into an aggregate of 13,351,902 shares of common stock.
	Vet Therapeutics Merger
	On October 15, 2013, the Company completed the acquisition of Vet Therapeutics, in which the Company issued 624,997 shares of common stock to the former equity and stock option holders of Vet Therapeutics. The fair value of the common stock at time of the acquisition was determined to be $14,700.
	Private Placement
	On October 13, 2013, the Company completed a private placement in which the Company issued and sold 1,234,375 shares of its common stock for $16.00 an aggregate purchase price of $19,750, or $16.00 per share.
	Public Offerings
	On February 3, 2014, the Company completed a public offering of its common stock in which the Company issued and sold 5,150,000 shares of common stock at a public offering price of $19.00 per share. The Company received net proceeds of approximately $90,507 after deducting underwriting discounts and commissions of approximately $5,871 and other offering expenses of approximately $1,472.

	On September 22, 2014, the Company completed a public offering of its common stock in which the Company issued and sold 5,175,000 shares of common stock at a public offering price of $9.25 per share. The Company received net proceeds of approximately $44,827 after deducting underwriting discounts and commissions of approximately $2,872 and other offering expenses of approximately $412.

StockBased_Awards

Stock-Based Awards	12 Months Ended
Stock-Based Awards	Dec. 31, 2014
Stock-Based Awards [Abstract]
Stock-Based Awards	17. Stock-Based Awards
	2010 Equity Incentive Plan
	In 2010, the Company’s Board of Directors adopted the 2010 Equity Incentive Plan (the “2010 Plan”). The 2010 Plan provided for the Company to sell or issue common stock or restricted common stock and to grant incentive stock options or nonqualified stock options for the purchase of common stock with a maximum term of ten years to employees, members of the Board of Directors and consultants of the Company. During the year ended December 31, 2014, no awards were granted from the 2010 Plan. With the adoption and approval of the 2013 Incentive Award Plan (the “2013 Plan”), no further awards will be granted from the 2010 plan.

	The 2010 Plan permits the exercise of stock options granted under the plan before the options are fully vested. If a stock option is early exercised in this circumstance, the issued common stock is subject to restrictions on the sale or transfer by the holder that lapse according to the vesting terms of the early-exercised stock option. Unvested shares may not be sold or transferred by the holder. In the event of termination of the holder’s employment, any unvested shares received upon early exercise are subject to repurchase by the Company, typically at the lesser of (1) the original purchase price per share or (2) the fair value of the common share on the date of termination. During the year ended December 31, 2012, the Company granted three restricted stock awards under the 2010 Plan that were subject to repurchase at the greater of (1) the original purchase price per share or (2) the fair value of the common share on the date of termination. Only one of these three restricted stock awards remain outstanding as of December 31, 2014.
	Under the 2010 Plan, the Company has 90 days from the effective termination of the holder’s employment or service to repurchase unvested shares that are issued upon the exercise of a stock award prior to its vesting. If, after 90 days, the Company elects not to repurchase these unvested shares, the shares become vested in full. The Company would then apply modification accounting and any resulting compensation expense would be immediately recognized related to the award. Upon vesting, these shares would be considered issued and outstanding shares of common stock for accounting purposes.
	Retrospective Reassessment of the Fair Value of Common Stock
	As required by the 2010 Plan, the exercise price for awards granted is not to be less than the fair market value of common stock as determined by the Company’s Board of Directors as of the date of grant. Prior to its initial public offering, the Company valued its ordinary shares by taking into consideration its most recently available valuation of common stock performed by management and the Board of Directors as well as additional factors which may have changed since the date of the most recent contemporaneous valuation through the date of grant. Between October 4, 2012 and December 31, 2012, the Board of Directors granted stock options for the purchase of 87,241 shares of common stocks with a weighted-average exercise price of $0.40 per share based on its determination of the value of common stock as of the date of grant. On February 28, 2013, the Board of Directors approved the pursuit of an initial public offering of the Company’s common stock. As a result, in connection with the preparation of the Company’s financial statements for the year ended December 31, 2012, the Company reexamined, for financial reporting purposes only, the fair value of common stock during 2012. In connection with that reexamination, the Company determined that a retrospective valuation of the fair value of common stock as of October 4, 2012 was appropriate due to the acceleration of the timeframe to a potential liquidity event, the proposed initial public offering, which had not been contemplated in the original determination of the fair value of the Company’s stock options granted on or after October 4, 2012. Based on this analysis, the fair value of common stock was determined to be $1.06 at October 4, 2012 and $2.59 at December 22, 2012 and remained unchanged through December 31, 2012. As a result, the grant-date fair value of each of the awards granted on October 4, 2012 and October 23, 2012 was revalued to reflect an underlying common stock fair value of $1.06 and the grant-date fair value of each of the awards granted on December 22, 2012 was revalued to reflect an underlying common stock fair value of $2.59. The difference between the original estimated fair value and the reassessed fair value of the Company’s common stock is being, and will continue to be, recorded as additional compensation expense in the statement of operations over the requisite service periods.
	Stock Options
	During the year ended December 31, 2013, the Company granted under the 2010 Plan stock options for the purchase of 231,445 shares of common stock to certain employees, non-employee consultants and directors. The vesting conditions for most of these awards are time-based, and the awards typically vest 25% after one year and monthly thereafter for the next 36 months. Awards typically expire after 10 years. The 2010 Plan allows for the early exercise of unvested stock options subject to certain restrictions, including the ability of the Company to repurchase such options upon an option holder’s termination of employment with the Company if such options have not yet vested.
	At the year ended December 31, 2014, 192,473 shares of restricted common shares issued due to early exercises were unvested and subject to repurchase. Early exercise is not considered an exercise for accounting purposes and, therefore, any payment for unvested shares is recognized as a liability at the original exercise price. As of December 31, 2014 and 2013, the liability related to the early exercise of awards was $76 and $132, respectively, and was recorded in other current liabilities and other long-term liabilities. During the year ended December 31, 2013, the Company repurchased 33,447 unvested shares from terminated employees. No early exercised stock option shares were repurchased by the Company during the year ended December 31, 2014.
	The table below summarizes activity related to stock options for the year ended December 31, 2014:



								WEIGHTED
			SHARES		WEIGHTED			AVERAGE
			ISSUABLE		AVERAGE			REMAINING		AGGREGATE
			UNDER		EXERCISE			CONTRACTUAL		INTRINSIC
			OPTIONS		PRICE			TERM		VALUE
								(IN YEARS)

	Outstanding as of December 31, 2013		263,467		$	1.25		8.94		$	4,704
	Granted		—			—
	Exercised		-47,555			0.40
	Forfeited		-45,446			0.40
	Expired		—			—
	Outstanding as of December 31, 2014		170,466		$	1.71		8.05		$	2,746
	Options vested and expected to vest as of December 31, 2014		166,712		$	1.70		8.05		$	2,687
	Options exercisable as of December 31, 2014		168,744		$	1.67		8.05		$	2,725

	For the years ended December 31, 2014, 2013, and 2012, the weighted average grant date fair value of stock options granted was $0.00 (no stock options granted), $ 2.48 and $0.33, respectively. For the years ended December 31, 2014, 2013, and 2012, the total intrinsic value of options exercised was $871, $4,840 and $2,160, respectively. For the years ended December 31, 2014, 2013 and 2012, the total fair value of awards vested during the period was $765, $98 and $85, respectively. The Company received cash proceeds of $19 and $153 from the exercise of stock options for the years ended December 31, 2014 and 2013, respectively, of which $0 and $97 were from the early exercise of stock options, respectively.
	During 2014, there were three awards subject to modification accounting under ASC 718-20-35-3 through 35-4. Per terms of separation with a former employee, all unvested shares of restricted stock held by the employee became fully vested upon the employee’s employment termination. In addition, six months of accelerated vesting was granted for the former employee’s two stock option awards. As the employee would have forfeited the unvested awards upon termination according to the awards’ original terms, the awards would not be expected to vest under the original vesting conditions. The accelerated/full vesting of the unvested awards resulted in a Type III modification and the incremental fair value is equal to the fair value of the awards on the modification date. This amount was recognized immediately as the awards did not require further service. The incremental expense for the stock option awards and restricted stock award was $327 and $649, respectively.
	During August 2013, the Company modified two stock option awards granted to the Company’s former President, for the purchase of 269,817 shares of common stock in the aggregate. The modifications included the expiration of options to purchase 9,228 shares of common stock, and extended the expiration date of options from August 9, 2013 to January 31, 2014. No additional stock-based compensation expense was recognized as a result of this modification.
	Restricted Common Stock
	The Company’s 2010 Plan provided for the award of restricted common stock. The Company has granted restricted common stock with time-based vesting conditions. Unvested shares of restricted common stock may not be sold or transferred by the holder. These restrictions lapse according to the time-based vesting.
	During the year ended December 31, 2013, the Company issued 76,496 shares of restricted common stock for no proceeds. The vesting of these awards is time-based, with terms between two and four years.

	The table below summarizes activity related to restricted stock for the year ended December 31, 2014:



					WEIGHTED
					AVERAGE GRANT
			SHARES		DATE FAIR VALUE
	Unvested restricted common stock as of December 31, 2013		237,740		$	0.82
	Restricted common stock issued		—			—
	Restricted common stock vested		-146,406			0.73
	Restricted common stock forfeited		—			—
	Unvested restricted common stock as of December 31, 2014		91,334		$	0.94
	For the years ended December 31, 2014, 2013, and 2012, the weighted average grant date fair value of restricted stock granted was $0.00 (none issued), $2.59 and $0.40, respectively. For the years ended December 31, 2014, 2013, and 2012 the total fair value of restricted shares vested was $2,615, $2,257 and $6 respectively. The Company received cash proceeds of $0 (none issued), $0 (none received), and $139 from the issuance of restricted common stock during the years ended December 31, 2014, 2013 and 2012, respectively.
	As of December 31, 2014 and 2013, 91,334 and 237,740 shares of common stock related to restricted stock awards were unvested and subject to repurchase, respectively.
	2013 Incentive Award Plan
	In 2013, the Company’s Board of Directors adopted and stockholders approved the 2013 Plan which became effective upon the day prior to the effective date of the Company’s initial public offering. The 2013 Plan currently allows for the issuance of up to 983,250 shares of common stock, plus any additional shares represented by the 2010 Plan that are forfeited or lapse unexercised. The number of shares of common stock that may be issued under the plan is also subject to an annual increase on January 1st of each calendar year beginning in 2014 and ending in 2023, equal to the lesser of (i) 1,203,369 shares, (ii) 4% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (iii) and amount determined by the Board of Directors. As of December 31, 2014, there were 103,054 shares available for future grant under the 2013 Plan. On January 1, 2015 the annual increase was determined to be 1,203,369.
	The 2013 Plan is administered by the Compensation Committee of the Board of Directors, which selects the individuals eligible to receive awards, determines or modifies the terms and condition of the awards granted, accelerates the vesting schedule of any award and generally administers and interprets the 2013 Plan. The 2013 Plan permits the granting of incentive and nonqualified stock options, with terms of up to ten years and the granting of restricted stock, restricted stock units, performance stock awards, dividend equivalent rights, stock payments (i.e. unrestricted stock), cash bonuses and stock appreciation rights to employees, consultants, and non-employee directors.
	Stock Options
	During the year ended December 31, 2014, the Company granted under the 2013 Plan stock options for the purchase of 856,211 shares of common stock to certain employees and non-employee directors. The vesting conditions for most of these awards are time-based, and the awards typically vest 25% after one year and monthly thereafter for the next 36 months. Awards typically expire after 10 years.
	The table below summarizes activity related to stock options for the year ended December 31, 2014:



								WEIGHTED
			SHARES		WEIGHTED			AVERAGE
			ISSUABLE		AVERAGE			REMAINING		AGGREGATE
		UNDER		EXERCISE			CONTRACTUAL		INTRINSIC
		OPTIONS		PRICE			TERM		VALUE


Outstanding as of December 31, 2013		685,934		$	15.32		9.68		$	4,151
Granted		856,211			17.83
Exercised		-34,386			6.00
Forfeited		-25,893			6.97
Expired		—			—
Outstanding as of December 31, 2014		1,481,866		$	17.13		8.96		$	3,835
Options vested and expected to vest as of December 31, 2014		1,374,792		$	17.13		8.96		$	3,577
Options exercisable as of December 31, 2014		176,174		$	16.15		8.69		$	865
For the years ended December 31, 2014 and 2013, the weighted average grant date fair value of stock options granted was $12.84 and $9.16, respectively. For the years ended December 31, 2014 and 2013, the total intrinsic value of options exercised was $214, and $0 (no exercises occurred), respectively. For the years ended December 31, 2014, and 2013, the total fair value of awards vested during the period was $1,888 and $0 (no awards vested), respectively. The Company received cash proceeds of $206 and $0 (no exercises occurred) from the exercise of stock options for the years ended December 31, 2014 and 2013, respectively.
Restricted Common Stock
The Company’s 2013 Plan provides for the award of restricted common stock. The Company has granted restricted common stock with time-based vesting conditions, with terms between several months and four years. Unvested shares of restricted common stock may not be sold or transferred by the holder. These restrictions lapse according to the time-based vesting.
The table below summarizes activity related to restricted stock for the year ended December 31, 2014:



				WEIGHTED
				AVERAGE GRANT
		SHARES		DATE FAIR VALUE
Unvested restricted common stock as of December 31, 2013		89,766		$	19.07
Restricted common stock issued		282,200			16.73
Restricted common stock vested		-94,122			18.40
Restricted common stock forfeited		—			—
Unvested restricted common stock as of December 31, 2014		277,844		$	16.92
For the years ended December 31, 2014 and 2013, the weighted average grant date fair value of restricted common stock granted was $16.73 and $18.91, respectively. For the years ended December 31, 2014 and 2013, the total fair value of restricted common stock vested was $94 and $25, respectively. The Company received no proceeds for any of the restricted common stock granted during the years ended December 31, 2014 and 2013.
Stock-Based Compensation
The fair value of each stock-based award is estimated using the Black-Scholes option-pricing model. Prior to 2014, due to the lack of company- specific historical and implied volatility information the Company estimated its expected volatility based on the historical volatility of the Company’s publicly-traded peer companies. Beginning in the first quarter of 2014, the Company began to base expected volatility on historical volatility of the Company’s common stock, as adequate historical data regarding the volatility of the Company’s common stock price had become available. The expected term of the Company’s stock options has been determined utilizing the “simplified” method as the Company has insufficient historical experience for option grants overall, rendering existing historical experience irrelevant to expectations for current grants. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.
The relevant data used to determine the value of the stock option grants is as follows, presented on a weighted average basis:




		YEAR ENDED DECEMBER 31,
		2014				2013				2012
Risk-free interest rate			1.88	%			1.59	%			0.90	%
Expected term (in years)			6.1				6.1				6.0
Expected volatility			84	%			66	%			67	%
Expected dividend yield			—	%			—	%			—	%
Compensation expense related to restricted stock granted to employees and non-employee directors is equal to the excess, if any, of the fair value of the Company’s common stock on date of grant over the original purchase price per share, multiplied by the number of shares of restricted common stock issued for employees. Compensation expense related to restricted stock granted to non-employee is equal to the excess, if any, of the fair value of the Company’s common stock on date of vesting over the original purchase price per share, multiplied by the number of shares of restricted common stock vesting.
The Company recognizes compensation expense for only the portion of awards that are expected to vest. In developing a forfeiture rate estimate, the Company has considered its historical experience to estimate pre-vesting forfeitures for service-based awards. The impact of a forfeiture rate adjustment will be recognized in full in the period of adjustment, and if the actual forfeiture rate is materially different from the Company’s estimate, the Company may be required to record adjustments to stock-based compensation expense in future periods.
The Company recorded stock-based compensation expense related to stock options and restricted stock as follows:



		YEAR ENDED DECEMBER 31,
		2014			2013			2012
Research and development		$	1,611		$	419		$	11
Cost of product sales			48			—			—
Selling, general and administrative			5,471			606			95
		$	7,130		$	1,025		$	106
The Company had an aggregate of $13,283 and $4,304 of unrecognized stock-based compensation expense for options outstanding and restricted stock awards, respectively, as of December 31, 2014, which is expected to be recognized over a weighted average period of 2.70 years.

Net_Loss_Per_Share

Net Loss Per Share	12 Months Ended
Net Loss Per Share	Dec. 31, 2014
Net Loss Per Share [Abstract]
Net Loss Per Share	18. Net Loss Per Share
	Basic and diluted net loss per share attributable to common stockholders was calculated as follows:



			YEAR ENDED DECEMBER 31,
			2014		2013		2012
					(As Restated)
	Numerator:
	Net loss		$	-38,816	$	-6,938	$	-11,636
	Unaccreted dividends on convertible preferred stock			—		—		-2,035
	Net loss attributable to common stockholders		$	-38,816	$	-6,938	$	-13,671
	Denominator:
	Weighted average shares outstanding – basic and diluted			29,767,429		11,059,382		395,918
	Net loss per share attributable to common stockholders – basic and diluted (1)		$	-1.3	$	-0.63	$	-34.53
	__________________
		-1		All per share amounts and shares outstanding for all periods reflect the 1-for-1.662 reverse stock split, which was effective May 22, 2013.
	Stock options for the purchase of 1,789,305, 1,294,146, and 952,957 shares of common stock were excluded from the computation of diluted net loss per share attributable to common stockholders for the years ended December 31, 2014, 2013 and 2012, respectively, because those options had an anti-dilutive impact due to the net loss attributable to common stockholders incurred for the period.

Commitments_And_Contingencies

Commitments And Contingencies	12 Months Ended
Commitments And Contingencies	Dec. 31, 2014
Commitments And Contingencies [Abstract]
Commitments And Contingencies	19. Commitments and Contingencies
	Operating Leases
	Future minimum lease payments for operating leases as of December 31, 2014 are as follows:




	YEAR ENDING DECEMBER 31,
	2015	$	558
	2016		299
	2017		226
	2018		196
	2019 and thereafter		46
	Total	$	1,325
	The Company leases facilities and certain operating equipment under operating leases expiring through 2019. The Company incurred rent expense of $565, $177 and $158 for the years ended December 31, 2014, 2013 and 2012, respectively.
	Contingent Consideration Obligations
	The Company determines the acquisition date fair value of the contingent consideration obligation based on a probability-weighted approach derived from the overall likelihood of achieving certain specified future milestones, such as certain regulatory and manufacturing milestones. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement (Note 4), as defined in fair value measurement accounting. The resultant probability-weighted earn-out payments are discounted using a discount rate based upon the Company’s current borrowing rate. At each reporting date, the Company revalues the contingent consideration obligations to the reporting date fair values and record increases and decreases in the fair values as income or expense in the consolidated statements of operations.
	Increases or decreases in the fair values of the contingent consideration obligations may result from changes in discount periods and rates, changes in the timing and amount of earn-out criteria and changes in probability assumptions with respect to the likelihood of achieving the various earn-out criteria.
	The Company has a contractual contingent purchase price consideration obligation related to acquisitions, as follows (in thousands):




						Maximum
						Remaining		Remaining
						Earn-out		Earn-out		Estimated
						Potential		Period		Fair Value
				Acquisition		as of		as of		as of		Payments
				Date Fair		December 31,		December 31,		December 31,		made
	Acquisition	Acquisition Date		Value		2014		2014		2014		during 2014
	Vet Therapeutics	October 15, 2013		$	3,810	$	5,000		—	$	4,248	$	—
						$	5,000		—	$	4,248	$	—

	Okapi Sciences	6-Jan-14		$	15,166	$	—		—	$	—	$	15,235
						$	—		—	$	—	$	15,235

	On January 2, 2015 the Company was granted a full product license for AT-004. The approval resulted in $3,000 of the contingent consideration being earned and due to the former Vet Therapeutics shareholders per the terms of Vet Therapeutics merger. Further, on February 24, 2015 in connection with the mutual termination of the NAH Agreement for AT-004, the Company’s obligation to pay additional consideration to the Vet Therapeutics shareholders upon achievement of certain manufacturing milestones ended. The Company paid the $3,000 contingent consideration in March 2015. During the first quarter of 2015, the Company will record a credit of $1,249 to reduce the fair value of the contingent consideration to zero as a result of the agreement the Vet Therapeutics shareholders.
	Litigation and Contingencies Related to Use of Intellectual Property
	From time to time, the Company may become subject to legal proceedings, claims and litigation arising in the ordinary course of business. The Company currently is not a party to any threatened or pending litigation. However, third parties might allege that the Company or its licensors are infringing their patent rights or that the Company is otherwise violating their intellectual property rights. Such third parties may resort to litigation against the Company or its licensors, which the Company has agreed to indemnify. With respect to some of these patents, the Company expects that it will be required to obtain licenses and could be required to pay license fees or royalties, or both. These licenses may not be available on acceptable terms, or at all. A costly license, or inability to obtain a necessary license, could have a material adverse effect on the Company’s financial condition, results of operations or cash flows. The Company accrues contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.
	Indemnification Agreements
	In the ordinary course of business, the Company may provide indemnifications of varying scope and terms to customers, vendors, lessors, business partners, and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements, from services to be provided by the Company, or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with certain of its officers and members of its Board of Directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, not readily quantifiable. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company does not believe that the outcome of any claims under indemnification arrangements will have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of December 31, 2014 or 2013.

Business_Combinations

Business Combinations	12 Months Ended
Business Combinations	Dec. 31, 2014
Business Combinations [Abstract]
Business Combinations	20. Business Combinations

	Acquisition of Okapi Sciences

	On January 6, 2014, the Company acquired Okapi Sciences, a Leuven, Belgium based company with a proprietary antiviral platform and three clinical/development stage product candidates. This acquisition further expanded the existing Company pipeline. The aggregate purchase price was approximately $44,439, which consisted of $14,139 in cash, a promissory note in the principal amount of $15,134 with a maturity date of December 31, 2014, and a contingent consideration of up to $16,308 with an acquisition fair value of $15,166. The promissory note bore interest at a rate of 7% per annum, payable quarterly in arrears, and was subject to mandatory prepayment in the event of a specified equity financing by the Company. On February 4, 2014, the promissory note and accrued interest was paid in cash in the amount of $15,158. On March 17, 2014, the contingent consideration was settled in cash in the amount of $15,235.

	Included in the Company’s consolidated statements of operations for the year ended December 31, 2014 is revenue totaling approximately $452 related to Okapi Sciences.

	The acquisition-date fair value of the consideration transferred to the sellers of Okapi Sciences, less cash acquired, was $43,376, which consisted of the following:




	Cash consideration		$	14,139
	Fair value of promissory note			15,134
	Fair value of contingent consideration			15,166
	Fair value of total consideration			44,439
	Less cash acquired			-1,063
	Total consideration transferred, net of cash acquired		$	43,376


	Fair Value of Contingent Consideration: The Company agreed to pay up to $16,308 on or prior to April 7, 2014, subject to mandatory prepayment in cash in the event of a specified future equity financing, provided that if not paid in cash by April 7, 2014, payment was to be made in the form of shares of the Company’s common stock-based on the average closing price of the Company’s common stock during the 10-trading day period ending April 4, 2014, subject to a maximum of 1,060,740 shares and a minimum of 707,160 shares. This contingent consideration was recorded as a liability and measured at fair value using a probability-weighted model utilizing significant observable and unobservable inputs, including the volatility in the market price of the Company’s common stock, the expected probability of settling the contingent consideration in either cash or shares and an estimated discount rate commensurate with the risks of these outcomes. The analysis resulted in an estimated fair value of contingent consideration of $15,166. The contingent consideration was settled March 17, 2014 for $15,235 and the difference between the initial fair value amount and settlement amount was $69 which is reflected as a charge to selling, general and administrative expenses in the consolidated statement of operations.

	The acquisition of Okapi Sciences was accounted for as a business combination under the acquisition method of accounting. Accordingly, the assets acquired and liabilities assumed were recorded at fair value with the remaining purchase price recorded as goodwill. The assets acquired and the liabilities assumed from Okapi Sciences have been recorded at their fair values at the date of acquisition, being January 6, 2014. The Company’s consolidated financial statements and results of operations include the results of Okapi Sciences from January 6, 2014.

	In the year ended December 31, 2014, the Company incurred expenses totaling $1 relating to the Okapi Sciences acquisition, which were recorded within Selling, general and administrative expenses in the Company’s consolidated statement of operations.



	The Company’s allocation of the purchase price to the assets acquired and liabilities assumed was as follows:




	Cash		$	1,063
	Accounts receivable			149
	Other receivables			60
	Prepaid expenses and other current assets			82
	Property and equipment			217
	Other long-term assets			18
	Identifiable intangible assets			29,400
	Accounts payable and accrued expenses			-586
	Deferred revenue			-83
	Deferred tax liabilities, net			-3,752
	Long-term debt			-4
	Total identifiable net assets			26,564
	Goodwill			17,909
	Total net assets acquired			44,439
	Less:
	Promissory note			15,134
	Contingent consideration			15,166
	Cash paid		$	14,139

	The following are the intangible assets acquired by drug program and their estimated useful lives as of the date of the acquisition:




			FAIR VALUE			USEFUL LIFE
	AT-006		$	3,400		13 years
	AT-007			13,500		15 years
	AT-008			5,300		13 years
	AT-011			7,200		14 years
	Total intangible assets		$	29,400


The identifiable intangible assets recognized by the Company as a result of the Okapi Sciences acquisition relate to Okapi Sciences technology, and consist primarily of its intellectual property related to Okapi Sciences AT-006, AT-007, AT-008 and AT-011 programs, and the estimated net present value of future cash flows from commercial agreements related to the AT-006 program.

All Okapi Sciences programs, which were considered in-process research and development (“IPR&D”) at the acquisition date, were valued using a multi-period excess earnings method, a form of the income approach, which incorporates the estimated future cash flows to be generated from this technology. Excess earnings are the earnings remaining after deducting the market rates of return on the estimated values of contributory assets, including debt-free net working capital, tangible, and intangible assets. The excess earnings are thereby calculated for each year of a multi-year projection period and discounted to present value. Accordingly, the primary components of this method consist of the determination of excess earnings and an appropriate rate of return.

The Company will not amortize the assets related to the Okapi Sciences programs until commercialization has been achieved.

The valuation analysis conducted by the Company determined that the aggregate fair value of identifiable assets acquired less the aggregate fair value of identifiable liabilities assumed by the Company is less than the purchase price. As the purchase price exceeds the fair value of assets and liabilities acquired or assumed, goodwill will be recognized. Goodwill is calculated as the difference between the Okapi Sciences acquisition date fair value of the consideration transferred and the fair values of the assets acquired and liabilities assumed. The goodwill is not expected to be deductible for income tax purposes. Goodwill is recorded as an indefinite-lived asset and is not amortized but tested for impairment on an annual basis or when indications of impairment exist.

The difference between the total consideration and the fair value of the net assets acquired of $17,909 was recorded as Goodwill in the consolidated balance sheet. This goodwill represents the excess of the purchase price over the fair value of the tangible and identifiable intangible assets acquired and liabilities assumed, principally representing the tax attributes of the acquisition and certain operational and strategic synergies such as advancement toward becoming a commercial company and acquiring a proprietary antiviral platform.

Acquisition of Vet Therapeutics, Inc. (As Restated)
On October 15, 2013, the Company acquired Vet Therapeutics, a San Diego, California based company with a proprietary antibody-based biologics platform. This acquisition further expanded the existing Company pipeline and will significantly accelerate Aratana’s pathway toward becoming a commercial-stage pet therapeutics company. The preliminary aggregate purchase price was approximately $51,515, which consisted of $30,005 in cash, 624,997 shares of Aratana’s common stock with an acquisition date fair value of $14,700, a promissory note in the principal amount of $3,000 with a maturity date of December 31, 2014, and contingent consideration of up to $5,000 with an acquisition-date fair value of $3,810. The promissory note bears interest at a rate of 7% per annum, payable quarterly in arrears, and was subject to prepayment in the event of a specified equity financing by the Company. The Company could have to pay up to $5,000 in contingent cash consideration in connection with the achievement of certain regulatory and manufacturing milestones for AT-004.
Included in the Company’s consolidated statements of operations for the years ended December 31, 2014, and December 31, 2013 is revenue totaling approximately $273, and $123, respectively, related to Vet Therapeutics. The amount of goodwill from this acquisition is not deductible for tax purposes.
The acquisition-date fair value of the consideration transferred to the sellers of Vet Therapeutics, less cash acquired, was $51,503, which consisted of the following:






Cash consideration		$	30,005
Fair value of promissory note			3,000
Fair value of merger shares			14,700
Fair value of contingent consideration			3,810
Fair value of total consideration			51,515
Less cash acquired			-12
Total consideration transferred, net of cash acquired		$	51,503


Fair Value of Merger Shares: The Company agreed to transfer 624,997 unregistered shares of its common stock without registration rights to former Vet Therapeutics stock and option holders. On October 15, 2013, the closing date of the Vet Merger, the fair market value of Aratana’s publicly traded common stock was $27.67 per share. In order to determine the fair value of consideration transferred to Vet Therapeutics stock and option holders related to the Merger Shares, the Company applied a discount for the lack of marketability of 15% to the Company’s closing stock price on the closing date of the Vet Merger to account for the lack of access to an active public market for these shares. This resulted in aggregate purchase consideration related to the Merger Shares of $14,700.
Fair Value of Contingent Consideration: The Company agreed to pay up to $5,000 in contingent cash consideration in connection with the achievement of certain regulatory and manufacturing milestones for AT-004. Contingent consideration is recorded as a liability and measured at fair value using a discounted cash flow model utilizing significant unobservable inputs, including the probability of achieving each of the potential milestones and an estimated discount rate commensurate with the risks of the expected cash flows attributable to the milestones. This resulted in aggregate contingent purchase consideration of $3,810. Significant increases or decreases in any of the probabilities of success would result in a significantly higher or lower fair value, respectively, and commensurate changes to this liability. The fair value of contingent consideration and the associated liability will be adjusted to fair value at each reporting date until actual settlement occurs, with the changes in fair value reflected in earnings.
The acquisition of Vet Therapeutics was accounted for as a business combination under the acquisition method of accounting. Accordingly, the assets acquired and liabilities assumed were recorded at fair value with the remaining purchase price recorded as goodwill. The assets acquired and the liabilities assumed from Vet Therapeutics have been recorded at their fair values at the date of acquisition, being October 15, 2013. The Company’s consolidated financial statements and results of operations include the results of Vet Therapeutics from October 16, 2013.
In the year ended December 31, 2013, the Company incurred expenses totaling $1,369 relating to the Vet Therapeutics acquisition, which were recorded within selling, general and administrative expenses in the Company’s consolidated statement of operations.

The Company’s allocation of the purchase price to the assets acquired and liabilities assumed was as follows:




Cash		$	12
Inventories			173
Other current assets			5
Property and equipment			73
Other long-term assets			3
Identifiable intangible assets (As Restated)			38,652
Accounts payable and accrued expenses			-273
Deferred revenue			-55
Deferred tax liabilities, net (As Restated)			-12,722
Total identifiable net assets		$	25,868
Goodwill (As Restated)			25,646
Total net assets acquired		$	51,514
Less:
Merger shares			14,700
Promissory note			3,000
Contingent consideration			3,810
Cash paid		$	30,005

The following are the intangible assets acquired by drug program and their estimated useful lives as of the date of the acquisition (as adjusted):




		FAIR VALUE			USEFUL LIFE
AT-004 (Antibody for B-cell lymphoma)		$	28,572		20 years
AT-005 (Antibody for T-cell lymphoma)			10,080		20 years
Total intangible assets subject to amortization		$	38,652





The identifiable intangible assets recognized by the Company as a result of the Vet Therapeutics acquisition relate to Vet Therapeutics’ technology, and consist primarily of its intellectual property related to Vet Therapeutics’ B-cell and T-cell antibodies, and the estimated net present value of future cash flows from commercial agreements related to the B-cell technology.
The Vet Therapeutics B-cell technology, which is now referred to as AT-004, was valued using the discounted cash flow method, a form of the income approach, which incorporates the estimated royalty income and milestone payments to be generated from this technology. The estimated cash flows are then discounted to present value. Accordingly, the primary components of this method consist of the determination of cash flows, the probability of achieving and the anticipated timing of the milestone payments, and an appropriate rate of return.
The Vet Therapeutics T-cell technology, which was considered in-process research and development at the acquisition date and which is now referred to as AT-005, was valued using a multi-period excess earnings method, a form of the income approach, which incorporates the estimated future cash flows to be generated from this technology. Excess earnings are the earnings remaining after deducting the market rates of return on the estimated values of contributory assets, including debt-free net working capital, tangible, and intangible assets. The excess earnings are thereby calculated for each year of a multi-year projection period and discounted to present value. Accordingly, the primary components of this method consist of the determination of excess earnings and an appropriate rate of return.
For the B-cell technology, the Company will recognize straight-line amortization expense over the estimated useful life of the asset. The Company began amortizing the asset related to the T-cell technology when the conditional license was issued during January of 2014.
The difference between the total consideration and the fair value of the net assets acquired of $25,646 was recorded to Goodwill in the consolidated balance sheet. This goodwill represents the excess of the purchase price over the fair value of the tangible and identifiable intangible assets acquired and liabilities assumed, principally representing the tax attributes of the acquisition and certain operational and strategic synergies such as advancement toward becoming a commercial company and acquiring a proprietary antibody-based biologics platform focused on the treatment of lymphoma.

Pro Forma Financial Information

The following pro forma financial information summarizes the combined results of operations for the Company as though the acquisition of Okapi Sciences occurred on January 1, 2013 and acquisition of Vet Therapeutics occurred on January 1, 2012. The unaudited pro forma financial information is as follows:





		YEAR ENDED DECEMBER 31,
		2014			2013
		(Unaudited)			(Unaudited)
Revenue		$	767		$	2,570
Net loss			-41,314			-22,977
Net loss attributable to common stockholders		$	-39,979		$	-24,448
Net loss per share attributable to common stockholders – basic and diluted		$	-1.34		$	-1.95


Pro forma results include non-recurring pro forma adjustments that were directly attributable to the business combinations. The following material non-recurring pro forma adjustments relating to charges recorded in 2014 have been assumed to have occurred in 2013 for pro forma purposes:

	·		Pre-tax increase in income of $440 in 2014, relating to acquisition-related transaction costs incurred by the Company and Okapi Sciences.

Additionally, the following material non-recurring pro forma adjustments relating to charges recorded in 2013 have been assumed to have occurred in 2012 for pro forma purposes:

	·		Pre-tax increase in income of $1,639 for 2013, relating to acquisition-related transaction costs incurred by the Company and Vet Therapeutics.


The pro forma financial information for all periods presented has been calculated after adjusting the results of the Company and Okapi Sciences and Vet Therapeutics to reflect the business combination accounting effects resulting from these acquisitions including the amortization expenses from acquired intangible assets, the depreciation expenses from acquired tangible assets, the stock-based compensation expense for unvested stock options and restricted stock units assumed and the related tax effects as though the acquisition occurred as of January 1, 2013 for Okapi Sciences and January 1, 2012 for Vet Therapeutics. The pro forma financial information is for informational purposes only and is not indicative of the results of operations that would have been achieved if the acquisition had taken place at the beginning of the Company’s 2013 fiscal year.

Income_Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2014
Income Taxes [Abstract]
Income Taxes	21. Income Taxes
	The components of income from continuing operations before provision for income taxes as follows:




			YEAR ENDED DECEMBER 31,
			2014			2013
						(As Restated)
	U.S.		$	-34,256		$	-19,660
	Non-U.S.			-6,003			—
	Income from continuing operations		$	-40,259		$	-19,660


	The components of the income tax benefit (provisions) from operations are as follows:




			YEAR ENDED DECEMBER 31,
			2014			2013
						(As Restated)
	Current:
	Federal		$	—		$	—
	State			—			—
	Deferred:
	Federal			—			10,782
	State			—			1,940
	Foreign			1,443			—
	Total		$	1,443		$	12,722

	A reconciliation of the U.S. federal statutory income tax rate to the Company’s effective income tax rate is as follows:




				YEAR ENDED DECEMBER 31,
				2014			2013
						(As Restated)
	Federal statutory income tax rate			34.0	%		34.0	%
	State income taxes, net of federal tax benefit			1.1			7.2
	Non-deductible expenses			-3			-2.5
	Research credits			0.8			0.9
	Losses benefitted/(not benefitted)			-29.3			25.3
	Total			3.6	%		64.9	%

	Net deferred tax assets consisted of the following:




			YEAR ENDED DECEMBER 31,
			2014			2013
						(As Restated)
	Net operating loss carry forwards		$	12,196		$	3,180
	Capitalized start-up costs			7,151			3,751
	Tax credit carry forwards			1,062			784
	Other temporary differences			1,469			1,421
	Capitalized research and development, net			10,378			5,788
	Intangibles, net			—			—
	Depreciation			—			—
	Total deferred tax assets			32,256			14,924
	Valuation allowance			-14,747			-3,118
	Net deferred tax assets			17,509			11,806
Intangibles, net			-19,356			-11,790
Depreciation			-18			-16
Total deferred tax liabilities			-19,374			-11,806
Net deferred tax liability		$	-1,865		$	—


As of December 31, 2014, the Company had net operating loss carryforwards for federal and state income tax purposes of $15,227 and $13,260, respectively, which begin to expire in fiscal year 2031 and 2021, respectively.
The Company also has available research and development tax credit carryforwards for federal and state income tax purposes of $738 and $490, respectively, which begin to expire in fiscal year 2031 and until utilized, respectively. Additionally, $4,321 of excess tax deductions from share-based payments were capitalized in 2013 and 2014 and are being amortized over 15 years for tax purposes. The tax benefits of these items would be credited to additional paid-in capital when the deductions reduce cash taxes payable. The Company has approximately $19,431 of foreign net operating loss carryforward, which may be carried forward indefinitely.
On January 6, 2014, we acquired Okapi Sciences. As a result of the acquisition, we recorded approximately $3,752 of net deferred tax liability primarily related to the step-up of intangible assets for book purposes. The taxable temporary difference from the acquisition is considered a source of future taxable income in determining the realizability of our deferred tax assets. During 2014, we recognized approximately $1,443 of income tax benefit for losses incurred in Aratana NV. During 2013, as a result of the acquisition of Vet Therapeutics, the Company recorded approximately $12,722 of net deferred tax liability, primarily related to the step-up of intangible assets for book purposes. The taxable temporary difference from the acquisition is considered as a source of future taxable income in determining the realizability of the Company’s deferred tax assets. The Company recognized a deferred tax benefit of approximately $12,722 due to a release of the valuation allowance against the Company’s federal deferred tax assets of $10,782 and a change in the valuation allowance against our state deferred tax assets of $1,940.
Utilization of the net operating loss and research and development credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes may limit the amount of net operating loss and research and development credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. The Company has not completed a study to assess whether an ownership change has occurred, or whether there have been multiple ownership changes since its formation, due to significant complexity and related costs associated with such a study.
Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2014, and 2013 were as follows:




		YEAR ENDED DECEMBER 31,
		2014			2013
					(As Restated)
Valuation allowance as of beginning of year		$	3,118		$	8,065
Decreases recorded as income tax benefit			—			-4,947
Increases due to acquisitions			271			—
Increases due to operations			11,358			—
Valuation allowance as of end of year		$	14,747		$	3,118
The Company has not recorded any amounts for unrecognized tax benefits as of December 31, 2014, and 2013. The Company will recognize interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2014, and 2013, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company’s consolidated statements of operations.
The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. The Company’s major taxing jurisdictions include the U.S. federal and states, and Belgium. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending income tax examinations. The Company’s tax years are still open under statute from 2011 to the present. The Company’s policy is to record interest and penalties related to income taxes as part of its income tax provision.
On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law reinstating the federal research and development credit for the 2012 and 2013 years. Under the accounting guidance on this topic, the effects are recognized as a component of income tax expense or benefit from continuing operations in the financial statements for the interim or annual period that includes the enactment date.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions	22. Related Party Transactions
	MPM Asset Management, LLC
	The Company has entered into a services agreement to sublease office space (Heartland House in Kansas City, Kansas) and received office related services from MPM Asset Management, LLC, formerly an affiliate of two of the Company’s principal stockholders. Rent paid in each of the years ended December 31, 2014 and December 31, 2013 was $67 and $59, respectively.
	The Company leased office space (Boston) and received certain office-related services. The term of the agreement was from February 9, 2013 through December 31, 2013. The Company then leased this space month-to-month through June 2014. Rent and services paid in the years ended December 31, 2014 and December 31, 3013 was $60 and $52, respectively.
	MPM Heartland House, LLC
	The Company leases its corporate headquarters office space in Kansas City, Kansas from MPM Heartland House, LLC, a company in which the current Chief Executive Officer and President of the Company, also a director of the Company, is the principal owner. Rent paid for the years ended December 31, 2014 and December 31, 2013 were $113 and $60, respectively. The current lease period is from May 1, 2013 to September 30, 2015. The rent payable under the lease is $115 per year. The Company believes the terms of the lease agreement with MPM Heartland House are no less favorable than those that the Company could have obtained from an unaffiliated third party. Also, the Company has a services agreement with MPM Heartland House, LLC which includes the lease of the furniture, janitorial and other services to care for the property. Service charges for the years ended December 31, 2014 and December 31, 2013 were $33 and $5, respectively.
	Indemnification Agreements
	The Company has entered into indemnification agreements with each of its directors and executive officers. These agreements, among other things, require the Company or will require the Company to indemnify each director (and in certain cases their related venture capital funds) and executive officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys’ fees, judgments, fines and settlement amounts incurred by the director or executive officer in any action or proceeding, including any action or proceeding by or in right of the Company, arising out of the person’s services as a director or executive officer.

Subsequent_Events

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	23. Subsequent Events

	AT-004 B-cell Lymphoma Monoclonal Antibody Received Full License

	On January 5, 2015 Aratana received notice that AT-004, the company's canine-specific monoclonal antibody targeting CD20 as an aid in the treatment of B-cell lymphoma in dogs, had received a full license from the USDA.

	Elanco Animal Health
	On February 24, 2015, the Company and our partner Elanco terminated by mutual consent an exclusive commercial license agreement for AT-004 in the U.S and Canada reverting control of all commercial, development and manufacturing activities of AT-004 back to the Company. As part of the termination agreement, Elanco agreed to pay the full approval milestone and all amounts due to product manufactured for Elanco in 2014 totaling $3,200. The Company agreed to pay Elanco $2,500 to reacquire all rights to AT-004, plus a milestone of $500 due after the Company completes its first commercial sale of the product, expected in the second half of 2015.

	Advaxis Stock Sale
	In March 2014, the Company entered into a license agreement with Advaxis for the development and commercialization of certain animal health products containing the active pharmaceutical ingredient included in Advaxis’ ADXS-cHER2 product in animal health applications, including AT-014. In January 2015, the Company sold shares of Advaxis common stock that was acquired as part of the license agreement for proceeds of $1,500.

Selected_Quarterly_Financial_D

Selected Quarterly Financial Data	12 Months Ended
Selected Quarterly Financial Data	Dec. 31, 2014
Selected Quarterly Financial Data [Abstract]
Selected Quarterly Financial Data
	24. Selected Quarterly Financial Data (unaudited)
	The following table presents selected unaudited quarterly financial data for each of the quarters in the years ended December 31, 2014 and 2013 (in thousands, except per share data):




			2014
			First		Second		Third		Fourth
			Quarter		Quarter		Quarter		Quarter
	Net revenue		$	176	$	300	$	43	$	248
	Gross profit			176		300		43		-85
	Net loss attributable to common stockholders			-9,152		-9,278		-10,130		-10,256
	Basic and diluted– loss per common share:
	Net loss per common share (1)			-0.34		-0.32		-0.35		-0.3
	Weighted average number of common shares outstanding, basic and diluted			26,765,565		28,761,326		29,348,375		34,118,255




			2013
			First		Second		Third		Fourth
			Quarter		Quarter		Quarter		Quarter (2)
										(As Restated)
	Net revenue		$	—	$	—	$	—	$	123
	Gross profit			—		—		—		15
	Net income (loss) and comprehensive income (loss)			-3,293		-3,440		-4,671		4,466
	Net income (loss) attributable to common stockholders			-4,066		-4,248		-4,671		4,466
	Basic and diluted– loss per common share:
	Net income (loss) per common share (1)			-4.73		-4.62		-0.22		0.21
	Diluted – income (loss) per common share:
	Net income (loss) per common share (1)		$	-4.73	$	-4.62	$	-0.22	$	0.20
	Weighted average number of common shares outstanding, basic			860,350		918,397		20,806,352		21,320,775
	Weighted average number of common shares outstanding, diluted			860,350		918,397		20,806,352		22,468,031	(3)
	__________________
		-1		Net income (loss) available to common stockholders and basic and diluted net income (loss) per common share are computed consistent with annual per share calculations described in Notes 3 (Net Loss Per Share) and 18 of its consolidated financial statements included elsewhere in this Annual Report on Form 10-K.
		-2		Included in the net income for the fourth quarter of 2013 is an income tax benefit of $12,722 related to the Vet Therapeutics acquisition.
		-3		Includes 1,147,256 dilutive shares related to employee stock compensation plans, net of assumed buy-back.

Recovered_Sheet1

Summary of Significant Accounting Policies (Policy)	12 Months Ended
	Dec. 31, 2014
Summary Of Significant Accounting Policies [Abstract]
Use Of Estimates	Use of Estimates
	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from those estimates.

Cash And Cash Equivalents	Cash and Cash Equivalents

	The Company classifies all highly liquid investments with stated maturities of three months or less from the date of purchase as cash equivalents. The Company held no cash equivalents as of December 31, 2013. In 2013, the Company held no overnight reverse repurchase agreements. Beginning in 2014, the Company began accounting for its overnight reverse repurchase agreements as cash equivalents.

Short-term Investments	Short-term Investments
	Reverse repurchase agreements other than overnight reverse repurchase agreements are classified as short-term investments. In 2013, the Company held no reverse repurchase agreements. During 2014, the Company began accounting for its reverse repurchase agreements with maturities greater than overnight as short-term investments and classified them as available-for-sale. Short-term investments for both 2014 and 2013 include short-term marketable securities as described below, consisting of certificate of deposits.

Marketable Securities	Marketable Securities
	The Company classifies all highly liquid investments with stated maturities of greater than three months from the date of purchase as marketable securities. The Company determines the appropriate classification of investments in marketable securities at the time of purchase and re-evaluates such designation at each consolidated balance sheet date. The Company classifies and accounts for marketable securities as available-for-sale. The Company may or may not hold securities with stated maturities greater than 12 months until maturity. After consideration of the risk versus reward objectives, as well as the Company’s liquidity requirements, the Company may sell these securities prior to their stated maturities. These securities are viewed as being available to support current operations. As a result, the Company classifies securities with maturities beyond 12 months as long-term assets under the caption long-term marketable securities in the consolidated balance sheet. The Company reports available-for-sale investments at fair value as of each consolidated balance sheet date and records any unrealized gains and losses as a component of stockholders’ equity (deficit). At December 31, 2013, the fair value of marketable securities approximated cost and as such, no gains or losses were recorded as a component of other comprehensive income (loss). At December 31, 2014, investments in equity securities were classified as long-term marketable securities and were carried at fair value, as determined by quoted market prices, as such, gains were recorded as a component of other comprehensive income. The cost of securities sold is determined on a specific identification basis, and realized gains and losses are included in other income (expense) in the consolidated statements of operations. If any adjustment to fair value reflects a decline in the value of the investment, the Company considers available evidence to evaluate the extent to which the decline is “other than temporary” and recognizes the impairment by releasing other comprehensive income to the consolidated statement of operations. There were no such adjustments necessary during the year ended December 31, 2014.


Accounts Receivable
	Accounts Receivable
	Accounts receivable are uncollateralized customer obligations due under normal trade terms generally requiring payment within 30 days of the invoice date.
	The Company provides an allowance for doubtful accounts equal to the estimated losses that will be incurred in collection of accounts receivable. This estimate is based on the current review of existing receivables and historical experience in the industry. The allowance and associated accounts receivable are reduced when the receivables are determined to be uncollectible. Currently, the Company considers accounts receivable to be fully collectible.

Inventory	Inventories
	Inventories are stated at the lower of cost or market and consist of raw materials, work-in-process and finished goods. Cost is determined by the average cost method for raw materials and standard cost for work-in-process and finished goods, which approximates average cost. Market is considered the lower of prevailing replacement cost or net realizable value. Inventories acquired in business combinations are recorded at fair value as of acquisition date.

Property And Equipment	Property and Equipment
	The Company records property and equipment at historical cost or, in the case of a business combination, at fair value on the date of the business combination, less accumulated depreciation and amortization. Depreciation expense is recognized using the straight-line method over the following estimated useful lives:




	Laboratory and office equipment		3–5 years
	Computer equipment		3–5 years
	Furniture		3–7 years
	Vehicles		3–5 years
	Leasehold improvements		3–10 years
	Leasehold improvements are amortized over the shorter of the life of the related asset or the term of the lease.
	Expenditures for repairs and maintenance of assets are charged to expense as incurred. Costs of major additions and betterments are capitalized and depreciated on a straight-line basis over their useful lives. When property and equipment are disposed of, the cost and respective accumulated depreciation and amortization are removed from the books. Any gain or loss on disposal is recorded in the consolidated statements of operations.

Goodwill	Goodwill
	Goodwill relates to amounts that arose in connection with the Company’s business combinations (Note 20) and represents the difference between the purchase price and the estimated fair value of the identifiable tangible and intangible net assets when accounted for using the acquisition method of accounting. Goodwill is not amortized, but is subject to periodic review for impairment.

	The Company tests goodwill at the reporting unit level for impairment on an annual basis and between annual tests, if events and circumstances indicate impairment may exist. Events that would indicate impairment and trigger an interim impairment assessment include, but are not limited to, current economic and market conditions, including a decline in market capitalization, a significant adverse change in legal factors, business climate or operational performance of the business and an adverse action or assessment by a regulator.

	The Company completed its annual goodwill impairment testing during the third quarter of 2014. The Company determined as of the testing date that it still consisted of one operating segment which is comprised of one reporting unit. In performing step one of the assessment, the Company determined that its fair value, determined to be its market capitalization, was greater than its carrying value, determined to be stockholders’ equity. Based on this result, step two of the assessment was not required to be performed, and the Company determined there was no impairment of goodwill as of the testing date.

	Impairment charges related to goodwill have no impact on the Company’s compliance with financial covenants.

Intangible Assets	Intangible Assets
	The Company’s intangible assets consist of intellectual property rights acquired for currently marketed products and intellectual property rights acquired for in-process research and development (“IPR&D”). All of the Company’s intangible assets were recorded in connection with the Company’s business combinations (Note 20). The Company’s intangible assets are recorded at fair value at the time of their acquisition. The Company amortizes intangible assets over their estimated useful lives once the acquired technology is developed into a commercially viable product.
	The estimated useful lives of the individual categories of intangible assets are based on the nature of the applicable intangible asset and the expected future cash flows to be derived from the intangible asset. Amortization of intangible assets with finite lives is recognized over the time the intangible assets are estimated to contribute to future cash flows. The Company amortizes finite-lived intangible assets using the straight-line method.

	Indefinite-lived IPR&D intangible assets are assessed for impairment at least annually. In addition, all intangible assets are reviewed for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows for definite-lived intangible assets and discounted cash flows for indefinite-lived IPR&D intangible assets expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted (definite-lived) or discounted (indefinite-lived) future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. To date, the Company has not recorded any impairment losses on intangible assets.

	The Company completed its annual indefinite-lived IPR&D intangible assets impairment testing during the fourth quarter of 2014. For purposes of impairment testing, the fair value of the indefinite-lived IPR&D intangible assets were determined by using the framework of ASC 820, Fair Value Measurement. When determining the fair value of the indefinite-lived IPR&D intangible assets, the Company revisited all assumptions used in measuring the indefinite-lived IPR&D intangible assets at the time of acquisition, and evaluated and considered new and updated data and information available. The Company noted the fair values for all indefinite-lived IPR&D intangible assets were greater than the carrying value. As such, no impairment was recognized as of the testing date.


Derivative Financial Instruments	Derivative Financial Instruments

	In 2013, the Company held no derivative financial instruments. Beginning in 2014, the Company began accounting for its derivative instruments as either assets or liabilities and carries them at fair value. The Company’s sole derivative (Note 11) is a warrant to purchase common stock and is adjusted to fair value through current income.

Foreign Currency	Foreign Currency

	During 2013, the Company had limited foreign currency exposure. With the acquisition of Okapi Sciences (Note 20) in 2014, the Company is exposed to effects of foreign currency from translation. Transactions in foreign currencies are translated into the relevant functional currency at the rate of exchange at the date of the transaction. Transaction gains and losses are recognized in other income (expense) in the consolidated statements of operations. The results of operations for subsidiaries, whose functional currency is not the U.S. Dollar, are translated into the U.S. Dollar at the average rates of exchange during the period, with the subsidiaries’ balance sheets translated at the rates accumulated at the balance sheet date. The cumulative effect of these exchange rate adjustments is included in a separate component of other comprehensive income (loss) in the consolidated balance sheets. Gains and losses arising from intercompany foreign currency transactions are included in loss from operations unless the gains and losses arise from long-term investments in subsidiaries. Gains and losses from long-term investments in subsidiaries are included in a separate component of other comprehensive income (loss).

Business Combinations	Business Combinations
	The Company’s business acquisitions were made at a price above the fair value of the assets acquired and liabilities assumed, resulting in goodwill, based on the Company’s expectations of synergies and other benefits of combining the businesses. These synergies and benefits include elimination of redundant facilities, functions and staffing; use of the Company’s existing commercial infrastructure to expand sales of the products of the acquired businesses; and use of the commercial infrastructure of the acquired businesses to expand product sales in a cost-efficient manner.
	Significant judgment is required in estimating the fair value of intangible assets and in assigning their respective useful lives. The fair value estimates are based on available historical information and on future expectations and assumptions deemed reasonable by management, but which are inherently uncertain.
	The Company generally employs the income method to estimate the fair value of intangible assets, which is based on forecasts of the expected future cash flows attributable to the respective assets. Significant estimates and assumptions inherent in the valuations reflect a consideration of other marketplace participants, and include the amount and timing of future cash flows (including expected growth rates and profitability), the underlying product life cycles, economic barriers to entry, a brand’s relative market position and the discount rate applied to the cash flows. Unanticipated market or macroeconomic events and circumstances may occur, which could affect the accuracy or validity of the estimates and assumptions.
	Net assets acquired are recorded at their fair value and are subject to adjustment upon finalization of the fair value analysis. The Company is not aware of any information that indicates the final fair value analysis will differ materially from the preliminary estimates.
	Contingent consideration is recorded as a liability and measured at fair value using a discounted cash flow model utilizing significant unobservable inputs, including the probability of achieving each of the potential milestones and an estimated discount rate commensurate with the risks of the expected cash flows attributable to the milestones. Significant increases or decreases in any of the probabilities of success would result in a significantly higher or lower fair value, respectively, and commensurate changes to this liability. At each reporting date, we revalue the contingent consideration obligations to the reporting date fair values and record increases and decreases in the fair values as income or expense in the consolidated statements of operations until actual settlement occurs.
	Increases or decreases in the fair values of the contingent consideration obligations may result from changes in discount periods and rates, changes in the timing and amount of earn-out criteria and changes in probability assumptions with respect to the likelihood of achieving the various earn-out criteria.

	On January 6, 2014, the Company acquired Okapi Sciences, a Leuven, Belgium based company with a proprietary antiviral platform and three clinical/development stage product candidates. The aggregate purchase price was approximately $44,439, which consisted of $14,139 in cash, a promissory note in the principal amount of $15,134 with a maturity date of December 31, 2014, and a contingent consideration of up to $16,308 with an acquisition fair value of $15,166. The promissory note bore interest at a rate of 7% per annum, payable quarterly in arrears, and was subject to mandatory prepayment in the event of a specified equity financing by the Company. On February 4, 2014, the promissory note and accrued interest was paid in cash in the amount of $15,158. On March 17, 2014, the contingent consideration was settled in cash in the amount of $15,235.

Deferred Public Offering Costs	Deferred Public Offering Costs
	The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as other assets until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders’ equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering. Should it no longer be considered probable that the equity financing will be consummated, the deferred offering costs would be expensed immediately as a charge to operating expenses in the consolidated statements of operations. The Company recorded $0 and $33 deferred offering costs as of December 31, 2014 and 2013, respectively.

Income Taxes	Income Taxes
	The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred taxes are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.
	The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.

Debt Issuance Costs, Net	Debt Issuance Costs, net
	Debt issuance costs, net represent legal and other direct costs related to the Company’s Credit Facility (Note 12). These costs are recorded as debt issuance costs on the consolidated balance sheet at the time they are incurred and are amortized to interest expense through the scheduled final principal payment date. During the year ended December 31, 2014, the Company recorded an additional $11 of debt issuance costs and recognized $41 of amortization expense related to debt issuance costs. During the year ended December 31, 2013, the Company recorded $83 of debt issuance costs and recognized $33 of amortization expense related to debt issuance costs.

Revenue Recognition	Revenue Recognition

	The Company’s principal revenue streams were licensing and collaboration and product sales. Beginning in 2014, as a result of the Okapi Sciences NV acquisition (Note 20), the Company generates revenue from research and development services. Revenues from the performance of research and development services are recorded as licensing and collaboration revenue in the consolidated statements of operations and are recognized on a proportional basis as costs are incurred.
	The Company recognizes revenue when all of the following conditions are met:
		·		there is persuasive evidence of an agreement or arrangement;
		·		delivery of products has occurred or services have been rendered;
		·		the seller’s price to the buyer is fixed or determinable; and
		·		collectibility is reasonably assured.
	The Company’s principal revenue streams and their respective accounting treatments are discussed below:
	(i) Product sales - Revenue for the sale of products is recognized when delivery has occurred and substantially all the risks and rewards of ownership have been transferred to the customer. Revenue for the sale of products are recorded net of sales returns, allowances and discounts.
	(ii) Royalty revenue - Royalty revenue relating to the Company’s out-licensed technology is recognized when reasonably estimable. The revenues are recorded based on estimates of the licensee’s sales that occurred during the relevant period. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically in the following quarter. If the Company is unable to reasonably estimate royalty revenue or does not have access to the information, then the Company records royalty revenue on a cash basis.
	(iii) Licensing and collaboration revenues - Revenues derived from product out-licensing arrangements typically consist of an initial up-front payment on inception of the license and subsequent milestone payments contingent on the achievement of certain clinical and sales milestones. Product out licensing arrangements may require the Company to provide multiple deliverables to the licensee which would require the total selling price to be allocated between each of the separable elements in the arrangement using the relative selling price method. An element is considered separable if it has value to the customer on a stand-alone basis. The selling price used for each separable element will be based on vendor specific objective evidence (“VSOE”) if available, third party evidence if VSOE is not available, or estimated selling price if neither VSOE nor third party evidence is available. Revenue is then recognized as each of the separable elements to which the revenue has been allocated is delivered.
	Milestone payments which are non-refundable, non-creditable and contingent on achieving certain development, regulatory, or commercial milestones are recognized as revenues either on achievement of such milestones or over the period the Company has continuing substantive performance obligations.

Research And Development Costs	Research and Development Costs
	Research and development costs are expensed as incurred. Included in research and development costs are wages, stock-based compensation and employee benefits, and other operational costs related to the Company’s research and development activities, including facility-related expenses, external costs of outside contractors engaged to conduct both preclinical and clinical studies and allocation of corporate costs. Payments received from external parties to fund the Company’s research and development activities are used to reduce the Company’s research and development expenses. If IPR&D is acquired in an asset purchase then the acquired IPR&D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred.

Patent Costs	Patent Costs
	All patent-related costs incurred in connection with filing and prosecuting patent applications are recorded as selling, general and administrative expenses as incurred, as recoverability of such expenditures is uncertain.


Shipping
	Shipping
	Shipping costs are included in cost of product sales.

Sales tax	Sales Tax
	The Company collects and remits taxes assessed by various governmental authorities. These taxes may include sales, use and value added taxes. These taxes are recorded on a net basis and are excluded from sales.

Accounting For Stock Based Compensation	Accounting for Stock-Based Compensation

	The Company’s stock-based compensation program grants awards that may consist of stock options and restricted stock awards. The fair values of stock option grants are determined as of the date of grant using the Black-Scholes option pricing method. This method incorporates the fair value of the Company’s common stock at the date of each grant and various assumptions such as the risk-free interest rate, expected volatility based on the volatility of the Company’s common stock price, expected dividend yield, and expected term of the options. The fair values of restricted stock awards are determined based on the fair value of the Company’s common stock. Prior to the Company’s initial public offering of its common stock in June 2013, the fair value of the common stock was determined by management and the Board of Directors, on the date of grant. Beginning in the first quarter of 2014, the Company began to base expected volatility on the historical volatility of its common stock, as adequate historical data regarding the volatility of its common stock price had become available.
	The fair values of the stock-based awards, including the effect of estimated forfeitures, are then expensed over the requisite service period, which is generally the award’s vesting period. The Company classifies stock-based compensation expense in the consolidated statements of operations in the same manner in which the respective award recipient’s payroll costs are classified.
	For stock-based awards granted to consultants and nonemployees, compensation expense is recognized over the period during which services are rendered by such consultants and nonemployees until completed. At the end of each financial reporting period prior to completion of the service, the value of these awards is re-measured using the then-current fair value of the Company’s common stock and updated assumption inputs in the Black-Scholes option pricing model.
	For stock-based awards granted to employees under the 2010 Equity Incentive Plan (the “2010 Plan”), the Company allows employees to exercise certain awards prior to vesting. However, the employee may not sell or transfer these awards prior to vesting. For most of these awards, the Company has the right, but not the obligation, to repurchase any unvested (but issued) shares of common stock upon termination of employment or service at the lesser of (1) the original purchase price per share or (2) the fair value of the common share on the date of termination. If a stock option is early exercised in this circumstance, the consideration received for an exercise of an option is considered a deposit of the exercise price, and the related dollar amount is recorded as a liability. The unvested shares and liability are reclassified to equity as the award vests. The Company has 90 days from the effective termination of employment or service to repurchase unvested shares that are issued upon the exercise of a stock option prior to its vesting. If, after 90 days, the Company has elected not to repurchase the unvested shares, the shares would become vested in full. The Company would then apply modification accounting and any resulting compensation expense would be immediately recognized related to the award. Upon vesting, these shares would be considered issued and outstanding shares of common stock for accounting purposes.

	In addition, the Company has granted restricted stock awards subject to repurchase to one employee, under which the Company has the right, but not the obligation, upon termination of the holder’s employment or service, to repurchase unvested shares at the greater of (1) the original purchase price per share or (2) the fair value of the common share on the date of termination (Note 16).

Comprehensive Loss	Comprehensive Loss

	During 2014, there were differences between net loss and comprehensive loss. The Company includes foreign currency translation adjustments related to the translation of foreign subsidiaries’ balance sheets and unrealized holding gains and losses on available-for-sale securities in comprehensive loss. For the year ended December 31, 2013, there was no difference between net loss and comprehensive loss.

Net Loss Per Share	Net Loss Per Share
	The Company follows the two-class method when computing net loss per share, as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.
	The Company’s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Similarly, restricted stock awards granted by the Company entitle the holder of such awards to dividends declared or paid by the Board of Directors, regardless of whether such awards are unvested, as if such shares were outstanding common shares at the time of the dividend. However, the unvested restricted stock awards are not entitled to share in the residual net assets (deficit) of the Company. Accordingly, in periods in which the Company reports a net loss or a net loss attributable to common stockholders resulting from preferred stock dividends, accretion or modifications, net losses are not allocated to participating securities. The Company reported a net loss attributable to common stockholders in each of the years ended December 31, 2014, 2013 and 2012.
	Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities, including outstanding stock options. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of shares of common stock, including potential dilutive shares of common stock assuming the dilutive effect of potentially dilutive securities. For periods in which the Company has reported net losses, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since their impact would be anti-dilutive to the calculation of net loss per share. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders for each of the years ended December 31, 2014, 2013 and 2012.

Concentration Of Credit Risk And Of Significant Suppliers And Customers	Concentration of Credit Risk and of Significant Suppliers and Customers
	Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, short-term investments and accounts receivable. At December 31, 2014, the Company’s short-term investments included reverse repurchase agreements that are tri-party, have maturities of 90 days or less at the time of investment and the underlying collateral is U.S. government securities including U.S. treasuries, agency debt and agency mortgage securities. At December 31, 2014 and 2013, all of the Company’s fixed income marketable securities were invested in Certificates of Deposit (“CDs”) insured by the Federal Deposit Insurance Corporation (“FDIC”). The Company also generally maintains balances in various operating accounts in excess of federally insured limits at two accredited financial institutions. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.
	The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients (“API”), and formulated drugs related to these programs. These programs would be adversely affected by a significant interruption in the supply of API.

Fair Value Measurements	Fair Value Measurements
	Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, is used to measure fair value:
		·		Level 1—Quoted prices in active markets for identical assets or liabilities.
		·		Level 2—Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.
		·		Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

Segment Data	Segment Data
	The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company is a pet therapeutics company developing compounds to address unmet and under-served medical needs in companion animals. All assets were held in the United States and Belgium as of December 31, 2014.

Recently Issued and Adopted Accounting Pronouncements	Recently Issued and Adopted Accounting Pronouncements
	Intangibles—Goodwill and Other: Testing Goodwill for Impairment: In September 2011 the Financial Accounting Standards Board (“FASB”) issued guidance that simplifies how an entity tests goodwill for impairment. This guidance allows an entity the option to first assess qualitative factors to determine whether it is necessary to perform the current two-step impairment test. If an entity believes, as a result the existence of its qualitative, events and circumstances indicates that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the quantitative two-step impairment test is required; otherwise, no further testing is required. This update does not change the current guidance for testing other indefinite-lived intangible assets for impairment. If an entity concludes that it is not more likely than not that the indefinite-lived intangible asset is impaired, then the entity is not required to take further action. However, if an entity concludes otherwise, then it is required to determine the fair value of the indefinite-lived intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying amount. An entity also has the option to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to performing the quantitative impairment test. An entity will be able to resume performing the qualitative assessment in any subsequent period. The adoption of this standard in 2014 resulted from the Company’s business combination and did not have any impact on the Company’s financial position, results of operations, comprehensive income or cash flows as the guidance did not apply be until the first year the Company completed a goodwill impairment test.

	Revenue from Contracts with Customers

	In May 2014, the Financial Accounting Standards Board (“FASB”) issued guidance on recognizing revenue in contracts with customers. The guidance affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). This guidance will supersede the revenue recognition requirements in topic, Revenue Recognition, and most industry-specific guidance. This guidance also supersedes some cost guidance included in subtopic, Revenue Recognition – Construction-Type and Production-Type Contracts. In addition, the existing requirements for the recognition of a gain or loss on the transfer of nonfinancial assets that are not in a contract with a customer (e.g., assets within the scope of topic, Property, Plant, and Equipment, and tangible assets within the scope of topic, Intangibles – Goodwill and Other) are amended to be consistent with the guidance on recognition and measurement (including the constraint on revenue) in this guidance. The Company does not expect that this guidance will have a material impact on its consolidated financial statements.

	The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

	These changes become effective for the Company on January 1, 2017 and early adoption is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is currently assessing the impact, if any, this new guidance will have on the Company’s financial condition, results of operations or cash flows.

	Development Stage Entities — Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance, Consolidations

	In June 2014, the FASB issued guidance that removes all incremental reporting requirements from GAAP for development stage entities, including the removal of the topic development stage entities. These changes eliminate the requirement to report inception-to-date information in the statements of income, cash flows, and shareholder equity. These changes become effective for the Company on January 1, 2015 and early adoption is permitted. The Company opted to adopt this guidance as of June 30, 2014. The adoption of this guidance resulted in decreased financial statement disclosures, but did not impact the Company’s financial condition, results of operations or cash flows.

	Disclosure of Uncertainties about an Entities Ability to Continue as a Going Concern

	In August 2014, the FASB issued guidance which requires management to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide disclosure in the footnotes under certain circumstances. This guidance is effective for fiscal years ending after December 15, 2016 with early adoption permitted. The Company does not expect that this guidance will have a material impact on its consolidated financial statements.

Restatement_Of_Consolidated_Fi1

Restatement Of Consolidated Financial Statements (Tables)	12 Months Ended
Restatement Of Consolidated Financial Statements (Tables)	Dec. 31, 2014
Restatement Of Consolidated Financial Statements [Abstract]
Restatement Of Consolidated Financial Statements	ARATANA THERAPEUTICS, INC.
	CONSOLIDATED BALANCE SHEETS




			31-Dec-13
			PREVIOUSLY			RESTATEMENT
			REPORTED			ADJUSTMENT			AS RESTATED
	Assets
	Current assets:
	Cash and cash equivalents		$	41,084		$	—		$	41,084
	Short-term marketable securities			4,670			—			4,670
	Receivable from stockholder			1,001			—			1,001
	Inventory			55			—			55
	Prepaid expenses and other current assets			274			—			274
	Deferred tax asset			1,381			-257			1,124
	Total current assets			48,465			-257			48,208
	Property and equipment, net			98			—			98
	Goodwill			20,796			4,850			25,646
	Intangible assets, net			46,140			-7,786			38,354
	Other long-term assets			37			—			37
	Total assets		$	115,536		$	-3,193		$	112,343
	Liabilities and Stockholders' Equity
	Current liabilities:
	Accounts payable		$	2,307		$	—		$	2,307
	Accrued expenses			2,495			—			2,495
	Current portion – loan payable			5,625			—			5,625
	Current portion – note payable			3,000			—			3,000
	Current portion – deferred licensing revenue			45			—			45
	Current portion – contingent consideration			2,572			—			2,572
	Deferred income			800			—			800
	Other current liabilities			57			—			57
	Total current liabilities			16,901			—			16,901
	Loan payable			9,310			—			9,310
	Contingent consideration			1,543			—			1,543
	Deferred tax liability			1,666			-542			1,124
	Other long-term liabilities			75			—			75
	Total liabilities			29,495			-542			28,953
	Stockholders’ equity:
	Common stock			23			—			23
	Additional paid-in capital			112,515			—			112,515
	Accumulated deficit			-26,497			-2,651			-29,148
	Total stockholders’ equity			86,041			-2,651			83,390
	Total liabilities and stockholders’ equity		$	115,536		$	-3,193		$	112,343
	___________________________


	ARATANA THERAPEUTICS, INC.
	CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS



			YEAR ENDED DECEMBER 31, 2013
			PREVIOUSLY			RESTATEMENT
			REPORTED			ADJUSTMENT			AS RESTATED

	Revenues:
	Licensing revenue		$	15		$	—		$	15
	Product sales			108			—			108
	Total revenues			123			—			123
	Costs and expenses:
	Cost of product sales			108			—			108
	Royalty expense			1			—			1
Research and development			10,925			—			10,925
General and administrative			8,572			—			8,572
In-process research and development			—			—			—
Amortization of acquired intangible assets			380			-82			298
Total costs and expenses			19,986			-82			19,904
Loss from operations			-19,863			82			-19,781
Other income (expense)
Interest income			75			—			75
Interest expense			-432			—			-432
Other income			478			—			478
Total other income (expense)			121			—			121
Loss before income taxes		$	-19,742		$	82		$	-19,660
Income tax benefit			15,455			-2,733			12,722
Net loss and comprehensive loss		$	-4,287		$	-2,651		$	-6,938
Net loss attributable to common stockholders		$	-4,287		$	-2,651		$	-6,938
Net loss per share, attributable to common stockholders, basic and diluted		$	-0.39		$	-0.24		$	-0.63



ARATANA THERAPEUTICS, INC.
CONSOLIDATED STATEMENT OF CASH FLOWS











		YEAR ENDED DECEMBER 31, 2013
		PREVIOUSLY			RESTATEMENT
		REPORTED			ADJUSTMENT			AS RESTATED
Cash flows from operating activities
Net loss		$	-4,287		$	-2,651		$	-6,938
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense			1,025			—			1,025
Depreciation and amortization expense			395			-82			313
Non-cash interest expense			23			—			23
Deferred income taxes			-15,455			2,733			-12,722
Changes in operating assets and liabilities:
Prepaid expenses			-249			—			-249
Other assets			-14			—			-14
Accounts payable			1,527			—			1,527
Accrued expenses and other liabilities			579			—			579
Net cash used in operating activities			-16,151			—			-16,151
Cash flows from investing activities
Purchases of property and equipment, net			-94			—			-94
Cash paid for acquisitions, net of cash received			-30,994			—			-30,994
Purchase of marketable securities			-5,169			—			-5,169
Proceeds from maturities of marketable securities			6,881			—			6,881
Change in restricted cash			141			—			141
Net cash used in investing activities			-29,235			—			-29,235
Cash flows from financing activities
Proceeds from the issuance of Series C convertible preferred stock, net of issuance costs			3,406			—			3,406
Proceeds from the issuance of debt, net of discount			14,914			—			14,914
Proceeds from stock option exercises			153			—			153
Repurchase, early exercised stock			-6			—			-6
Proceeds from public offering, net of commission			36,897			—			36,897
Payments of public offering costs			-2,617			—			-2,617
Issuance of common stock private investment in public entity			19,750			—			19,750
Net cash provided by financing activities			72,497			—			72,497
Net increase in cash and cash equivalents			27,111			—			27,111
Cash and cash equivalents, beginning of year			13,973			—			13,973
Cash and cash equivalents, end of year		$	41,084		$	—		$	41,084

Summary_Of_Significant_Account1

Summary Of Significant Accounting Policies (Tables)	12 Months Ended
Summary Of Significant Accounting Policies (Tables)	Dec. 31, 2014
Summary Of Significant Accounting Policies [Abstract]
Estimated Useful Lives Of Property, Plant And Equipment

	Laboratory and office equipment	3–5 years
	Computer equipment	3–5 years
	Furniture	3–7 years
	Vehicles	3–5 years
	Leasehold improvements	3–10 years

Fair_Value_Of_Financial_Assets1

Fair Value Of Financial Assets And Liabilities (Tables)	12 Months Ended
Fair Value Of Financial Assets And Liabilities (Tables)	Dec. 31, 2014
Fair Value Of Financial Assets And Liabilities [Abstract]
Summary Of Information About Company's Financial Assets And Liabilities Subject To Fair Value Measurement On Recurring Basis

					FAIR VALUE MEASUREMENTS AS OF
			CARRYING		DECEMBER 31, 2014 USING:
			VALUE		LEVEL 1			LEVEL 2		LEVEL 3		TOTAL
	Assets:
	Cash equivalents:
	Certificates of deposit		$	6,972	$	—		$	6,972	$	—	$	6,972
	Money market fund			45		—			45		—		45
	Short-term investments:
	Short-term marketable securities - Certificate of deposit			249		—			249		—		249
	Reverse repurchase agreements			88,000		—			88,000		—		88,000
	Long-term marketable securities:
	Common Stock			2,452		2,452			—		—		2,452
	Derivative financial instruments			1,108		—			1,108		—		1,108
			$	98,826	$	2,452		$	96,374	$	—	$	98,826
	Liabilities:
	Contingent consideration		$	4,248	$	—		$	—	$	4,248	$	4,248
			$	4,248	$	—		$	—	$	4,248	$	4,248




					FAIR VALUE MEASUREMENTS AS OF
			CARRYING		DECEMBER 31, 2013 USING:
			VALUE		LEVEL 1			LEVEL 2		LEVEL 3		TOTAL
	Assets:
	Short-term investments:
	Short-term marketable securities - Certificate of deposits		$	4,670	$	—		$	4,670	$	—	$	4,670
			$	4,670	$	—		$	4,670	$	—	$	4,670
	Liabilities:
	Contingent consideration(1)		$	4,115	$	—		$	—	$	4,115	$	4,115
			$	4,115	$	—		$	—	$	4,115	$	4,115
	__________________
		-1		Contingent consideration consists of current portion: $2,572 and long-term contingent consideration: $1,543 in the consolidated balance sheet.

Change In Fair Value Of Company's Contingent Consideration Payable Measured At Fair Value On Recurring Basis

			2014		2013
	As of January 1,		$	4,115	$	—
	Initial recognition of contingent consideration payable			15,166		3,810
	Settlement of contingent consideration payable			-15,235		—
	Recognition of change in fair value in the consolidated statement of operations (within selling, general and administrative)			202		305
	As of December 31,		$	4,248	$	4,115


Quantitative Information About Company's Recurring Level 3 Fair Value Measurements



			FAIR VALUE AT MEASUREMENT DATE
					Valuation		Significant			Weighted
	At December 31, 2014		Fair value		technique		unobservable inputs		Range	average
	Contingent consideration		$	4,248	Income approach (probability weighted discounted cash flow)		Probability of milestones being achieved		25.00% to 97.50%	68.43%
							Assumed market participant discount rate		5.50%
							Periods in which milestones are expected to be achieved		2015






			FAIR VALUE AT MEASUREMENT DATE
					Valuation		Significant			Weighted
	At December 31, 2013		Fair value		technique		unobservable inputs		Range	average
	Contingent consideration		$	4,115	Income approach (probability weighted discounted cash flow)		Probability of milestones being achieved		3.8% to 95.00%	71.44%
							Assumed market participant discount rate		5.50%
							Periods in which milestones are expected to be achieved		2014 to 2015


Carrying Amounts And Estimated Fair Value Of Company's Financial Assets And Liabilities Not Measured At Fair Value On Recurring Basis

			31-Dec-14
			CARRYING VALUE		FAIR VALUE
	Financial liabilities:
	Loan payable (Level 2)		$	14,963	$	14,933




			31-Dec-13
			CARRYING VALUE		FAIR VALUE
	Financial liabilities:
	Loan payable (Level 2)		$	14,935	$	15,040

Investments_Tables

Investments (Tables)	12 Months Ended
Investments (Tables)	Dec. 31, 2014
Investments [Abstract]
Fair Value Of Available-For-Sale Marketable Securities

		31-Dec-14
				GROSS		GROSS
		AMORTIZED		UNREALIZED		UNREALIZED		FAIR
		COST		GAINS		LOSSES		VALUE
	Short-term marketable securities:
	Certificate of Deposit	$	249	$	—	$	—	$	249
	Long-term marketable securities:
	Common stock		1,200	$	1,252	$	—	$	2,452
	Total	$	1,449	$	1,252	$	—	$	2,701

	At December 31, 2014, unrealized gains in the amount of $1,252 were recorded as a component of other comprehensive loss.



		31-Dec-13
				GROSS		GROSS
		AMORTIZED		UNREALIZED		UNREALIZED		FAIR
		COST		GAINS		LOSSES		VALUE
	Short-term marketable securities:
	Certificates of deposit	$	4,670	$	—	$	—	$	4,670
	Total	$	4,670	$	—	$	—	$	4,670

Receivable_From_Stockholder_Ta

Receivable From Stockholder (Tables)	12 Months Ended
Receivable From Stockholder (Tables)	Dec. 31, 2014
Receivable From Stockholder [Abstract]
Receivable From Stockholder

		DECEMBER 31,		DECEMBER 31,
		2014		2013
	Receivable from stockholder	$	—	$	1,001

Inventories_Tables

Inventories (Tables)	12 Months Ended
Inventories (Tables)	Dec. 31, 2014
Inventories [Abstract]
Components Of Inventories

		DECEMBER 31,		DECEMBER 31,
		2014		2013
	Raw materials	$	115		—
	Work-in-process		206	$	55
	Finished goods		106		—
		$	427	$	55

Property_and_Equipment_Net_Tab

Property and Equipment, Net (Tables)	12 Months Ended
Property and Equipment, Net (Tables)	Dec. 31, 2014
Property And Equipment, Net [Abstract]
Schedule Of Property And Equipment

		DECEMBER 31,		DECEMBER 31,
		2014		2013
	Laboratory and office equipment	$	478	$	90
	Computer equipment and software		68		40
	Furniture		71		2
	Vehicles		34		—
	Leasehold improvements		102		—
	Construction in process		49		7
	Total property and equipment		802		139
	Less: Accumulated depreciation and amortization		-182		-41
	Property and equipment, net	$	620	$	98

Goodwill_Tables

Goodwill (Tables)	12 Months Ended
Goodwill (Tables)	Dec. 31, 2014
Goodwill And Intangible Assets Disclosure [Abstract]
Summary Of Goodwill

		GROSS		IMPAIRMENT		NET
		CARRYING AMOUNT		LOSSES		CARRYING VALUE
	Goodwill	$	41,398	$	—	$	41,398


Summary Of Change In The Net Book Value Of Goodwill

		2014		2013
				(As Restated)
	As of January 1,	$	25,646	$	—
	Acquisition		17,909		25,646
	Effect of foreign currency exchange		-2,157		—
	As of December 31,	$	41,398	$	25,646

Intangible_Assets_Net_Tables

Intangible Assets, Net (Tables)	12 Months Ended
Intangible Assets, Net (Tables)	Dec. 31, 2014
Goodwill And Intangible Assets Disclosure [Abstract]
Summary Of Unamortized Intangible Assets

		GROSS
		CARRYING
	Unamortized intangible assets:	VALUE

	Intellectual property rights acquired for IPR&D	$	25,860


Summary Of Amortized Intangible Assets


		GROSS				NET		WEIGHTED
		CARRYING		ACCUMULATED		CARRYING		AVERAGE
	Amortized intangible assets:	VALUE		AMORTIZATION		VALUE		USEFUL LIFE
	Intellectual property rights for currently marketed products:
	AT-004	$	28,572	$	1,726	$	26,846	20	Years
	AT-005(1)	$	10,080	$	462	$	9,618	20	Years

	(1) AT-005 received a conditional license in early 2014 which initiated amortization for this intangible.

Summary Of Change In The Net Book Value Of Other Intangible Assets

		2014		2013
				(As Restated)
	As of January 1,	$	38,354	$	—
	Acquisitions		29,400		38,652
	Amortization charged		-1,891		-298
	Effect of foreign currency exchange		-3,540		—
	As of December 31,	$	62,323	$	38,354


Estimated Aggregate Amortization Expense Of Intangible Assets

	YEAR ENDING DECEMBER 31,
	2015	$	1,933
	2016		1,933
	2017		1,933
	2018		1,933
	2019		1,933

Derivative_Financial_Instrumen1

Derivative Financial Instruments (Tables)	12 Months Ended
Derivative Financial Instruments (Tables)	Dec. 31, 2014
Derivative Financial Instruments [Abstract]
Derivative Instrument At Gross Fair Value As Reflected

		FAIR VALUE OF DERIVATIVES NOT
		DESIGNATED AS HEDGE INSTRUMENT
		31-Dec-14			31-Dec-13
	Derivative assets:
	Warrant (Notes 4 and 14)	$	1,108		$	—


Gain (Loss) Recognized In Other Income (Expense)

		GAIN RECOGNIZED IN
		OTHER INCOME
		YEAR ENDED
		DECEMBER 31,
		2014			2013
	Derivative assets:
	Warrant	$	465		$	—


Notional Principal Amounts Of Outstanding Derivative Instruments And Credit Risk Amounts Associated With Outstanding Or Unsettled Derivative Instruments

		31-Dec-14
		NOTIONAL/		CREDIT
		PRINCIPAL/SHARES		RISK
	Instruments not designated as hedging instruments:
	Warrant	153,061		$	476

Debt_Tables

Debt (Tables)	12 Months Ended
Debt (Tables)	Dec. 31, 2014
Debt [Abstract]
Estimated Future Principal Payments Under Additional Term Loan

	YEARS ENDING DECEMBER 31,
	2015	$	—
	2016		15,000
	2017		—
	2018		—
	2019		—
	Thereafter		—
	Total	$	15,000

Accrued_Expenses_Other_Current1

Accrued Expenses, Other Current Liabilities And Other Long-Term Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Accrued Expenses, Other Current Liabilities And Other Long-Term Liabilities [Abstract]
Summary Of Accrued Expenses

		DECEMBER 31,		DECEMBER 31,
		2014		2013
	Accrued expenses:
	Accrued payroll and related expenses	$	2,017	$	1,017
	Accrued professional fees		429		600
	Accrued royalty expense		72		70
	Accrued interest expense		41		71
	Accrued research and development costs		663		662
	Accrued other		7		75
		$	3,229	$	2,495

	Other current liabilities:
	Early exercise of stock-based awards	$	46	$	57
		$	46	$	57

	Other long-term liabilities:
	Early exercise of stock-based awards	$	30	$	75
		$	30	$	75

Preferred_Stock_Tables

Preferred Stock (Tables)	12 Months Ended
Preferred Stock (Tables)	Dec. 31, 2014
Equity [Abstract]
Issuance of Convertible Preferred Stock

			PREFERRED					COMMON
		PREFERRED	STOCK					STOCK
		STOCK	ISSUED AND	LIQUIDATION		CARRYING		ISSUABLE UPON
		AUTHORIZED	OUTSTANDING	PREFERENCE		VALUE		CONVERSION
	Series A convertible preferred stock	10,000,000	9,999,999	$	11,674	$	9,951	6,016,849
	Series A-1 convertible preferred stock	2,750,000	2,750,000		5,500		4,662	1,654,632
	Series B convertible preferred stock	5,166,667	5,141,667		16,691		15,241	3,093,655
	Series C convertible preferred stock	3,000,000	2,349,541		9,404		9,343	1,413,671
		20,916,667	20,241,207	$	43,269	$	39,197	12,178,807

StockBased_Awards_Tables

Stock-Based Awards (Tables)	12 Months Ended
Stock-Based Awards (Tables)	Dec. 31, 2014
2010 Equity Incentive Plan [Member]
Compensation Related Costs, Share-based Payments [Line Items]
Summary Of Stock Option Activity

							WEIGHTED
		SHARES		WEIGHTED			AVERAGE
		ISSUABLE		AVERAGE			REMAINING		AGGREGATE
		UNDER		EXERCISE			CONTRACTUAL		INTRINSIC
		OPTIONS		PRICE			TERM		VALUE
							(IN YEARS)

	Outstanding as of December 31, 2013	263,467		$	1.25		8.94		$	4,704
	Granted	—			—
	Exercised	-47,555			0.40
	Forfeited	-45,446			0.40
	Expired	—			—
	Outstanding as of December 31, 2014	170,466		$	1.71		8.05		$	2,746
	Options vested and expected to vest as of December 31, 2014	166,712		$	1.70		8.05		$	2,687
	Options exercisable as of December 31, 2014	168,744		$	1.67		8.05		$	2,725



Summary Of Restricted Stock Activity

				WEIGHTED
				AVERAGE GRANT
		SHARES		DATE FAIR VALUE
	Unvested restricted common stock as of December 31, 2013	237,740		$	0.82
	Restricted common stock issued	—			—
	Restricted common stock vested	-146,406			0.73
	Restricted common stock forfeited	—			—
	Unvested restricted common stock as of December 31, 2014	91,334		$	0.94


2013 Equity Incentive Plan [Member]
Compensation Related Costs, Share-based Payments [Line Items]
Summary Of Stock Option Activity

							WEIGHTED
		SHARES		WEIGHTED			AVERAGE
		ISSUABLE		AVERAGE			REMAINING		AGGREGATE
		UNDER		EXERCISE			CONTRACTUAL		INTRINSIC
		OPTIONS		PRICE			TERM		VALUE


	Outstanding as of December 31, 2013	685,934		$	15.32		9.68		$	4,151
	Granted	856,211			17.83
	Exercised	-34,386			6.00
	Forfeited	-25,893			6.97
	Expired	—			—
	Outstanding as of December 31, 2014	1,481,866		$	17.13		8.96		$	3,835
	Options vested and expected to vest as of December 31, 2014	1,374,792		$	17.13		8.96		$	3,577
	Options exercisable as of December 31, 2014	176,174		$	16.15		8.69		$	865


Summary Of Restricted Stock Activity

				WEIGHTED
				AVERAGE GRANT
		SHARES		DATE FAIR VALUE
	Unvested restricted common stock as of December 31, 2013	89,766		$	19.07
	Restricted common stock issued	282,200			16.73
	Restricted common stock vested	-94,122			18.40
	Restricted common stock forfeited	—			—
	Unvested restricted common stock as of December 31, 2014	277,844		$	16.92


Data Used To Determine Value Of Stock Option Grants

		YEAR ENDED DECEMBER 31,
		2014				2013				2012
	Risk-free interest rate		1.88	%			1.59	%			0.90	%
	Expected term (in years)		6.1				6.1				6.0
	Expected volatility		84	%			66	%			67	%
	Expected dividend yield		—	%			—	%			—	%


Summary Of Stock-Based Compensation Expense Related To Stock Options And Restricted Stock

		YEAR ENDED DECEMBER 31,
		2014			2013			2012
	Research and development	$	1,611		$	419		$	11
	Cost of product sales		48			—			—
	Selling, general and administrative		5,471			606			95
		$	7,130		$	1,025		$	106

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	12 Months Ended
Net Loss Per Share (Tables)	Dec. 31, 2014
Net Loss Per Share [Abstract]
Schedule Of Basic And Diluted Net Loss Per Share Attributable To Common Stockholders


			YEAR ENDED DECEMBER 31,
			2014		2013		2012
					(As Restated)
	Numerator:
	Net loss		$	-38,816	$	-6,938	$	-11,636
	Unaccreted dividends on convertible preferred stock			—		—		-2,035
	Net loss attributable to common stockholders		$	-38,816	$	-6,938	$	-13,671
	Denominator:
	Weighted average shares outstanding – basic and diluted			29,767,429		11,059,382		395,918
	Net loss per share attributable to common stockholders – basic and diluted (1)		$	-1.3	$	-0.63	$	-34.53
	__________________
		-1		All per share amounts and shares outstanding for all periods reflect the 1-for-1.662 reverse stock split, which was effective May 22, 2013.

Commitments_And_Contingencies_

Commitments And Contingencies (Tables)	12 Months Ended
Commitments And Contingencies (Tables)	Dec. 31, 2014
Commitments And Contingencies [Abstract]
Future Minimum Lease Payments For Operating Leases

	YEAR ENDING DECEMBER 31,
	2015	$	558
	2016		299
	2017		226
	2018		196
	2019 and thereafter		46
	Total	$	1,325


Summary Of Contractual Contingent Purchase Price Consideration Obligation

						Maximum
						Remaining		Remaining
						Earn-out		Earn-out		Estimated
						Potential		Period		Fair Value
				Acquisition		as of		as of		as of		Payments
				Date Fair		December 31,		December 31,		December 31,		made
	Acquisition	Acquisition Date		Value		2014		2014		2014		during 2014
	Vet Therapeutics	October 15, 2013		$	3,810	$	5,000		—	$	4,248	$	—
						$	5,000		—	$	4,248	$	—

	Okapi Sciences	6-Jan-14		$	15,166	$	—		—	$	—	$	15,235
						$	—		—	$	—	$	15,235

Business_Combinations_Tables

Business Combinations (Tables)	12 Months Ended
Business Combinations (Tables)	Dec. 31, 2014
Business Acquisition [Line Items]
Summary Of Proforma Financial Information

		YEAR ENDED DECEMBER 31,
		2014		2013
		(Unaudited)		(Unaudited)
	Revenue	$	767	$	2,570
	Net loss		-41,314		-22,977
	Net loss attributable to common stockholders	$	-39,979	$	-24,448
	Net loss per share attributable to common stockholders – basic and diluted	$	-1.34	$	-1.95


Okapi Sciences NV [Member]
Business Acquisition [Line Items]
Acquisition Date Fair Value Of Consideration Transferred

	Cash consideration	$	14,139
	Fair value of promissory note		15,134
	Fair value of contingent consideration		15,166
	Fair value of total consideration		44,439
	Less cash acquired		-1,063
	Total consideration transferred, net of cash acquired	$	43,376


Allocation Of Purchase Price To Assets Acquired And Liabilities Assumed

	Cash	$	1,063
	Accounts receivable		149
	Other receivables		60
	Prepaid expenses and other current assets		82
	Property and equipment		217
	Other long-term assets		18
	Identifiable intangible assets		29,400
	Accounts payable and accrued expenses		-586
	Deferred revenue		-83
	Deferred tax liabilities, net		-3,752
	Long-term debt		-4
	Total identifiable net assets		26,564
	Goodwill		17,909
	Total net assets acquired		44,439
	Less:
	Promissory note		15,134
	Contingent consideration		15,166
	Cash paid	$	14,139


Components Of Intangible Assets Acquired

		FAIR VALUE		USEFUL LIFE
	AT-006	$	3,400	13 years
	AT-007		13,500	15 years
	AT-008		5,300	13 years
	AT-011		7,200	14 years
	Total intangible assets	$	29,400


Vet Therapeutics Inc., [Member]
Business Acquisition [Line Items]
Acquisition Date Fair Value Of Consideration Transferred

	Cash consideration	$	30,005
	Fair value of promissory note		3,000
	Fair value of merger shares		14,700
	Fair value of contingent consideration		3,810
	Fair value of total consideration		51,515
	Less cash acquired		-12
	Total consideration transferred, net of cash acquired	$	51,503


Allocation Of Purchase Price To Assets Acquired And Liabilities Assumed



	Cash	$	12
	Inventories		173
	Other current assets		5
	Property and equipment		73
	Other long-term assets		3
	Identifiable intangible assets (As Restated)		38,652
	Accounts payable and accrued expenses		-273
	Deferred revenue		-55
	Deferred tax liabilities, net (As Restated)		-12,722
	Total identifiable net assets	$	25,868
	Goodwill (As Restated)		25,646
	Total net assets acquired	$	51,514
	Less:
	Merger shares		14,700
	Promissory note		3,000
	Contingent consideration		3,810
	Cash paid	$	30,005


Components Of Intangible Assets Acquired

		FAIR VALUE		USEFUL LIFE
	AT-004 (Antibody for B-cell lymphoma)	$	28,572	20 years
	AT-005 (Antibody for T-cell lymphoma)		10,080	20 years
	Total intangible assets subject to amortization	$	38,652

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2014
Income Taxes [Abstract]
Components Of Income From Continuing Operations Before Provision For Income Taxes

		YEAR ENDED DECEMBER 31,
		2014			2013
					(As Restated)
	U.S.	$	-34,256		$	-19,660
	Non-U.S.		-6,003			—
	Income from continuing operations	$	-40,259		$	-19,660


Components Of Income Tax Benefit (Provisions) From Operations

		YEAR ENDED DECEMBER 31,
		2014			2013
					(As Restated)
	Current:
	Federal	$	—		$	—
	State		—			—
	Deferred:
	Federal		—			10,782
	State		—			1,940
	Foreign		1,443			—
	Total	$	1,443		$	12,722


Reconciliation Of U.S. Federal Statutory Income Tax Rate To Effective Income Tax Rate

			YEAR ENDED DECEMBER 31,
			2014			2013
					(As Restated)
	Federal statutory income tax rate		34.0	%		34.0	%
	State income taxes, net of federal tax benefit		1.1			7.2
	Non-deductible expenses		-3			-2.5
	Research credits		0.8			0.9
	Losses benefitted/(not benefitted)		-29.3			25.3
	Total		3.6	%		64.9	%


Net Deferred Tax Assets

		YEAR ENDED DECEMBER 31,
		2014			2013
					(As Restated)
	Net operating loss carry forwards	$	12,196		$	3,180
	Capitalized start-up costs		7,151			3,751
	Tax credit carry forwards		1,062			784
	Other temporary differences		1,469			1,421
	Capitalized research and development, net		10,378			5,788
	Intangibles, net		—			—
	Depreciation		—			—
	Total deferred tax assets		32,256			14,924
	Valuation allowance		-14,747			-3,118
	Net deferred tax assets		17,509			11,806
	Intangibles, net		-19,356			-11,790
	Depreciation		-18			-16
	Total deferred tax liabilities		-19,374			-11,806
	Net deferred tax liability	$	-1,865		$	—


Changes In Valuation Allowance For Deferred Tax Assets

		YEAR ENDED DECEMBER 31,
		2014			2013
					(As Restated)
	Valuation allowance as of beginning of year	$	3,118		$	8,065
	Decreases recorded as income tax benefit		—			-4,947
	Increases due to acquisitions		271			—
	Increases due to operations		11,358			—
	Valuation allowance as of end of year	$	14,747		$	3,118

Subsequent_Events_Tables

Subsequent Events (Tables) (Okapi Sciences NV [Member])	12 Months Ended
Subsequent Events (Tables) (Okapi Sciences NV [Member])	Dec. 31, 2014
Okapi Sciences NV [Member]
Acquisition Date Fair Value Of Consideration Transferred

	Cash consideration	$	14,139
	Fair value of promissory note		15,134
	Fair value of contingent consideration		15,166
	Fair value of total consideration		44,439
	Less cash acquired		-1,063
	Total consideration transferred, net of cash acquired	$	43,376


Allocation Of Purchase Price To Assets Acquired And Liabilities Assumed

	Cash	$	1,063
	Accounts receivable		149
	Other receivables		60
	Prepaid expenses and other current assets		82
	Property and equipment		217
	Other long-term assets		18
	Identifiable intangible assets		29,400
	Accounts payable and accrued expenses		-586
	Deferred revenue		-83
	Deferred tax liabilities, net		-3,752
	Long-term debt		-4
	Total identifiable net assets		26,564
	Goodwill		17,909
	Total net assets acquired		44,439
	Less:
	Promissory note		15,134
	Contingent consideration		15,166
	Cash paid	$	14,139


Components Of Intangible Assets Acquired

		FAIR VALUE		USEFUL LIFE
	AT-006	$	3,400	13 years
	AT-007		13,500	15 years
	AT-008		5,300	13 years
	AT-011		7,200	14 years
	Total intangible assets	$	29,400

Selected_Quarterly_Financial_D1

Selected Quarterly Financial Data (Tables)	12 Months Ended
Selected Quarterly Financial Data (Tables)	Dec. 31, 2014
Selected Quarterly Financial Data [Abstract]
Selected Quarterly Financial Data


			2014
			First		Second		Third		Fourth
			Quarter		Quarter		Quarter		Quarter
	Net revenue		$	176	$	300	$	43	$	248
	Gross profit			176		300		43		-85
	Net loss attributable to common stockholders			-9,152		-9,278		-10,130		-10,256
	Basic and diluted– loss per common share:
	Net loss per common share (1)			-0.34		-0.32		-0.35		-0.3
	Weighted average number of common shares outstanding, basic and diluted			26,765,565		28,761,326		29,348,375		34,118,255




			2013
			First		Second		Third		Fourth
			Quarter		Quarter		Quarter		Quarter (2)
										(As Restated)
	Net revenue		$	—	$	—	$	—	$	123
	Gross profit			—		—		—		15
	Net income (loss) and comprehensive income (loss)			-3,293		-3,440		-4,671		4,466
	Net income (loss) attributable to common stockholders			-4,066		-4,248		-4,671		4,466
	Basic and diluted– loss per common share:
	Net income (loss) per common share (1)			-4.73		-4.62		-0.22		0.21
	Diluted – income (loss) per common share:
	Net income (loss) per common share (1)		$	-4.73	$	-4.62	$	-0.22	$	0.20
	Weighted average number of common shares outstanding, basic			860,350		918,397		20,806,352		21,320,775
	Weighted average number of common shares outstanding, diluted			860,350		918,397		20,806,352		22,468,031	(3)
	__________________
		-1		Net income (loss) available to common stockholders and basic and diluted net income (loss) per common share are computed consistent with annual per share calculations described in Notes 3 (Net Loss Per Share) and 18 of its consolidated financial statements included elsewhere in this Annual Report on Form 10-K.
		-2		Included in the net income for the fourth quarter of 2013 is an income tax benefit of $12,722 related to the Vet Therapeutics acquisition.
	Includes 1,147,256 dilutive shares related to employee stock compensation plans, net of assumed buy-back

Nature_Of_The_Business_And_Bas1

Nature Of The Business And Basis Of Presentation (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
	item
Nature Of The Business And Basis Of Presentation [Abstract]
Date of incorporation	1-Dec-10
Number of licensed and developing compounds	18
Culmulative ne loss	$67,964

Restatement_Of_Consolidated_Fi2

Restatement Of Consolidated Financial Statements (Narrative) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Intangible assets, net	$62,323	$38,354	[1]
Goodwill	41,398	25,646	[1]
Accumulated deficit	-67,964	-29,148	[1]
Deferred tax asset	158	1,124	[1]
Restatement Adjustment [Member]
Intangible assets, net		-7,786
Goodwill		4,850
Accumulated deficit		-2,651
Deferred tax asset		($257)

[1]	as restated

Restatement_Of_Consolidated_Fi3

Restatement Of Consolidated Financial Statements (Consolidated Balance Sheets) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Current assets:
Cash and cash equivalents	$9,823	$41,084	[1]	$13,973	[1]	$6,002
Short-term investments	88,249	4,670	[1]
Receivable from stockholder		1,001	[1]
Inventories	427	55	[1]
Prepaid expenses and other current assets	900	274	[1]
Deferred tax asset	158	1,124	[1]
Total current assets	99,909	48,208	[1]
Property and equipment, net	620	98	[1]
Goodwill	41,398	25,646	[1]
Intangible assets, net	62,323	38,354	[1]
Other long-term assets	1,201	37	[1]
Total assets	207,903	112,343	[1]
Current liabilities:
Accounts payable	1,532	2,307	[1]
Accrued expenses	3,229	2,495	[1]
Current portion-loan payable		5,625	[1]
Current portion-note payable		3,000	[1]
Current portion-deferred licensing revenue		45	[1]
Current portion-contingent consideration	4,248	2,572	[1]
Deferred income		800	[1]
Other current liabilities	46	57	[1]
Total current liabilities	9,468	16,901	[1]
Loan payable	14,963	9,310	[1]
Contingent consideration		1,543	[1]
Deferred tax liability	1,610	1,124	[1]
Other long-term liabilities	30	75	[1]
Total liabilities	26,071	28,953	[1]
Stockholders' equity:
Common stock	34	23	[1]
Additional paid-in capital	254,993	112,515	[1]
Accumulated deficit	-67,964	-29,148	[1]
Total stockholders' equity	181,832	83,390	[1]	-21,555		-10,271
Total liabilities and stockholders' equity	207,903	112,343	[1]
Previously Reported [Member]
Current assets:
Cash and cash equivalents		41,084		13,973
Short-term investments		4,670
Receivable from stockholder		1,001
Inventories		55
Prepaid expenses and other current assets		274
Deferred tax asset		1,381
Total current assets		48,465
Property and equipment, net		98
Goodwill		20,796
Intangible assets, net		46,140
Other long-term assets		37
Total assets		115,536
Current liabilities:
Accounts payable		2,307
Accrued expenses		2,495
Current portion-loan payable		5,625
Current portion-note payable		3,000
Current portion-deferred licensing revenue		45
Current portion-contingent consideration		2,572
Deferred income		800
Other current liabilities		57
Total current liabilities		16,901
Loan payable		9,310
Contingent consideration		1,543
Deferred tax liability		1,666
Other long-term liabilities		75
Total liabilities		29,495
Stockholders' equity:
Common stock		23
Additional paid-in capital		112,515
Accumulated deficit		-26,497
Total stockholders' equity		86,041
Total liabilities and stockholders' equity		115,536
Restatement Adjustment [Member]
Current assets:
Deferred tax asset		-257
Total current assets		-257
Goodwill		4,850
Intangible assets, net		-7,786
Total assets		-3,193
Current liabilities:
Deferred tax liability		-542
Total liabilities		-542
Stockholders' equity:
Accumulated deficit		-2,651
Total stockholders' equity		-2,651
Total liabilities and stockholders' equity		($3,193)

[1]	as restated

Restatement_Of_Consolidated_Fi4

Restatement Of Consolidated Financial Statements (Consolidated Statements Of Operations And Comprehensive Loss) (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013		Dec. 31, 2012
Revenues:
Licensing and collaboration revenue									$500,000	$15,000	[1]
Product sales									267,000	108,000	[1]
Total revenues	248,000	43,000	300,000	176,000	123,000				767,000	123,000	[1]
Costs and expenses:
Cost of product sales									333,000	108,000	[1]
Royalty expense									72,000	1,000	[1]
Research and development									19,985,000	10,925,000	[1]	7,291,000
General and administrative									17,938,000	8,572,000	[1]	2,987,000
In-process research and development									2,157,000		[1]	1,500,000
Amortization of acquired intangible assets									1,891,000	298,000	[1]
Total costs and expenses									42,376,000	19,904,000	[1]	11,778,000
Loss from operations									-41,609,000	-19,781,000	[1]	-11,778,000
Other income (expense)
Interest income									123,000	75,000	[1]	21,000
Interest expense									-1,060,000	-432,000	[1]
Other income (expense), net									2,287,000	478,000	[1]	121,000
Total other income (expense)									1,350,000	121,000	[1]	142,000
Loss before income taxes									-40,259,000	-19,660,000	[1]	-11,636,000
Income tax benefit									1,443,000	12,722,000	[1]
Net loss					4,466,000	-4,671,000	-3,440,000	-3,293,000	-38,816,000	-6,938,000	[1]	-11,636,000
Net loss and comprehensive loss attributable to common stockholders	-10,256,000	-10,130,000	-9,278,000	-9,152,000	4,466,000	-4,671,000	-4,248,000	-4,066,000	-38,816,000	-6,938,000	[1]	-13,671,000
Net loss per share, attributable to common stockholders, basic and diluted									($1.30)	($0.63)	[1]	($34.53)
Previously Reported [Member]
Revenues:
Licensing and collaboration revenue										15,000
Product sales										108,000
Total revenues										123,000
Costs and expenses:
Cost of product sales										108,000
Royalty expense										1,000
Research and development										10,925,000
General and administrative										8,572,000
Amortization of acquired intangible assets										380,000
Total costs and expenses										19,986,000
Loss from operations										-19,863,000
Other income (expense)
Interest income										75,000
Interest expense										-432,000
Other income (expense), net										478,000
Total other income (expense)										121,000
Loss before income taxes										-19,742,000
Income tax benefit										15,455,000
Net loss										-4,287,000
Net loss and comprehensive loss attributable to common stockholders										-4,287,000
Net loss per share, attributable to common stockholders, basic and diluted										($0.39)
Restatement Adjustment [Member]
Costs and expenses:
Amortization of acquired intangible assets										-82,000
Total costs and expenses										-82,000
Loss from operations										82,000
Other income (expense)
Loss before income taxes										82,000
Income tax benefit										-2,733,000
Net loss										-2,651,000
Net loss and comprehensive loss attributable to common stockholders										($2,651,000)
Net loss per share, attributable to common stockholders, basic and diluted										($0.24)

[1]	as restated

Restatement_Of_Consolidated_Fi5

Restatement Of Consolidated Financial Statements (Consolidated Statements Of Cash Flows) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Cash flows from operating activities
Net loss	($38,816)		($6,938)	[1]	($11,636)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	7,130		1,025	[1]	106
Depreciation and amortization expense	2,043		313	[1]	13
Non-cash interest expense	41		23	[1]
Deferred income benefit	-1,443		-12,722	[1]
Changes in operating assets and liabilities:
Prepaid expenses	-642		-249	[1]
Other assets	-45		-14	[1]	-32
Accounts payable	-1,143		1,527	[1]	536
Accrued expenses and other liabilities	482		579	[1]	897
Net cash used in operating activities	-32,188		-16,151	[1]	-7,816
Cash flows from investing activities
Purchase of property and equipment, net	-471		-94	[1]	-10
Cash paid for acquisitions, net of cash received	-12,075		-30,994	[1]
Purchase of investments	-371,449		-5,169	[1]	-6,627
Proceeds from maturities of investments	286,670		6,881	[1]	6,627
Change in restricted cash			141	[1]
Net cash used in investing activities	-100,125		-29,235	[1]	-1,010
Cash flows from financing activities
Proceeds from the issuance of debt, net of discount			14,914	[1]
Proceeds from stock options exercised	225		153	[1]	266
Repurchase, early exercised stock			-6	[1]
Proceeds from public offering, net of commission	137,220		36,897	[1]
Payments of public offering costs	-2,153		-2,617	[1]
Issuance of common stock private investment in public entitiy			19,750	[1]
Net cash provided by financing activities	100,978		72,497	[1]	16,797
Net increase in cash and cash equivalents	-31,261		27,111	[1]	7,971
Cash and cash equivalents, beginning of period	41,084	[1]	13,973	[1]	6,002
Cash and cash equivalents, end of period	9,823		41,084	[1]	13,973	[1]
Series B Convertible Preferred Stock [Member]
Cash flows from financing activities
Proceeds from the issuance of convertible preferred stock, net of issuance costs					7,699
Series C Convertible Preferred Stock [Member]
Cash flows from financing activities
Proceeds from the issuance of convertible preferred stock, net of issuance costs			3,406	[1]	8,693
Payments of public offering costs			-9		-55
Previously Reported [Member]
Cash flows from operating activities
Net loss			-4,287
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense			1,025
Depreciation and amortization expense			395
Non-cash interest expense			23
Deferred income benefit			-15,455
Changes in operating assets and liabilities:
Prepaid expenses			-249
Other assets			-14
Accounts payable			1,527
Accrued expenses and other liabilities			579
Net cash used in operating activities			-16,151
Cash flows from investing activities
Purchase of property and equipment, net			-94
Cash paid for acquisitions, net of cash received			-30,994
Purchase of investments			-5,169
Proceeds from maturities of investments			6,881
Change in restricted cash			141
Net cash used in investing activities			-29,235
Cash flows from financing activities
Proceeds from the issuance of debt, net of discount			14,914
Proceeds from stock options exercised			153
Repurchase, early exercised stock			-6
Proceeds from public offering, net of commission			36,897
Payments of public offering costs			-2,617
Issuance of common stock private investment in public entitiy			19,750
Net cash provided by financing activities			72,497
Net increase in cash and cash equivalents			27,111
Cash and cash equivalents, beginning of period			13,973
Cash and cash equivalents, end of period			41,084
Previously Reported [Member] \| Series C Convertible Preferred Stock [Member]
Cash flows from financing activities
Proceeds from the issuance of convertible preferred stock, net of issuance costs			3,406
Restatement Adjustment [Member]
Cash flows from operating activities
Net loss			-2,651
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense			-82
Deferred income benefit			$2,733

[1]	as restated

Summary_Of_Significant_Account2

Summary Of Significant Accounting Policies (Details) (USD $)	0 Months Ended	12 Months Ended			0 Months Ended
	Apr. 06, 2014	Dec. 31, 2014	Dec. 31, 2013		Apr. 07, 2014	Mar. 17, 2014	Feb. 04, 2014	Jan. 06, 2014	Dec. 31, 2012
	Apr. 06, 2014	item	Dec. 31, 2013		Apr. 07, 2014	Mar. 17, 2014	Feb. 04, 2014	Jan. 06, 2014	Dec. 31, 2012
Summary Of Significant Accounting Policies [Line Items]
Cash equivalents			$0
Unrealized gain (loss) related to marketable securities			0
Debt issuance costs		11,000	83,000
Expense related to debt issuance costs		41,000	33,000
Number of financial institutions		2
Recorded total assets		12,075,000	30,994,000	[1]
Contingent consideration, value, high	16,308,000
Settlement of contingent consideration payable		-15,235,000
Deferred Offering Costs			0						33,000
Okapi Sciences NV [Member]
Summary Of Significant Accounting Policies [Line Items]
Recorded total assets		43,376,000						43,376,000
Purchase price of acquisition								44,439,000
Aggregate merger consideration, cash paid								14,139,000
Promissory note								15,134,000
Contingent consideration, value, high								16,308,000
Contingent consideration					15,166,000			15,166,000
Interest rate								7.00%
Payment of promissory note							15,158,000
Settlement of contingent consideration payable		($15,235,000)				($15,235,000)

[1]	as restated

Recovered_Sheet2

Summary of Significant Accounting Policies (Estimated Useful Lives Of Property, Plant And Equipment) (Details)	12 Months Ended
	Dec. 31, 2014
Laboratory and Office Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Laboratory and Office Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Computer Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Computer Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Furniture [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Furniture [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	7 years
Vehicles [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Vehicles [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Leasehold Improvements [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Leasehold Improvements [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	10 years

Fair_Value_Of_Financial_Assets2

Fair Value Of Financial Assets And Liabilities (Narrative) (Details) (USD $)	12 Months Ended			3 Months Ended	0 Months Ended	1 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013		Mar. 31, 2015	Mar. 13, 2015	Mar. 31, 2015	Oct. 15, 2013	Jan. 02, 2015
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value, Assets, Level 1 to Level 2 Transfers, Amount	$2,452
Contingent consideration	4,248	4,115
Cash paid for contingent consideration	15,166
Change in fair value of contingent consideration	-133	305	[1]
Vet Therapeutics Inc., [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent consideration	4,248						3,810
Vet Therapeutics Inc., [Member] \| Scenario, Forecast [Member] \| AT-004 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Change in fair value of contingent consideration				-1,249
Vet Therapeutics Inc., [Member] \| Subsequent Event [Member] \| AT-004 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent consideration								3,000
Cash paid for contingent consideration					3,000	3,000
Vet Therapeutics Inc., [Member] \| Subsequent Event [Member] \| Scenario, Forecast [Member] \| AT-004 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Change in fair value of contingent consideration				($1,249)

[1]	as restated

Fair_Value_Of_Financial_Assets3

Fair Value Of Financial Assets And Liabilities (Summary Of Information About Company's Financial Assets And Liabilities Subject To Fair Value Measurement On Recurring Basis) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Assets:
Short-term marketable securities - Certificate of deposit	$249	$4,670
Derivative financial instruments	1,108
Marketable securities	2,452
Assets, fair value	98,826	4,670
Liabilities:
Contingent consideration	4,248	4,115
Liabilities, fair value	4,248	4,115
Current portion-contingent consideration	4,248	2,572	[1]
Long-term portion contingent consideration		1,543	[1]
Certificates of Deposit [Member]
Assets:
Cash equivalents	6,972
Money Market Funds [Member]
Assets:
Cash equivalents	45
Reverse Repurchase Agreements [Member]
Assets:
Reverse repurchase agreements	88,000
Level 1 [Member]
Assets:
Cash equivalents
Short-term marketable securities - Certificate of deposit
Long-term marketable securities - Common Stock
Derivative financial instruments
Marketable securities	2,452
Assets, fair value	2,452
Liabilities:
Contingent consideration
Liabilities, fair value
Level 1 [Member] \| Certificates of Deposit [Member]
Assets:
Cash equivalents
Level 1 [Member] \| Money Market Funds [Member]
Assets:
Cash equivalents
Level 1 [Member] \| Reverse Repurchase Agreements [Member]
Assets:
Reverse repurchase agreements
Level 2 [Member]
Assets:
Short-term marketable securities - Certificate of deposit	249	4,670
Derivative financial instruments	1,108
Assets, fair value	96,374	4,670
Level 2 [Member] \| Certificates of Deposit [Member]
Assets:
Cash equivalents	6,972
Level 2 [Member] \| Money Market Funds [Member]
Assets:
Cash equivalents	45
Level 2 [Member] \| Reverse Repurchase Agreements [Member]
Assets:
Reverse repurchase agreements	88,000
Level 3 [Member]
Assets:
Cash equivalents
Short-term marketable securities - Certificate of deposit
Long-term marketable securities - Common Stock
Derivative financial instruments
Marketable securities
Assets, fair value
Liabilities:
Contingent consideration	4,248	4,115
Liabilities, fair value	4,248	4,115
Level 3 [Member] \| Certificates of Deposit [Member]
Assets:
Cash equivalents
Level 3 [Member] \| Money Market Funds [Member]
Assets:
Cash equivalents
Level 3 [Member] \| Reverse Repurchase Agreements [Member]
Assets:
Reverse repurchase agreements
Carrying Value [Member]
Assets:
Short-term marketable securities - Certificate of deposit	249	4,670
Derivative financial instruments	1,108
Marketable securities	2,452
Assets, fair value	98,826	4,670
Liabilities:
Contingent consideration	4,248	4,115
Liabilities, fair value	4,248	4,115
Carrying Value [Member] \| Certificates of Deposit [Member]
Assets:
Cash equivalents	6,972
Carrying Value [Member] \| Money Market Funds [Member]
Assets:
Cash equivalents	45
Carrying Value [Member] \| Reverse Repurchase Agreements [Member]
Assets:
Reverse repurchase agreements	$88,000

[1]	as restated

Fair_Value_Of_Financial_Assets4

Fair Value Of Financial Assets And Liabilities (Change In Fair Value Of Company's Contingent Consideration Payable Measured At Fair Value On Recurring Basis) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Fair Value Of Financial Assets And Liabilities [Abstract]
As of January 1	$4,115
Initial recognition of contingent consideration payable	15,166	3,810
Settlement of contingent consideration payable	-15,235
Recognition of change in fair value in the consolidated statement of operations (within selling, general and administrative)	202	305
As of the end of the period	$4,248	$4,115

Fair_Value_Of_Financial_Assets5

Fair Value Of Financial Assets And Liabilities (Quantitative Information About Company's Recurring Level 3 Fair Value Measurements) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent consideration, Fair value	$4,248	$4,115
Level 3 [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent consideration, Fair value	4,248	4,115
Income Approach Valuation Technique [Member] \| Level 3 [Member] \| Fair Value, Measurements, Recurring [Member] \| Contingent Consideration [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent consideration, Fair value	$4,248	$4,115
Contingent consideration, Valuation technique	Income approach (probability weighted discounted cash flow)	Income approach (probability weighted discounted cash flow)
Assumed market participant discount rate	5.50%	5.50%
Periods in which milestones are expected to be achieved	2015
Income Approach Valuation Technique [Member] \| Level 3 [Member] \| Minimum [Member] \| Fair Value, Measurements, Recurring [Member] \| Contingent Consideration [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Probability of milestones being achieved	25.00%	3.80%
Periods in which milestones are expected to be achieved		2014
Income Approach Valuation Technique [Member] \| Level 3 [Member] \| Maximum [Member] \| Fair Value, Measurements, Recurring [Member] \| Contingent Consideration [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Probability of milestones being achieved	97.50%	95.00%
Periods in which milestones are expected to be achieved		2015
Income Approach Valuation Technique [Member] \| Level 3 [Member] \| Weighted Average [Member] \| Fair Value, Measurements, Recurring [Member] \| Contingent Consideration [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Probability of milestones being achieved	68.43%	71.44%

Fair_Value_Of_Financial_Assets6

Fair Value Of Financial Assets And Liabilities (Carrying Amounts And Estimated Fair Value Of Company's Financial Assets And Liabilities Not Measured At Fair Value On Recurring Basis) (Details) (Level 2 [Member], Fair Value, Measurements, Nonrecurring [Member], USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Level 2 [Member] \| Fair Value, Measurements, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loan payable, Carrying Amount	$14,963	$14,935
Loan payable, Fair Value	$14,933	$15,040

Investment_Narrative_Details

Investment (Narrative) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Investments [Abstract]
Unrealized gain (loss) on available securities recorded in other comprehensive income	$1,252
Reverse repurchase agreements, collateral securities, percentage of principal and interest required	102.00%

Investments_Fair_Value_Of_Avai

Investments (Fair Value Of Available-For-Sale Marketable Securities) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$1,449	$4,670
Gross Unrealized Gains	1,252
Gross Unrealized Losses
Fair Value	2,701	4,670
Certificates of Deposit [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	249	4,670
Gross Unrealized Gains
Gross Unrealized Losses
Fair Value	249	4,670
Common Stock [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	1,200
Gross Unrealized Gains	1,252
Gross Unrealized Losses
Fair Value	$2,452

Receivable_From_Stockholder_Re

Receivable From Stockholder (Receivable From Stockholder) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Stockholder Loans Receivable [Line Items]
Receivable from stockholder		$1,001	[1]
Vet Therapeutics Inc., [Member]
Stockholder Loans Receivable [Line Items]
Receivable from stockholder		$1,001

[1]	as restated

Inventories_Components_Of_Inve

Inventories (Components Of Inventories) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Inventories [Abstract]
Raw materials	$115
Work-in-process	206	55
Finished goods	106
Total inventories	$427	$55	[1]

[1]	as restated

Property_And_Equipment_Net_Nar

Property And Equipment, Net (Narrative) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property And Equipment, Net [Abstract]
Depreciation expense	$152	$16	$13
Assets sold or disposed	53
Gain (loss) on assets sold	($1)	$0

Property_And_Equipment_Net_Sch

Property And Equipment, Net (Schedule Of Property And Equipment) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Total property and equipment	$802	$139
Less: Accumulated depreciation and amortization	-182	-41
Property and equipment, net	620	98	[1]
Laboratory And Office Equipment [Member]
Total property and equipment	478	90
Computer Equipment And Software [Member]
Total property and equipment	68	40
Furniture [Member]
Total property and equipment	71	2
Vehicles [Member]
Total property and equipment	34
Leasehold Improvements [Member]
Total property and equipment	102
Construction In Progress [Member]
Total property and equipment	$49	$7

[1]	as restated

Goodwill_Narrative_Details

Goodwill (Narrative) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Goodwill [Line Items]
Goodwill Acquired During Period	$17,909	$25,646
Vet Therapeutics Inc., [Member]
Goodwill [Line Items]
Goodwill Acquired During Period		25,646
Okapi Sciences NV [Member]
Goodwill [Line Items]
Goodwill Acquired During Period	$17,909

Goodwill_Summary_Of_Goodwill_D

Goodwill (Summary Of Goodwill) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]
Gross Carrying Amount	$41,398
Impairment Losses
Net Carrying Value	$41,398	$25,646	[1]

[1]	as restated

Goodwill_Summary_Of_Change_In_

Goodwill (Summary Of Change In The Net Book Value Of Goodwill) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]
As of January 1	$25,646	[1]
Acquisition	17,909		25,646
Effect of foreign currency exchange	-2,157
As of the end of the period	$41,398		$25,646	[1]

[1]	as restated

Intangible_Assets_Net_Narrativ

Intangible Assets, Net (Narrative) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$1,891	$298	[1]

[1]	as restated

Intangible_Assets_Net_Summary_

Intangible Assets, Net (Summary Of Unamortized Intangible Assets) (Details) (Intellectual Property Rights Acquired For IPR&D [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Intellectual Property Rights Acquired For IPR&D [Member]
Acquired Indefinite-lived Intangible Assets [Line Items]
Gross Carrying Amount	$25,860

Intangible_Assets_Net_Summary_1

Intangible Assets, Net (Summary Of Armortized Intangible Assets) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Intangible assets, net	$62,323	$38,354	[1]
AT-004 [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value	28,572
Accumulated amortizationd	1,726
Intangible assets, net	26,846
Weighted average useful life	20 years
AT-005 [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value	10,080
Accumulated amortizationd	462
Intangible assets, net	$9,618
Weighted average useful life	20 years

[1]	as restated

Intangible_Assets_Net_Summary_2

Intangible Assets, Net (Summary Of Change In The Net Book Value Of Other Intangible Assets) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]
As of January 1,	$38,354	[1]
Acquisitions	29,400		38,652
Amortization charged	-1,891		-298	[1]
Effect of foreign currency exchange	3,540
As of December 31,	$62,323		$38,354	[1]

[1]	as restated

Intangible_Assets_Net_Estimate

Intangible Assets, Net (Estimated Aggregate Amortization Expense Of Intangible Assets) (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified	Dec. 31, 2014
Goodwill And Intangible Assets Disclosure [Abstract]
2015	$1,933
2016	1,933
2017	1,933
2018	1,933
2019	$1,933

Derivative_Financial_Instrumen2

Derivative Financial Instruments (Derivative Instrument At Gross Fair Value As Reflected) (Details) (Warrant [Member], USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Warrant [Member]
Derivative assets:
Fair value of derivatives not designated as hedge instrument	$1,108

Derivative_Financial_Instrumen3

Derivative Financial Instruments (Gain (Loss) Recognized In Other Income (Expense)) (Details) (Warrant [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Warrant [Member]
Derivative assets:
Gain/(loss) recognized in other income/(expense)	$465

Derivative_Financial_Instrumen4

Derivative Financial Instruments (Notional Principal Amounts Of Outstanding Derivative Instruments And Credit Risk Amounts Associated With Outstanding Or Unsettled Derivative Instruments) (Details) (Warrant [Member], USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	item	Dec. 31, 2013
Warrant [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional/Principal/Shares	153,061,000
Credit risk		$476

Debt_Narrative_Details

Debt (Narrative) (Details) (USD $)	12 Months Ended		0 Months Ended
Debt (Narrative) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Feb. 14, 2014	Feb. 04, 2014	Jun. 13, 2014	Oct. 11, 2013	Mar. 04, 2013	Jan. 06, 2014
Debt Instrument [Line Items]
Debt issuance costs	$11,000	$83,000
Debt outstanding	15,000,000
Vet Therapeutics Inc., [Member]
Debt Instrument [Line Items]
Date of maturity	31-Dec-14
Repayments of Notes Payable			20,000
Okapi Sciences NV [Member]
Debt Instrument [Line Items]
Interest rate								7.00%
Date of maturity	31-Dec-14
Repayments of Notes Payable				15,158,000
Credit Facility [Member]
Debt Instrument [Line Items]
Interest expense	875,000	357,000
Promissory Note [Member] \| Vet Therapeutics Inc., [Member]
Debt Instrument [Line Items]
Principal amount of debt	3,000,000
Interest rate	7.00%
Date of maturity	31-Dec-14
Term Loan [Member]
Debt Instrument [Line Items]
Principal amount of debt							5,000,000
Remaining borrowing capacity							5,000,000
Maximum borrowing capacity						10,000,000	10,000,000
Credit facility maturity date					13-Jun-16
Interest rate					5.50%
Fee on sale of assets or capital stock							13,000
Increased credit facility						5,000,000
Outstanding term loans converted					15,000,000
Debt discount							73,000
Debt discount, net	39,000
Accretion amount recognized as interest expense	41,000
Term Loan [Member] \| Vet Therapeutics Inc., [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity						$10,000,000

Debt_Estimated_Future_Principa

Debt (Estimated Future Principal Payments Under Additional Term Loan) (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified	Dec. 31, 2014
Debt [Abstract]
2015
2016	15,000
2017
2018
2019
Thereafter
Total	$15,000

Accrued_Expenses_Other_Current2

Accrued Expenses, Other Current Liabilities And Other Long-Term Liabilities (Summary Of Accrued Expenses) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Accrued expenses:
Accrued payroll and related expenses	$2,017	$1,017
Accrued professional fees	429	600
Accrued minimum royalties	72	70
Accrued interest	41	71
Accrued research and development costs	663	662
Accrued other	7	75
Accrued expenses, Total	3,229	2,495	[1]
Early exercise of stock-based awards	46	57
Other current liabilities, Total	46	57	[1]
Early exercise of stock-based awards	30	75
Other long term liabilities, Total	$30	$75	[1]

[1]	as restated

Agreements_RaQualia_Pharma_Inc

Agreements (RaQualia Pharma Inc Narrative) (Details) (USD $)	12 Months Ended		0 Months Ended	3 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Jul. 12, 2012	Dec. 31, 2014	Dec. 27, 2010	Oct. 31, 2014
	Dec. 31, 2014	Dec. 31, 2013	Jul. 12, 2012	Dec. 31, 2014	agreement	Oct. 31, 2014
RaQualia Agreements [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number of license agreements					2
Accrued milestones	$0	$0		$0
Milestones paid	0	0
Royalty payments	0	0
AT-001 [Member] \| RaQualia API Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Receivable on agreement execution			800
Eligible research and development funding			800
Accounts receivable for successful development and delivery	800			800		800
Deferred revenue recognized				1,600
Deferred revenue	800			800
Maximum [Member] \| AT-001 [Member] \| RaQualia Agreements [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestones payable					10,000
Maximum [Member] \| AT-002 [Member] \| RaQualia Agreements [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestones payable					8,500

Agreements_Pacira_Pharmaceutic

Agreements (Pacira Pharmaceuticals, Inc. Narrative) (Details) (USD $)	12 Months Ended				0 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013		Dec. 31, 2012	Dec. 05, 2012
Research and Development Arrangement, Contract to Perform for Others [Line Items]
In-process research and development	$2,157		[1]	$1,500
AT-003 [Member] \| Pacira Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
License fee					1,000
In-process research and development					1,000
Milestones payable		500
Milestones paid		500
AT-003 [Member] \| Pacira Agreement [Member] \| Maximum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestones payable					$42,500

[1]	as restated

Agreements_Alere_Inc_Narrative

Agreements (Alere Inc. Narrative) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty expense	$72	$1	[1]
Alere Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty expense	$1	$1

[1]	as restated

Agreements_Crucell_Holland_BV_

Agreements (Crucell Holland B.V. Narrative) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013		Apr. 02, 2013
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty expense	$72	$1	[1]
Crucell Commercial Agreement [Member] \| Vet Therapeutics Inc., [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Accrued milestones				0
Royalty expense	72
Crucell Commercial Agreement [Member] \| Vet Therapeutics Inc., [Member] \| Minimum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Accrued royalties	70			70
Crucell Commercial Agreement [Member] \| Vet Therapeutics Inc., [Member] \| Maximum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestones payable				$405

[1]	as restated

Agreements_Elanco_Animal_Healt

Agreements (Elanco Animal Health Narrative) (Details)

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2014

Oct. 15, 2013

Jan. 06, 2014

Dec. 06, 2012

Aug. 21, 2013

Dec. 31, 2014

Aug. 21, 2013

Mar. 31, 2015

Feb. 24, 2015

Mar. 31, 2015

Feb. 24, 2015

Jan. 02, 2015

Mar. 31, 2015

Dec. 06, 2012

USD ($)

Vet Therapeutics Inc., [Member]

Okapi Sciences NV [Member]

AT-004 [Member]

AT-006 [Member]

Subsequent Event [Member]

Regulatory And Development Milestones [Member]

USD ($)

NAH Agreement [Member]

Elanco Agreement [Member]

NAH Agreement [Member]

Elanco Agreement [Member]

AT-004 [Member]

Vet Therapeutics Inc., [Member]

Okapi Sciences NV [Member]

Vet Therapeutics Inc., [Member]

USD ($)

Vet Therapeutics Inc., [Member]

NAH Agreement [Member]

USD ($)

Maximum [Member]

USD ($)

Vet Therapeutics Inc., [Member]

USD ($)

EUR (€)

USD ($)

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Upfront nonrefundable payment received

$2,000

Upfront nonrefundable payment received for conditional license

2,000

Consideration recognized related to milestones

7,500

3,000

5,000

Licensing revenue

500

[1]

3,000

Contingent consideration

4,248

4,115

4,248

3,810

15,166

3,000

Payment for termination of license agreement

2,500

Milestones payable

500

Current liability

9,468

16,901

[1]

500

Reimbursement receovable for development expenses

2,500

Development expenses

19,985

10,925

[1]

7,291

930

Deferred revenue

1,570

Recognized revenue from research and development services

452

Accrued milestones

Royalty revenue

[1]

as restated

Agreements_Kansas_Bioscience_A

Agreements (Kansas Bioscience Authority Narrative) (Details) (Kansas Bioscience Authority ("KBA") Programs [Member], USD $)	0 Months Ended		12 Months Ended			49 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 06, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014
	Mar. 31, 2014	item	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Funding term		2 years
Number of development programs receiving conditional licenses		2
Grant term	24 months
Recognized income			$62	$478	$100
Amount received during life of agreement			641
Proceeds from the issuance of convertible preferred stock, net of issuance costs						1,300
Agreement term			10 years
Maximum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development grant receivable		1,333

Agreements_Advaxis_Inc_Narrati

Agreements (Advaxis Inc. Narrative) (Details) (USD $)	12 Months Ended				0 Months Ended	1 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013		Dec. 31, 2012	Mar. 19, 2014	Jan. 31, 2015
	Dec. 31, 2014	Dec. 31, 2013		Dec. 31, 2012	item	Jan. 31, 2015
Research and Development Arrangement, Contract to Perform for Others [Line Items]
In-process research and development	$2,157		[1]	$1,500
Advaxis Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number of products					3
Number of types of cancer					3
Cash payment related to license agreement					2,500
In-process research and development					657
Warrants exercisable date					19-Mar-24
Exercise price per share of additional warrants					$4.90
Advaxis Agreement [Member] \| Subsequent Event [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Sale of common stock, shares						124,971
Proceeds from sale of common stock						1,500
Advaxis Agreement [Member] \| Common Stock [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Cash payment related to license agreement					1,200
Common stock acquired					306,122
Common stock called by warrant acquired					153,061
Advaxis Agreement [Member] \| Warrant [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Cash payment related to license agreement					643
Advaxis Agreement [Member] \| Common Stock and Warrant [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Cash payment related to license agreement					1,843
Advaxis Agreement [Member] \| Clinical Development And Regulatory Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number of products					4
Advaxis Agreement [Member] \| Maximum [Member] \| Product Sales [Member] \| Royalties [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Concentration risk percentage					10.00%
Advaxis Agreement [Member] \| Maximum [Member] \| Clinical Development And Regulatory Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestones payable					6,000
Advaxis Agreement [Member] \| Maximum [Member] \| Commercial Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestones payable					28,500
Licensed Technology [Member] \| Advaxis Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Cash payment related to license agreement					$657

[1]	as restated

Agreements_VetStem_Inc_Narrati

Agreements (Vet-Stem, Inc. Narrative) (Details) (USD $)	12 Months Ended				0 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013		Dec. 31, 2012	Jun. 12, 2014
Research and Development Arrangement, Contract to Perform for Others [Line Items]
In-process research and development	$2,157		[1]	$1,500
Development expenses	19,985	10,925	[1]	7,291
AT-016 [Member] \| Vet-Stem Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
License fee					500
In-process research and development					500
Development expenses					3,600
AT-016 [Member] \| Vet-Stem Agreement [Member] \| Maximum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestones payable					$4,500

[1]	as restated

Agreements_Atopix_Therapeutics

Agreements (Atopix Therapeutics Ltd. Narrative) (Details) (USD $)	12 Months Ended				0 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013		Dec. 31, 2012	Oct. 10, 2014
Research and Development Arrangement, Contract to Perform for Others [Line Items]
In-process research and development	$2,157		[1]	$1,500
AT-018 [Member] \| Atopix Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
License fee					1,000
In-process research and development					1,000
AT-018 [Member] \| Atopix Agreement [Member] \| Maximum [Member] \| Clinical Development And Regulatory Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestones payable					$4,500

[1]	as restated

Agreements_Exclusive_Option_Pr

Agreements (Exclusive Option Programs Narrative) (Details) (USD $)	12 Months Ended				1 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013		Dec. 31, 2012	Jan. 31, 2014	Jun. 30, 2014
	Dec. 31, 2014	Dec. 31, 2013		Dec. 31, 2012	item	Jun. 30, 2014
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Development expenses	$19,985	$10,925	[1]	$7,291
Exclusive Option Programs [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number of option programs expired					1
Development expenses	$307	$915
AT-Beta [Member] \| Exclusive Option Programs [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Option program extension						12 months

[1]	as restated

Preferred_Stock_Narrative_Deta

Preferred Stock (Narrative) (Details) (USD $)	0 Months Ended					1 Months Ended	12 Months Ended				0 Months Ended	1 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 22, 2014	Feb. 03, 2014	Jun. 26, 2013	22-May-13	22-May-13	Jul. 31, 2013	Dec. 31, 2014	Dec. 31, 2013		Dec. 31, 2012	Feb. 15, 2012	Jun. 30, 2013	Jul. 02, 2013	Feb. 28, 2013
Class of Stock [Line Items]
Preferred stock shares, outstanding										20,241,207
Preferred stock shares authorized										20,916,667			10,000,000
Preferred stock, par value													$0.00
Holding percentage of share for conversion			75.00%
Convertible preferred stock converted into common stock								13,351,902
Preferred stock, shares issued										15,320,832
Issuance of preferred/common stock, net of issuance cost, shares	5,175,000	5,150,000				6,612,500
Share issue price	$9.25	$19				$6
Issuance costs							$2,153	$2,617	[1]
Reverse stock split ratio				1.662
Reverse stock split ratio on shares				1.662	1.662			1.662
Preferred stock, conversion basis										0.601685
Automatically Conversion, Scenario Two [Member] \| Minimum [Member]
Class of Stock [Line Items]
Preferred stock, conversion prices per share							$9
Preferred stock , redemption value							40,000
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares, outstanding										2,349,541
Preferred stock shares authorized										3,000,000				3,050,000
Issuance of preferred/common stock, net of issuance cost, shares								693,571		2,349,541
Share issue price								$4		4
Gross proceeds received								2,774		9,398
Issuance costs								9		55
Preferred stock, conversion prices per share							$6.65
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares, outstanding										5,141,667
Preferred stock shares authorized										5,166,667				5,141,667
Issuance of preferred/common stock, net of issuance cost, shares											2,570,834
Share issue price											$3
Gross proceeds received											7,712
Issuance costs											$13
Preferred stock, conversion prices per share							$4.99
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares, outstanding										9,999,999
Preferred stock shares authorized										10,000,000
Preferred stock, conversion prices per share							$1.66
Percentage of elected shareholder to convert common stock												75.00%
Series A Convertible Preferred Stock [Member] \| Automatically Conversion, Scenario One [Member]
Class of Stock [Line Items]
Percentage of elected shareholder to convert common stock							75.00%
Series A-1 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares, outstanding										2,750,000
Preferred stock shares authorized										2,750,000
Preferred stock, conversion prices per share							$3.32

[1]	as restated

Preferred_Stock_Summary_Of_Pre

Preferred Stock (Summary Of Preferred Stock) (Details) (USD $)	Jul. 02, 2013	Dec. 31, 2012	Feb. 28, 2013
In Thousands, except Share data, unless otherwise specified	Jul. 02, 2013	Dec. 31, 2012	Feb. 28, 2013
Class of Stock [Line Items]
Preferred stock Authorized	10,000,000	20,916,667
Preferred Stock Issued and Outstanding		20,241,207
Liquidation Preference		$43,269
Carrying Value		39,197
Common Stock Issuable Upon Conversion		12,178,807
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock Authorized		10,000,000
Preferred Stock Issued and Outstanding		9,999,999
Liquidation Preference		11,674
Carrying Value		9,951
Common Stock Issuable Upon Conversion		6,016,849
Series A-1 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock Authorized		2,750,000
Preferred Stock Issued and Outstanding		2,750,000
Liquidation Preference		5,500
Carrying Value		4,662
Common Stock Issuable Upon Conversion		1,654,632
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock Authorized		5,166,667	5,141,667
Preferred Stock Issued and Outstanding		5,141,667
Liquidation Preference		16,691
Carrying Value		15,241
Common Stock Issuable Upon Conversion		3,093,655
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock Authorized		3,000,000	3,050,000
Preferred Stock Issued and Outstanding		2,349,541
Liquidation Preference		9,404
Carrying Value		$9,343
Common Stock Issuable Upon Conversion		1,413,671

Common_Stock_Details

Common Stock (Details) (USD $)	0 Months Ended			1 Months Ended	12 Months Ended			0 Months Ended	1 Months Ended	0 Months Ended
Common Stock (Details) (USD $)	Sep. 22, 2014	Feb. 03, 2014	22-May-13	Jul. 31, 2013	Dec. 31, 2014	Dec. 31, 2013		Oct. 13, 2013	Jun. 30, 2013	Oct. 15, 2013	Jul. 03, 2013	Jul. 02, 2013	Feb. 28, 2013
Class of Stock [Line Items]
Common stock outstanding, shares					34,147,861	23,425,487
Common stock, authorized					100,000,000	100,000,000					100,000,000	25,041,667	25,041,667
Common stock, par value					$0.00	$0.00						$0.00
Reverse stock split ratio			1.662
Number of fractional shares issued for reverse stock split			0
Issuance of preferred/common stock, net of issuance cost, shares	5,175,000	5,150,000		6,612,500
Share issue price	$9.25	$19		$6
Net proceeds from public offering		$90,507,000		$34,274,000	$137,220,000	$36,897,000	[1]
Underwriting discount and commission	2,872,000	5,871,000		2,777,000
Offering expenses	412,000	1,472,000		2,617,000
Convertible preferred stock converted into common stock						13,351,902
Issuance of common stock relating to Vet Therapeutics, Inc. acquisition						14,700,000
Proceeds from issuance of private placement						19,750,000	[1]
Net proceeds from public offering	44,827,000
Private Placement [Member]
Class of Stock [Line Items]
Issuance of preferred/common stock, net of issuance cost, shares								1,234,375
Share issue price								$16
Proceeds from issuance of private placement								19,750,000
Unvested Restricted Common Stock [Member]
Class of Stock [Line Items]
Common stock outstanding, shares					561,651	672,251
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Percentage of elected shareholder to convert common stock									75.00%
Vet Therapeutics Inc., [Member]
Class of Stock [Line Items]
Issued of stock to Vet Therapeutics										624,997
Issuance of common stock relating to Vet Therapeutics, Inc. acquisition										$14,700,000
2010 Equity Incentive Plan [Member] \| Unvested Restricted Common Stock [Member]
Class of Stock [Line Items]
Stock repurchased					0	33,447

[1]	as restated

StockBased_Awards_Narrative_De

Stock-Based Awards (Narrative) (Details) (USD $)	12 Months Ended				0 Months Ended		1 Months Ended	3 Months Ended	1 Months Ended	0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013		Dec. 31, 2012	Dec. 22, 2012	Oct. 04, 2012	Oct. 31, 2012	Dec. 31, 2012	Aug. 31, 2013	Jan. 01, 2015
	Dec. 31, 2014	Dec. 31, 2013		Dec. 31, 2012	Dec. 22, 2012	Oct. 04, 2012	Oct. 31, 2012	Dec. 31, 2012	item	Jan. 01, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cash proceeds	$225,000	$153,000	[1]	$266,000
Proceeds from the issuance of restricted stock				139,000
One Emplyee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested, other than options		33,447
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested, other than options	192,473
Unrecognized stock-based compensation expense, other than options	76,000	132,000
2010 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award, expiration period	10 years
Shares available for future grant	0
Grants in period
Grants, exercise price
Weighted average grant date fair value of options granted					$2.59	$1.06
Unvested, other than options	91,334	237,740
Fair value stock awards, vested					2.59		1.06
Expirations in period
Vesting period	90 days
Issuance of common stock related to stock option exercises, shares	47,555
Weighted average grant date fair value, grants
Incremental expense for stock option awards	327,000
Incremental expense for restricted stock award	649,000
2010 Equity Incentive Plan [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period				3
Unvested, other than options	91,334	237,740
Fair value stock awards, vested	2,615,000	2,257,000		6,000
Issuance of restricted stock awards to employees, in shares		76,496
Proceeds from the issuance of restricted stock	0	0		139,000
Weighted average grant date fair value, grants	$0	$2.59		$0.40
2010 Equity Incentive Plan [Member] \| Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award, expiration period	10 years
Grants in period	0							87,241
Grants, exercise price								$0.40
Weighted average grant date fair value of options granted	$0	$2.48		$0.33
Vesting percentage	25.00%
Aggregate intrinsic value	871,000	4,840,000		2,160,000
Fair value stock awards, vested	765,000	98,000		85,000
Cash proceeds	19,000	153,000
Proceed from early options exercised	0	97,000
Issuance of restricted stock awards to employees, in shares		231,445
2010 Equity Incentive Plan [Member] \| Stock Option [Member] \| Former President [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards modified									2
Expirations in period									9,228
Issuance of common stock related to stock option exercises, shares									269,817
2013 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grant	103,054
Grants in period	856,211
Grants, exercise price	$17.83
Unvested, other than options	277,844	89,766
Unrecognized stock-based compensation expense, other than options	4,304,000
Expirations in period
Issuance of common stock related to stock option exercises, shares	34,386
Weighted average grant date fair value, grants	$16.73
Shares authorized for issuance		983,250
Percentage increase of shares		4.00%
Unrecognized stock-based compensation expense for options outstanding	13,283,000
Unrecognized stock-based compensation expense, recognition period	2 years 8 months 12 days
2013 Equity Incentive Plan [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from the issuance of restricted stock	0	0
Weighted average grant date fair value, grants	$16.73	$18.91
Fair value stock awards, vested, other than options	94,000	25,000
2013 Equity Incentive Plan [Member] \| Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award, expiration period	10 years
Grants in period	856,211
Weighted average grant date fair value of options granted	$12.84	$9.16
Vesting percentage	25.00%
Aggregate intrinsic value	214,000	0
Fair value stock awards, vested	1,888,000	0
Cash proceeds	$206,000	$0
Minimum [Member] \| 2010 Equity Incentive Plan [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		2 years
Minimum [Member] \| 2010 Equity Incentive Plan [Member] \| Stock Option [Member] \| Former President [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration date of options									9-Aug-13
Maximum [Member] \| 2010 Equity Incentive Plan [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		4 years
Maximum [Member] \| 2010 Equity Incentive Plan [Member] \| Stock Option [Member] \| Former President [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration date of options									31-Jan-14
Maximum [Member] \| 2013 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum increase in shares authorized		1,203,369
Subsequent Event [Member] \| 2013 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Annual increase in shares										1,203,369

[1]	as restated

StockBased_Awards_Summary_Of_S

Stock-Based Awards (Summary Of Stock Option Activity) (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
2010 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Issuable Under Options, Outstanding as of December 31, 2013	263,467
Shares Issuable Under Options, Granted
Shares Issuable Under Options, Exercised	-47,555
Shares Issuable Under Options, Forfeited	-45,446
Shares Issuable Under Options, Expired
Shares Issuable Under Options, Outstanding as of December 31, 2014	170,466	263,467
Shares Issuable Under Options, Options vested and expected to vest as of December 31, 2014	166,712
Shares Issuable Under Options, Options exercisable as of December 31, 2014	168,744
Weighted Average Exercise Price, Outstanding as of December 31, 2013	$1.25
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised	$0.40
Weighted Average Exercise Price, Forfeited	$0.40
Weighted Average Exercise Price, Expired
Weighted Average Exercise Price, Outstanding as of December 31, 2014	$1.71	$1.25
Weighted Average Exercise Price, Options vested and expected to vest as of December 31, 2014	$1.70
Weighted Average Exercise Price, Options exercisable as of December 31, 2014	$1.67
Weighted Average Remaining Contractual Term, Outstanding	8 years 18 days	8 years 11 months 9 days
Weighted Average Remaining Contractual Term, Options vested and expected	8 years 18 days
Weighted Average Remaining Contractual Term, Options exercisable	8 years 18 days
Aggregate Intrinsic Value, Outstanding	$2,746	$4,704
Aggregate Intrinsic Value, Options vested and expected	2,687
Aggregate Intrinsic Value, Options exercisable	2,725
2013 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Issuable Under Options, Outstanding as of December 31, 2013	685,934
Shares Issuable Under Options, Granted	856,211
Shares Issuable Under Options, Exercised	-34,386
Shares Issuable Under Options, Forfeited	-25,893
Shares Issuable Under Options, Expired
Shares Issuable Under Options, Outstanding as of December 31, 2014	1,481,866	685,934
Shares Issuable Under Options, Options vested and expected to vest as of December 31, 2014	1,374,792
Shares Issuable Under Options, Options exercisable as of December 31, 2014	176,174
Weighted Average Exercise Price, Outstanding as of December 31, 2013	$15.32
Weighted Average Exercise Price, Granted	$17.83
Weighted Average Exercise Price, Exercised	$6
Weighted Average Exercise Price, Forfeited	$6.97
Weighted Average Exercise Price, Expired
Weighted Average Exercise Price, Outstanding as of December 31, 2014	$17.13	$15.32
Weighted Average Exercise Price, Options vested and expected to vest as of December 31, 2014	$17.13
Weighted Average Exercise Price, Options exercisable as of December 31, 2014	$16.15
Weighted Average Remaining Contractual Term, Outstanding	8 years 11 months 16 days	9 years 8 months 5 days
Weighted Average Remaining Contractual Term, Options vested and expected	8 years 11 months 16 days
Weighted Average Remaining Contractual Term, Options exercisable	8 years 8 months 9 days
Aggregate Intrinsic Value, Outstanding	3,835	4,151
Aggregate Intrinsic Value, Options vested and expected	3,577
Aggregate Intrinsic Value, Options exercisable	$865

StockBased_Awards_Summary_Of_R

Stock-Based Awards (Summary Of Restricted Stock Activity) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
2010 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested restricted common stock as of December 31, 2013, Shares	237,740
Restricted common stock issued, Shares
Restricted common stock vested, Shares	-146,406
Restricted common stock forfeited, Shares
Unvested restricted common stock as of December 31, 2014, Shares	91,334
Unvested restricted common stock as of December 31, 2013, Weighted Average Grant Date Fair Value	$0.82
Restricted common stock issued, Weighted Average Grant Date Fair Value
Restricted common stock vested, Weighted Average Grant Date Fair Value	$0.73
Restricted common stock forfeited, Weighted Average Grant Date Fair Value
Unvested restricted common stock as of December 31, 2014, Weighted Average Grant Date Fair Value	$0.94
2013 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested restricted common stock as of December 31, 2013, Shares	89,766
Restricted common stock issued, Shares	282,200
Restricted common stock vested, Shares	-94,122
Restricted common stock forfeited, Shares
Unvested restricted common stock as of December 31, 2014, Shares	277,844
Unvested restricted common stock as of December 31, 2013, Weighted Average Grant Date Fair Value	$19.07
Restricted common stock issued, Weighted Average Grant Date Fair Value	$16.73
Restricted common stock vested, Weighted Average Grant Date Fair Value	$18.40
Restricted common stock forfeited, Weighted Average Grant Date Fair Value
Unvested restricted common stock as of December 31, 2014, Weighted Average Grant Date Fair Value	$16.92

StockBased_Awards_Data_Used_To

Stock-Based Awards (Data Used To Determine Value Of Stock Option Grants) (Details) (2013 Equity Incentive Plan [Member])	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
2013 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	1.88%	1.59%	0.90%
Expected term (in years)	6 years 1 month 6 days	6 years 1 month 6 days	6 years
Expected volatility	84.00%	66.00%	67.00%
Expected dividend yield

StockBased_Awards_Summary_Of_S1

Stock-Based Awards (Summary Of Stock-Based Compensation Expense Related To Stock Options And Restricted Stock) (Details) (2013 Equity Incentive Plan [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$7,130	$1,025	$106
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	1,611	419	11
Cost of Product Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	48
Selling, General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$5,471	$606	$95

Net_Loss_Per_Share_Narrative_D

Net Loss Per Share (Narrative) (Details) (Stock Options [Member])	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock Options [Member]
Dilutive Securities Included And Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock excluded from diluted net loss per share	1,789,305	1,294,146	952,957

Net_Loss_Per_Share_Schedule_Of

Net Loss Per Share (Schedule Of Basic And Diluted Net Loss Per Share Attributable To Common Stockholders) (Details) (USD $)	0 Months Ended		3 Months Ended								12 Months Ended
	22-May-13	22-May-13	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013		Dec. 31, 2012
Numerator:
Net loss							$4,466,000	($4,671,000)	($3,440,000)	($3,293,000)	($38,816,000)	($6,938,000)	[1]	($11,636,000)
Unaccreted dividends on convertible preferred stock														-2,035,000
Net loss and comprehensive loss attributable to common stockholders			($10,256,000)	($10,130,000)	($9,278,000)	($9,152,000)	$4,466,000	($4,671,000)	($4,248,000)	($4,066,000)	($38,816,000)	($6,938,000)	[1]	($13,671,000)
Denominator:
Weighted average shares outstanding, basic and diluted											29,767,429	11,059,382	[1]	395,918
Net loss per share, attributable to common stockholders, basic and diluted											($1.30)	($0.63)	[1]	($34.53)
Reverse stock split ratio on shares	1.662	1.662										1.662

[1]	as restated

Commitments_And_Contingencies_1

Commitments And Contingencies (Narrative) (Details) (USD $)	12 Months Ended				3 Months Ended	0 Months Ended	1 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013		Dec. 31, 2012	Mar. 31, 2015	Mar. 13, 2015	Mar. 31, 2015	Oct. 15, 2013	Jan. 02, 2015
Business Acquisition Contingent Consideration [Line Items]
Rent expense	$565	$177		$158
Contingent consideration	4,248	4,115
Cash paid for contingent consideration	15,166
Change in fair value of contingent consideration	-133	305	[1]
Vet Therapeutics Inc., [Member]
Business Acquisition Contingent Consideration [Line Items]
Contingent consideration	4,248							3,810
AT-004 [Member] \| Scenario, Forecast [Member] \| Vet Therapeutics Inc., [Member]
Business Acquisition Contingent Consideration [Line Items]
Change in fair value of contingent consideration					-1,249
AT-004 [Member] \| Subsequent Event [Member] \| Vet Therapeutics Inc., [Member]
Business Acquisition Contingent Consideration [Line Items]
Contingent consideration									3,000
Cash paid for contingent consideration						3,000	3,000
AT-004 [Member] \| Subsequent Event [Member] \| Scenario, Forecast [Member] \| Vet Therapeutics Inc., [Member]
Business Acquisition Contingent Consideration [Line Items]
Change in fair value of contingent consideration					($1,249)

[1]	as restated

Commitments_And_Contingencies_2

Commitments And Contingencies (Future Minimum Lease Payments For Operating Leases) (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified	Dec. 31, 2014
Commitments And Contingencies [Abstract]
2015	$558
2016	299
2017	226
2018	196
2019 and thereafter	46
Operating leases total future minimum lease payments	$1,325

Commitments_And_Contingencies_3

Commitments And Contingencies (Summary Of Contractual Contingent Purchase Price Consideration Obligation) (Details) (USD $)	12 Months Ended	0 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Mar. 17, 2014	Dec. 31, 2013	Oct. 15, 2013	Jan. 06, 2014
Business Acquisition, Contingent Consideration [Line Items]
Maximum Remaining Earn-out Potential	$5,000
Estimated Fair Value	4,248		4,115
Payments made during 2014	15,235
Vet Therapeutics Inc., [Member]
Business Acquisition, Contingent Consideration [Line Items]
Acquisition date	15-Oct-13
Maximum Remaining Earn-out Potential	5,000
Estimated Fair Value	4,248			3,810
Okapi Sciences NV [Member]
Business Acquisition, Contingent Consideration [Line Items]
Acquisition date	6-Jan-14
Estimated Fair Value					15,166
Payments made during 2014	$15,235	$15,235

Business_Combinations_Narrativ

Business Combinations (Narrative) (Details) (USD $)

0 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

In Thousands, except Share data, unless otherwise specified

Apr. 06, 2014

Jan. 06, 2014

Oct. 15, 2013

Dec. 31, 2014

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Mar. 17, 2014

Feb. 04, 2014

Apr. 04, 2014

Feb. 14, 2014

item

Business Acquisition [Line Items]

Number of clinical/development state product candidates

Contingent consideration, value, high

$16,308

Estimated Fair Value

4,248

4,115

4,248

4,115

Settlement of contingent liability

15,235

Total revenue

248

300

176

123

767

123

[1]

Total consideration paid, net of cash acquired

12,075

30,994

[1]

Debt Instrument interest rate percentage

7.00%

Fair market value of publicly traded common stock

$27.67

Discount for lack of marketability

15.00%

Goodwill

41,398

25,646

[1]

41,398

25,646

[1]

Pre-tax increase in come

-40,259

-19,660

[1]

-11,636

Okapi Sciences NV [Member]

Business Acquisition [Line Items]

Acquisition date

6-Jan-14

Purchase price of acquisition

44,439

Aggregate merger consideration, cash paid

14,139

Aggregate merger consideration, principal amount of promissory note issued

15,134

Contingent consideration, value, high

16,308

Estimated Fair Value

15,166

Repayments of Notes Payable

15,158

Settlement of contingent liability

15,235

Promissory note maturity date

31-Dec-14

Total revenue

452

Total consideration paid, net of cash acquired

43,376

Goodwill

17,909

Okapi Sciences NV [Member] | Acquisition-related Costs [Member]

Business Acquisition [Line Items]

Pre-tax increase in come

440

Okapi Sciences NV [Member] | General and Administrative [Member]

Business Acquisition [Line Items]

Contingent consideration difference in fair value and settlement amount

Business acquisition expenses

Okapi Sciences NV [Member] | Maximum [Member]

Business Acquisition [Line Items]

Aggregate merger consideration, shares issued/issuable

1,060,740

Okapi Sciences NV [Member] | Minimum [Member]

Business Acquisition [Line Items]

Aggregate merger consideration, shares issued/issuable

707,160

Vet Therapeutics Inc., [Member]

Business Acquisition [Line Items]

Acquisition date

15-Oct-13

Purchase price of acquisition

51,515

Aggregate merger consideration, cash paid

30,005

Aggregate merger consideration, principal amount of promissory note issued

3,000

Contingent consideration, value, high

5,000

Estimated Fair Value

3,810

4,248

Repayments of Notes Payable

Promissory note maturity date

31-Dec-14

Total revenue

273

123

Total consideration paid, net of cash acquired

51,503

Aggregate merger consideration, shares issued/issuable

624,997

Aggregate merger consideration, value of shares issued

14,700

Debt Instrument interest rate percentage

7.00%

Goodwill

25,646

Vet Therapeutics Inc., [Member] | Acquisition-related Costs [Member]

Business Acquisition [Line Items]

Pre-tax increase in come

1,639

Vet Therapeutics Inc., [Member] | General and Administrative [Member]

Business Acquisition [Line Items]

Business acquisition expenses

$1,369

[1]

as restated

Business_Combinations_Acquisit

Business Combinations (Acquisition Date Fair Value Of Consideration Transferred - Okapi Sciences NV) (Details) (USD $)	12 Months Ended			0 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013		Apr. 07, 2014	Jan. 06, 2014
Business Acquisition [Line Items]
Total consideration transferred, net of cash acquired	$12,075	$30,994	[1]
Okapi Sciences NV [Member]
Business Acquisition [Line Items]
Cash consideration					14,139
Fair value of promissory note					15,134
Fair value of contingent consideration				15,166	15,166
Fair value of total consideration					44,439
Less cash acquired					-1,063
Total consideration transferred, net of cash acquired	$43,376				$43,376

[1]	as restated

Business_Combinations_Acquisit1

Business Combinations (Acquisition Date Fair Value Of Consideration Transferred - Vet Therapeutics Inc.) (Details) (USD $)	12 Months Ended			0 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013		Oct. 15, 2013
Business Acquisition [Line Items]
Total consideration transferred, net of cash acquired	$12,075	$30,994	[1]
Vet Therapeutics Inc., [Member]
Business Acquisition [Line Items]
Cash consideration				30,005
Fair value of promissory note				3,000
Fair value of merger shares				14,700
Fair value of contingent consideration				3,810
Fair value of total consideration				51,515
Less cash acquired				-12
Total consideration transferred, net of cash acquired				$51,503

[1]	as restated

Business_Combinations_Allocati

Business Combinations (Allocation Of Purchase Price To Assets Acquired And Liabilities Assumed - Okapi Sciences NV) (Details) (USD $)	0 Months Ended
In Thousands, unless otherwise specified	Apr. 07, 2014	Jan. 06, 2014	Dec. 31, 2014	Dec. 31, 2013
Business Acquisition [Line Items]
Goodwill			$41,398	$25,646	[1]
Okapi Sciences NV [Member]
Business Acquisition [Line Items]
Cash		1,063
Accounts receivable		149
Other receivables		60
Prepaid expenses and other current assets		82
Property and equipment		217
Other long-term assets		18
Identifiable intangible assets		29,400
Accounts payable and accrued expenses		-586
Deferred revenue		-83
Deferred tax liabilities, net		-3,752
Long-term debt		-4
Total identifiable net assets		26,564
Goodwill		17,909
Total net assets acquired		44,439
Less:
Promissory note		15,134
Contingent consideration	15,166	15,166
Cash paid		$14,139

[1]	as restated

Business_Combinations_Allocati1

Business Combinations (Allocation Of Purchase Price To Assets Acquired And Liabilities Assumed - Vet Therapeutics Inc) (Details) (USD $)	0 Months Ended
In Thousands, unless otherwise specified	Oct. 15, 2013	Dec. 31, 2014	Dec. 31, 2013
Business Acquisition [Line Items]
Goodwill		$41,398	$25,646	[1]
Vet Therapeutics Inc., [Member]
Business Acquisition [Line Items]
Cash	12
Inventories	173
Other current assets	5
Property and equipment	73
Other long-term assets	3
Identifiable intangible assets	38,652
Accounts payable and accrued expenses	-273
Deferred revenue	-55
Deferred tax liabilities, net	-12,722		-12,722
Total identifiable net assets	25,868
Goodwill	25,646
Total net assets acquired	51,514
Less:
Merger Shares	14,700
Promissory note	3,000
Contingent consideration	3,810
Cash paid	$30,005

[1]	as restated

Business_Combinations_Componen

Business Combinations (Components Of Intangible Assets Acquired - Okapi Sciences NV) (Details) (Okapi Sciences NV [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Jan. 06, 2014
Business Acquisition [Line Items]
Total intangible assets subject to amortization, fair value		$29,400
AT-006 [Member]
Business Acquisition [Line Items]
Total intangible assets subject to amortization, fair value		3,400
Total intangible assets subject to amortization, useful life	13 years
AT-007 [Member]
Business Acquisition [Line Items]
Total intangible assets subject to amortization, fair value		13,500
Total intangible assets subject to amortization, useful life	15 years
AT-008 [Member]
Business Acquisition [Line Items]
Total intangible assets subject to amortization, fair value		5,300
Total intangible assets subject to amortization, useful life	13 years
AT-011 [Member]
Business Acquisition [Line Items]
Total intangible assets subject to amortization, fair value		$7,200
Total intangible assets subject to amortization, useful life	14 years

Business_Combinations_Componen1

Business Combinations (Components Of Intangible Assets Acquired - Vet Therapeutics Inc) (Details) (Vet Therapeutics Inc., [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Oct. 15, 2013
Business Acquisition [Line Items]
Total intangible assets subject to amortization, fair value		$38,652
Total intangible assets subject to amortization, useful life	20 years
AT-004 [Member]
Business Acquisition [Line Items]
Total intangible assets subject to amortization, fair value		28,572
AT-005 [Member]
Business Acquisition [Line Items]
Total intangible assets subject to amortization, fair value		$10,080

Business_Combinations_Summary_

Business Combinations (Summary Of Proforma Financial Information - Vet Therapeutics Inc.) (Details) (Vet Therapeutics Inc., [Member], USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Vet Therapeutics Inc., [Member]
Business Acquisition [Line Items]
Revenue	$767	$2,570
Net loss	-41,314	-22,977
Net loss attributable to common stockholders	($39,979)	($24,448)
Net loss per share attributable to common stockholders b basic and diluted	($1.34)	($1.95)

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	12 Months Ended			3 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013		Dec. 31, 2013	Dec. 31, 2012	Jan. 06, 2014	Oct. 15, 2013
Income Taxes [Line Items]
Excess tax deducation capitalized	$4,321
Income tax benefit recognized	-1,443	-12,722	[1]
Change in valuation allowance		12,722
Valuation allowance	14,747	3,118		3,118	8,065
Deferred income taxes	1,443
Unrecognized Tax Benefits	0	0		0
Accrued interest or penalities related to uncertain tax position	0	0		0
Recognized accrued or interest or penalities	0	0
Okapi Sciences NV [Member]
Income Taxes [Line Items]
Deferred tax liabilities recognized						3,752
Vet Therapeutics Inc., [Member]
Income Taxes [Line Items]
Income tax benefit recognized				-12,722
Deferred tax liabilities recognized		12,722		12,722			12,722
Research And Development [Member]
Income Taxes [Line Items]
Tax Credit Carryforward, Expiration Date	31-Dec-31
Tax Year 2031 [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards, Expiration Date	31-Dec-31
Tax Year 2021 [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards, Expiration Date	31-Dec-21
Federal [Member]
Income Taxes [Line Items]
Net operating loss carryforwards	15,227
Change in valuation allowance		-10,782
Federal [Member] \| Research And Development [Member]
Income Taxes [Line Items]
Tax credit carryforwards	738
State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Net operating loss carryforwards	13,260
Change in valuation allowance		-1,940
State and Local Jurisdiction [Member] \| Research And Development [Member]
Income Taxes [Line Items]
Tax credit carryforwards	490
Foreign Tax Authority [Member]
Income Taxes [Line Items]
Net operating loss carryforwards	$19,431

[1]	as restated

Income_Taxes_Components_Of_Inc

Income Taxes (Components Of Income From Continuing Operations Before Provision For Income Taxes) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Income Taxes [Abstract]
U.S.	($34,256)	($19,660)
Non-U.S.	-6,003
Income from continuing operations	($40,259)	($19,660)

Income_Taxes_Components_Of_Inc1

Income Taxes (Components Of Income Tax Benefit (Provisions) From Operations) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Deferred:
Federal		($10,782)
State		-1,940
Foreign	-1,443
Total	($1,443)	($12,722)	[1]

[1]	as restated

Income_Taxes_Reconciliation_Of

Income Taxes (Reconciliation Of U.S. Federal Statutory Income Tax Rate To Effective Income Tax Rate) (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Taxes [Abstract]
Federal statutory income tax rate	34.00%	34.00%
State income taxes, net of federal tax benefit	1.10%	7.20%
Non-deductible expenses	-3.00%	-2.50%
Research credits	0.80%	0.90%
Losses benefitted/(not benefitted)	-29.30%	25.30%
Total	3.60%	64.90%

Income_Taxes_Net_Deferred_Tax_

Income Taxes (Net Deferred Tax Assets) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Taxes [Abstract]
Net operating loss carry forwards	$12,196	$3,180
Capitalized start-up costs	7,151	3,751
Tax credit carryforwards	1,062	784
Other temporary differences	1,469	1,421
Capitalized research and development, net	10,378	5,788
Total deferred tax assets	32,256	14,924
Valuation allowance	-14,747	-3,118	-8,065
Net deferred tax assets	17,509	11,806
Intangibles, net	-19,356	-11,790
Depreciation	-18	-16
Total deferred tax liabilities	-19,374	-11,806
Net deferred tax liability	($1,865)

Income_Taxes_Changes_In_Valuat

Income Taxes (Changes In Valuation Allowance For Deferred Tax Assets) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Income Taxes [Abstract]
Valuation allowance as of beginning of year	$3,118	$8,065
Decreases recorded as income tax benefit		-4,947
Increases due to acquisitions	271
Increases due to operations	11,358
Valuation allowance as of end of year	$14,747	$3,118

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Related Party Transaction [Line Items]
Rent payable under lease	$1,325
MPM Asset Management, LLC [Member]
Related Party Transaction [Line Items]
Agreement period start date	9-Feb-13
Agreement period end date	31-Dec-13
Rent paid	67	59
Rent and services paid	60	52
MPM Heartland House, LLC [Member]
Related Party Transaction [Line Items]
Agreement period start date	1-May-13
Agreement period end date	30-Sep-15
Rent paid	113	60
Rent and services paid	33	5
Rent payable under lease	$115

Subsequent_Events_Narrative_De

Subsequent Events (Narrative) (Details) (USD $)	1 Months Ended	0 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2015	Feb. 24, 2015
Elanco [Member]
Subsequent Event [Line Items]
Contractual obligation		$3,200
Subsequent Event [Member] \| Advaxis [Member]
Subsequent Event [Line Items]
Proceeds from sale of common stock	1,500
AT-004 [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Payment for termination of license agreement		2,500
Milestones payable		$500

Selected_Quarterly_Financial_D2

Selected Quarterly Financial Data (Details) (USD $)	3 Months Ended								12 Months Ended
Selected Quarterly Financial Data (Details) (USD $)	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013		Dec. 31, 2012
Net revenue	$248,000	$43,000	$300,000	$176,000	$123,000				$767,000	$123,000	[1]
Gross profit	-85,000	43,000	300,000	176,000	15,000
Net income (loss) and comprehensive income (loss)					4,466,000	-4,671,000	-3,440,000	-3,293,000	-38,816,000	-6,938,000	[1]	-11,636,000
Net income (loss) attributable to common stockholders	-10,256,000	-10,130,000	-9,278,000	-9,152,000	4,466,000	-4,671,000	-4,248,000	-4,066,000	-38,816,000	-6,938,000	[1]	-13,671,000
Basic-income (loss) per common share:
Net income (loss) per common share	($0.30)	($0.35)	($0.32)	($0.34)	$0.21	($0.22)	($4.62)	($4.73)
Diluted-income (loss) per common share:
Net income (loss) per common share					$0.20	($0.22)	($4.62)	($4.73)
Weighted average number of common shares outstanding, basic	34,118,255	29,348,375	28,761,326	26,765,565	21,320,775	20,806,352	918,397	860,350
Weighted average shares outstanding, basic and diluted									29,767,429	11,059,382	[1]	395,918
Weighted average number of common shares outstanding, diluted					22,468,031	20,806,352	918,397	860,350
Income tax benefit									1,443,000	12,722,000	[1]
Change in fair value of contingent consideration									-133,000	305,000	[1]
Dilutive shares related to employee									1,147,256
Vet Therapeutics Inc., [Member]
Net revenue									273,000	123,000
Diluted-income (loss) per common share:
Income tax benefit					$12,722,000

[1]	as restated